

**CUMULATIVE
SUPPLEMENT 5
MAY 2004**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

RM
301.45
.A66
2004
v.24
suppl.5

2004

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

Library Use Only

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

Cumulative Supplement 5

May 2004

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Ribavirin 200mg Oral Capsule.....	v
1.4 Availability of the Edition.....	v
1.5 Report of Counts for the Prescription Drug Product List.....	vi
1.6 Cumulative Supplement Change Legend	vii
 DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. Additional details will be made available in future Cumulative Supplement publications.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

**CUMULATIVE SUPPLEMENT 5
May 2004**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between the applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)

BERLEX
(BERLEX)
BERLEX LABORATORIES INC
(BERLEX LABS)
BERLEX LABORATORIES INC SUB SCHERING AG
(BERLEX)
AMERSHAM HEALTH
(AMERSHAM)

NEW APPLICANT NAME (NEW ABBREVIATED NAME)

BERLEX INC
(BERLEX INC)
BERLEX INC
(BERLEX INC)
BERLEX INC
(BERLEX INC)
GE HEALTHCARE
(GE HEALTHCARE)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribavirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder/orange/24bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated approximately weekly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket #95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website,
<http://forms/psc.gov/forms/FDA/fda.html>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2003) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2003</u>	<u>MAR 2004</u>	<u>JUN 2004</u>	<u>SEP 2004</u>
DRUG PRODUCTS LISTED	10665	10668		
SINGLE SOURCE	2423 (22.7%)	2404 (22.5%)		
MULTISOURCE	8134 (76.3%)	8156 (76.5%)		
THERAPEUTICALLY EQUIVALENT	7856 (73.7%)	7885 (73.9%)		
NOT THERAPEUTICALLY EQUIVALENT	278 (2.6%)	271 (2.5%)		
EXCEPTIONS ¹	108 (1.0%)	108 (1.0%)		
NEW MOLECULAR ENTITIES APPROVED	6	3		
NUMBER OF APPLICANTS	601	586		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA + AMARIN PHARMS 120MG/5ML;12MG/5ML N86024 001 Apr CRLD

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

>D> + AAIPHARMA 500MG;100MG N76429 001 Sep 10, 2003 May CRLD

>A> 500MG;100MG N76429 001 Sep 10, 2003 May CRLD

>A> PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN VINTAGE PHARMS 325MG;100MG N76743 001 May 07, 2004 May NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

>D> AP ABBOTT EQ 500MG BASE/VIAL N40108 001 Oct 30, 1995 May CAHN

>A> AP HOSPIRA EQ 500MG BASE/VIAL N40108 001 Oct 30, 1995 May CAHN

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

>D> AT ABBOTT 250MG/100ML N17656 001 May CAHN

>A> AT HOSPIRA 250MG/100ML N17656 001 May CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

+ CUMBERLAND PHARMS 6GM /30ML(200MG/ML)

N21539 001 Jan 23, 2004 Jan NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

>D> AN ABBOTT 10% N73664 001 Aug 30, 1994 May CAHN

>D> AN 20% N74037 001 Aug 30, 1994 May CAHN

>A> AN HOSPIRA 10% N73664 001 Aug 30, 1994 May CAHN

>A> AN 20% N74037 001 Aug 30, 1994 May CAHN

ACITRETIN

CAPSULE; ORAL

SORIATANE

CONNNETICS

10MG

N19821 001 Oct 28, 1996 Mar CAHN

+ 25MG

N19821 002 Oct 28, 1996 Mar CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D> AP ABBOTT EQ 500MG BASE/VIAL N74663 001 Apr 22, 1997 May CAHN

>D> AP EQ 500MG BASE/VIAL N74758 001 Apr 22, 1997 May CAHN

>D> AP EQ 1GM BASE/VIAL N74663 002 Apr 22, 1997 May CAHN

>D> AP EQ 1GM BASE/VIAL N74758 002 Apr 22, 1997 May CAHN

>A> AP HOSPIRA EQ 500MG BASE/VIAL N74663 001 Apr 22, 1997 May CAHN

>A> AP EQ 500MG BASE/VIAL N74758 001 Apr 22, 1997 May CAHN

>A> AP EQ 1GM BASE/VIAL N74663 002 Apr 22, 1997 May CAHN

>A> AP EQ 1GM BASE/VIAL N74758 002 Apr 22, 1997 May CAHN

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP MAYNE PHARMA USA EQ 50MG BASE/ML N75065 001 Feb 25, 1999 Apr CAHN

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

+ PLIVA	EQ 4MG BASE	N76130 002 Sep 26, 2002 Jan CRLD
+ VOLMAX	EQ 8MG BASE	N76130 003 Sep 26, 2002 Jan CRLD
@ MURO	EQ 4MG BASE	N19604 002 Dec 23, 1992 Jan DISC
@	EQ 8MG BASE	N19604 001 Dec 23, 1992 Jan DISC

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

>D> AP ABBOTT	5ML/100ML;5GM/100ML	N83263 001 May CAHN
>A> AP HOSPIRA	5ML/100ML;5GM/100ML	N83263 001 May CAHN

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTANIL

>D> AP ABBOTT	EQ 0.5MG BASE/ML	N75221 001 Oct 28, 1999 May CAHN
>A> AP HOSPIRA	EQ 0.5MG BASE/ML	N75221 001 Oct 28, 1999 May CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>D> AP ABBOTT	EQ 50MG BASE/ML	N63263 001 Nov 30, 1994 May CAHN
>D> AP	EQ 62.5MG BASE/ML	N63283 001 Oct 31, 1994 May CAHN
>D> AP	EQ 250MG BASE/ML	N63264 001 Nov 30, 1994 May CAHN
>D> @	EQ 250MG BASE/ML	N64098 001 Jun 26, 1995 May CAHN
>D> @	EQ 250MG BASE/ML	N64099 001 Jun 20, 1995 May CAHN
>A> AP HOSPIRA	EQ 50MG BASE/ML	N63263 001 Nov 30, 1994 May CAHN
>A>	EQ 62.5MG BASE/ML	N63283 001 Oct 31, 1994 May CAHN
>A> AP	EQ 250MG BASE/ML	N63264 001 Nov 30, 1994 May CAHN
>A> AP	EQ 250MG BASE/ML	N64098 001 Jun 26, 1995 May CAHN
>A> @	EQ 250MG BASE/ML	N64099 001 Jun 20, 1995 May CAHN
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
>D> ABBOTT	EQ 500MG BASE/100ML	N64146 001 Apr 02, 1997 May CAHN
>A> HOSPIRA	EQ 500MG BASE/100ML	N64146 001 Apr 02, 1997 May CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

>D> ABBOTT	10% (10GM/100ML)	N17673 003 May CAHN
>A> HOSPIRA	10% (10GM/100ML)	N17673 003 May CAHN
AMINOSYN 10% (PH6)		
>D> ABBOTT	10% (10GM/100ML)	N17673 008 Nov 18, 1985 May CAHN
>A> HOSPIRA	10% (10GM/100ML)	N17673 008 Nov 18, 1985 May CAHN
AMINOSYN 3.5%		
>D> ABBOTT	3.5% (3.5GM/100ML)	N17789 004 May CAHN
>A> HOSPIRA	3.5% (3.5GM/100ML)	N17789 004 May CAHN
AMINOSYN 5%		
>D> ABBOTT	5% (5GM/100ML)	N17673 001 May CAHN
>A> HOSPIRA	5% (5GM/100ML)	N17673 001 May CAHN

INJECTABLE; INJECTION

AMINOSYN 7%

>D>	ABBOTT	7% (7GM/100ML)	N17673 002	May CAHN
>A>	HOSPIRA	7% (7GM/100ML)	N17673 002	May CAHN
AMINOSYN 7% (PH6)				
>D>	ABBOTT	7% (7GM/100ML)	N17673 006	Nov 18, 1985 May CAHN
>A>	HOSPIRA	7% (7GM/100ML)	N17673 006	Nov 18, 1985 May CAHN
AMINOSYN 8.5%				
>D>	ABBOTT	8.5% (8.5GM/100ML)	N17673 004	May CAHN
>A>	HOSPIRA	8.5% (8.5GM/100ML)	N17673 004	May CAHN
AMINOSYN 8.5% (PH6)				
>D>	ABBOTT	8.5% (8.5GM/100ML)	N17673 007	Nov 18, 1985 May CAHN
>A>	HOSPIRA	8.5% (8.5GM/100ML)	N17673 007	Nov 18, 1985 May CAHN
AMINOSYN II 10%				
>D>	ABBOTT	10% (10GM/100ML)	N19438 005	Apr 03, 1986 May CAHN
>A>	HOSPIRA	10% (10GM/100ML)	N19438 005	Apr 03, 1986 May CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER				
>D>	ABBOTT	10% (10GM/100ML)	N20015 001	Dec 19, 1991 May CAHN
>A>	HOSPIRA	10% (10GM/100ML)	N20015 001	Dec 19, 1991 May CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER				
>D>	ABBOTT	15% (15GM/100ML)	N20041 001	Dec 19, 1991 May CAHN
>A>	HOSPIRA	15% (15GM/100ML)	N20041 001	Dec 19, 1991 May CAHN
AMINOSYN II 3.5%				
>D>	ABBOTT	3.5% (3.5GM/100ML)	N19438 001	Apr 03, 1986 May CAHN
>A>	HOSPIRA	3.5% (3.5GM/100ML)	N19438 001	Apr 03, 1986 May CAHN
AMINOSYN II 5%				
>D>	ABBOTT	5% (5GM/100ML)	N19438 002	Apr 03, 1986 May CAHN
>A>	HOSPIRA	5% (5GM/100ML)	N19438 002	Apr 03, 1986 May CAHN
AMINOSYN II 7%				
>D>	ABBOTT	7% (7GM/100ML)	N19438 003	Apr 03, 1986 May CAHN
>A>	HOSPIRA	7% (7GM/100ML)	N19438 003	Apr 03, 1986 May CAHN
AMINOSYN II 8.5%				
>D>	ABBOTT	8.5% (8.5GM/100ML)	N19438 004	Apr 03, 1986 May CAHN
>A>	HOSPIRA	8.5% (8.5GM/100ML)	N19438 004	Apr 03, 1986 May CAHN
AMINOSYN-HBC 7%				
>D>	ABBOTT	7% (7GM/100ML)	N19374 001	Jul 12, 1985 May CAHN
>A>	HOSPIRA	7% (7GM/100ML)	N19374 001	Jul 12, 1985 May CAHN
AMINOSYN-HF 8%				
>D>	ABBOTT	8% (8GM/100ML)	N20345 001	Apr 04, 1996 May CAHN
>A>	HOSPIRA	8% (8GM/100ML)	N20345 001	Apr 04, 1996 May CAHN
AMINOSYN-PF 10%				
>D>	ABBOTT	10% (10GM/100ML)	N19492 002	Oct 17, 1986 May CAHN
>A>	HOSPIRA	10% (10GM/100ML)	N19492 002	Oct 17, 1986 May CAHN
AMINOSYN-PF 7%				
>D>	ABBOTT	7% (7GM/100ML)	N19398 001	Sep 06, 1985 May CAHN
>A>	HOSPIRA	7% (7GM/100ML)	N19398 001	Sep 06, 1985 May CAHN
AMINOSYN-RF 5.2%				
>D>	ABBOTT	5.2% (5.2GM/100ML)	N18429 001	May CAHN
>A>	HOSPIRA	5.2% (5.2GM/100ML)	N18429 001	May CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

>D>	ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 001	Nov 07, 1988 May CAHN
-----	--------	---	------------	-----------------------

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
 >A> HOSPIRA 3.5%;36.8MG/100ML;25GM/100ML;51MG N19683 001 Nov 07, 1988 May CAHN
 /100ML;22.4MG/100ML;261MG/100ML;2
 05MG/100ML

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
 >D> ABBOTT 4.25%;36.8MG/100ML;20GM/100ML;51M N19683 002 Nov 07, 1988 May CAHN
 G/100ML;22.4MG/100ML;261MG/100ML;
 205MG/100ML

>A> HOSPIRA 4.25%;36.8MG/100ML;20GM/100ML;51M N19683 002 Nov 07, 1988 May CAHN
 G/100ML;22.4MG/100ML;261MG/100ML;
 205MG/100ML

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
 >D> ABBOTT 4.25%;36.8MG/100ML;25GM/100ML;51M N19683 003 Nov 07, 1988 May CAHN
 G/100ML;22.4MG/100ML;261MG/100ML;
 205MG/100ML

>A> HOSPIRA 4.25%;36.8MG/100ML;25GM/100ML;51M N19683 003 Nov 07, 1988 May CAHN
 G/100ML;22.4MG/100ML;261MG/100ML;
 205MG/100ML

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
 >D> @ ABBOTT 5%;36.8MG/100ML;25GM/100ML;51MG/1 N19683 004 Nov 07, 1988 May CAHN
 00ML;22.4MG/100ML;261MG/100ML;205
 MG/100ML

>A> @ HOSPIRA 5%;36.8MG/100ML;25GM/100ML;51MG/1 N19683 004 Nov 07, 1988 May CAHN
 00ML;22.4MG/100ML;261MG/100ML;205
 MG/100ML

AMINO ACIDS; DEXTROSEINJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 >D> ABBOTT 3.5%;25GM/100ML N19681 001 Nov 01, 1988 May CAHN
 >A> HOSPIRA 3.5%;25GM/100ML N19681 001 Nov 01, 1988 May CAHN

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
 >D> ABBOTT 3.5%;5GM/100ML N19681 002 Nov 01, 1988 May CAHN
 >A> HOSPIRA 3.5%;5GM/100ML N19681 002 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
 >D> ABBOTT 4.25%;10GM/100ML N19681 004 Nov 01, 1988 May CAHN
 >A> HOSPIRA 4.25%;10GM/100ML N19681 004 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
 >D> ABBOTT 4.25%;20GM/100ML N19681 005 Nov 01, 1988 May CAHN
 >A> HOSPIRA 4.25%;20GM/100ML N19681 005 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
 >D> ABBOTT 4.25%;25GM/100ML N19681 003 Nov 01, 1988 May CAHN
 >A> HOSPIRA 4.25%;25GM/100ML N19681 003 Nov 01, 1988 May CAHN

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 >D> ABBOTT 5%;25GM/100ML N19681 006 Nov 01, 1988 May CAHN
 >A> HOSPIRA 5%;25GM/100ML N19681 006 Nov 01, 1988 May CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
 >D> @ ABBOTT 4.25%;10GM/100ML;51MG/100ML;176.5 N19682 003 Nov 01, 1988 May CAHN
 MG/100ML;22.4MG/100ML;104.5MG/100
 ML;205MG/100ML

>A> @ HOSPIRA 4.25%;10GM/100ML;51MG/100ML;176.5 N19682 003 Nov 01, 1988 May CAHN
 MG/100ML;22.4MG/100ML;104.5MG/100
 ML;205MG/100ML

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> ABBOTT 3.5%;5GM/100ML;30MG/100ML;97MG/10 OML;120MG/100ML;49.3MG/100ML N19682 001 Nov 01, 1988 May CAHN

>A> HOSPIRA 3.5%;5GM/100ML;30MG/100ML;97MG/10 OML;120MG/100ML;49.3MG/100ML N19682 001 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

>D> ABBOTT 4.25%;5GM/100ML;30MG/100ML;97MG/10 OML;120MG/100ML;49.3MG/100ML N19682 002 Nov 01, 1988 May CAHN

>A> HOSPIRA 4.25%;5GM/100ML;30MG/100ML;97MG/10 OML;120MG/100ML;49.3MG/100ML N19682 002 Nov 01, 1988 May CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

>D> ABBOTT 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N17789 003 May CAHN

>A> HOSPIRA 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N17789 003 May CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

>D> @ ABBOTT 3.5%;21MG/100ML;128MG/100ML;234MG/100ML N17789 005 May CAHN

>A> @ HOSPIRA 3.5%;21MG/100ML;128MG/100ML;234MG/100ML N17789 005 May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

>D> ABBOTT 10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 004 Apr 03, 1986 May CAHN

>A> HOSPIRA 10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 004 Apr 03, 1986 May CAHN

AMINOSYN II 7% W/ ELECTROLYTES

>D> @ ABBOTT 7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 006 Apr 03, 1986 May CAHN

>A> @ HOSPIRA 7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 006 Apr 03, 1986 May CAHN

AMINOSYN II 8.5% W/ ELECTROLYTES

>D> ABBOTT 8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 005 Apr 03, 1986 May CAHN

>A> HOSPIRA 8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 005 Apr 03, 1986 May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

>D> @ ABBOTT 3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML N19437 007 Apr 03, 1986 May CAHN

>A> @ HOSPIRA 3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML N19437 007 Apr 03, 1986 May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

>D> ABBOTT 7%;102MG/100ML;522MG/100ML;410MG/100ML N17789 002 May CAHN

INJECTABLE; INJECTIONAMINOSYN 7% W/ ELECTROLYTES

>A>	HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N17789 002	May CAHN
>D>	ABBOTT	8.5%;102MG/100ML;522MG/100ML;410MG/G/100ML	N17673 005	May CAHN
>A>	HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/G/100ML	N17673 005	May CAHN

AMINOCAPROIC ACIDINJECTABLE; INJECTIONAMINOCAPROIC ACID

>D> AP	ABBOTT	250MG/ML	N70888 001 Jun 16, 1988	May CAHN
>A> AP	HOSPIRA	250MG/ML	N70888 001 Jun 16, 1988	May CAHN
AMINOCAPROIC ACID IN PLASTIC CONTAINER				
>D> AP	ABBOTT	250MG/ML	N70010 001 Mar 09, 1987	May CAHN
>A> AP	HOSPIRA	250MG/ML	N70010 001 Mar 09, 1987	May CAHN

AMINOPHYLLINEINJECTABLE; INJECTIONAMINOPHYLLINE

>D> AP	ABBOTT	25MG/ML	N87242 001 Oct 26, 1983	May CAHN
>D> AP	+	25MG/ML	N87601 001 Jul 23, 1982	May CAHN
>A> AP	HOSPIRA	25MG/ML	N87242 001 Oct 26, 1983	May CAHN
>A> AP	+	25MG/ML	N87601 001 Jul 23, 1982	May CAHN
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
>D>	ABBOTT	100MG/100ML	N88147 002 May 03, 1983	May CAHN
>D>	+	200MG/100ML	N88147 003 May 03, 1983	May CAHN
>A>	+	100MG/100ML	N88147 002 May 03, 1983	May CAHN
>A>	+	200MG/100ML	N88147 003 May 03, 1983	May CAHN
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
>D>	@ ABBOTT	100MG/100ML	N18924 001 Dec 12, 1984	May CAHN
>D>	@	200MG/100ML	N18924 002 Dec 12, 1984	May CAHN
>D>	@	400MG/100ML	N18924 003 Dec 12, 1984	May CAHN
>D>	@	500MG/100ML	N18924 004 Dec 12, 1984	May CAHN
>A>	@ HOSPIRA	100MG/100ML	N18924 001 Dec 12, 1984	May CAHN
>A>	@	200MG/100ML	N18924 002 Dec 12, 1984	May CAHN
>A>	@	400MG/100ML	N18924 003 Dec 12, 1984	May CAHN
>A>	@	500MG/100ML	N18924 004 Dec 12, 1984	May CAHN

AMIODARONE HYDROCHLORIDEINJECTABLE; INJECTIONAMIODARONE HCL

>D> AP	ABBOTT	50MG/ML	N75955 001 Oct 18, 2002	May CAHN
>A> AP	HOSPIRA	50MG/ML	N75955 001 Oct 18, 2002	May CAHN
AMIODARONE HYDROCHLORIDE				
AP	INTL MEDICATION SYS	50MG/ML	N21594 001 Feb 04, 2004	Feb NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUMTABLET; ORALCADUETPFIZER

EQ 5MG BASE;EQ 10MG BASE	N21540 001 Jan 30, 2004	Jan NEWA
EQ 5MG BASE;EQ 20MG BASE	N21540 002 Jan 30, 2004	Jan NEWA
EQ 5MG BASE;EQ 40MG BASE	N21540 003 Jan 30, 2004	Jan NEWA
EQ 5MG BASE;EQ 80MG BASE	N21540 004 Jan 30, 2004	Jan NEWA
EQ 10MG BASE;EQ 10MG BASE	N21540 005 Jan 30, 2004	Jan NEWA
EQ 10MG BASE;EQ 20MG BASE	N21540 006 Jan 30, 2004	Jan NEWA

TABLET; ORAL

CADUET

PFIZER

EQ 10MG BASE;EQ 40MG BASE N21540 007 Jan 30, 2004 Jan NEWA

+ EQ 10MG BASE;EQ 80MG BASE N21540 008 Jan 30, 2004 Jan NEWA

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

@ DR REDDYS LABS INC 2.5MG
@ 5MG
@ 10MG

N21435 001 Oct 31, 2003 Mar DISC

N21435 002 Oct 31, 2003 Mar DISC

N21435 003 Oct 31, 2003 Mar DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

>D>

+ ABBOTT 5MEQ/ML

N88366 001 Jun 13, 1984 May CAHN

>A>

+ HOSPIRA 5MEQ/ML

N88366 001 Jun 13, 1984 May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

AMMONIUM LACTATE

>A>

AB TARO EQ 12% BASE

N76216 001 May 28, 2004 May NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>

AB TEVA 200MG/5ML;EQ 28.5MG BASE/5ML

N65089 001 May 25, 2004 May NEWA

>A>

AB 400MG/5ML;EQ 57MG BASE/5ML

N65089 002 May 25, 2004 May NEWA

AB

600MG/5ML;EQ 42.9MG BASE/5ML

N65162 001 Mar 12, 2004 Mar NEWA

AUGMENTIN ES-600

AB

+ GLAXOSMITHKLINE 600MG/5ML;EQ 42.9MG BASE/5ML

N50755 001 Jun 22, 2001 Mar CPTG

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

BERTEK

+

20MG/2ML (10MG/ML)

N21264 001 Apr 20, 2004 Apr NEWA

30MG/3ML (10MG/ML)

N21264 002 Apr 20, 2004 Apr NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SABEX 2002

80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL

N21646 001 Jan 29, 2004 Jan NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ MAYNE PHARMA USA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIA L;5MG/VIAL;0.01MG/VIAL;0.14MG/VIA L;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1 .4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N18920 001 Sep 21, 2000 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+ MAYNE PHARMA USA 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5M G/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ AAIPHARMA LLC 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL

+ MAYNE PHARMA USA 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ AAIPHARMA LLC 200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML

+ MAYNE PHARMA USA 200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

>A> + MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.5UGM/ML;1.5M G/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.6MG/ML;330 UNITS/ML;1 IU/ML

ATRACURIUM BESYLATEINJECTABLE; INJECTIONATRACURIUM BESYLATE

>D> AP ABBOTT 10MG/ML N74632 001 Dec 23, 1996 May CAHN

>A> AP HOSPIRA 10MG/ML N74632 001 Dec 23, 1996 May CAHN

ATRACURIUM BESYLATE PRESERVATIVE FREE

>D> AP ABBOTT 10MG/ML N74633 001 Dec 23, 1996 May CAHN

>D> AP HOSPIRA 10MG/ML N74639 001 Mar 25, 1997 May CAHN

>A> AP HOSPIRA 10MG/ML N74633 001 Dec 23, 1996 May CAHN

>A> AP 10MG/ML N74639 001 Mar 25, 1997 May CAHN

TRACRIUM

>D> AP + ABBOTT 10MG/ML N18831 002 Jun 20, 1985 May CAHN

>A> AP + HOSPIRA 10MG/ML N18831 002 Jun 20, 1985 May CAHN

TRACRIUM PRESERVATIVE FREE

>D> AP + ABBOTT 10MG/ML N18831 001 Nov 23, 1983 May CAHN

>A> AP + HOSPIRA 10MG/ML N18831 001 Nov 23, 1983 May CAHN

ATROPINE SULFATE

INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSRY PLASTIC SYRINGE

>D>	ABBOTT	0.05MG/ML	N21146 002 Jul 09, 2001 May CAHN
>D>	+	0.1MG/ML	N21146 001 Jul 09, 2001 May CAHN
>A>	HOSPIRA	0.05MG/ML	N21146 002 Jul 09, 2001 May CAHN
>A>	+	0.1MG/ML	N21146 001 Jul 09, 2001 May CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOPEN

>D>	+	AMARIN PHARMS	0.025MG;1MG	N17744 002 May CAHN
>A>	+	VALEANT	0.025MG;1MG	N17744 002 May CAHN
MOTOPEN HALF-STRENGTH				
>D>	@	AMARIN PHARMS	0.025MG;0.5MG	N17744 001 May CAHN
>A>	@	VALEANT	0.025MG;0.5MG	N17744 001 May CAHN

AZACITIDINE

>A> INJECTABLE; SUBCUTANEOUS
>A> VIDAZA
>A> + PHARMION 100MG/VIAL N50794 001 May 19, 2004 May NEWA

AZATADINE MALEATE

>D> TABLET; ORAL
>D> OPTIMINE
>D> + SCHERING 1MG N17601 001 May DISC
>A> @ 1MG N17601 001 May DISC

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

>D> TABLET, EXTENDED RELEASE; ORAL
>D> TRINALIN
>D> + SCHERING 1MG;120MG N18506 001 Mar 23, 1982 May DISC
>A> @ 1MG;120MG N18506 001 Mar 23, 1982 May DISC

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
AZATHIOPRINE SODIUM

>D> AP	BEDFORD	EQ 100MG BASE/VIAL	N74419 001 Mar 31, 1995 May CRLD
>A>	+	EQ 100MG BASE/VIAL	N74419 001 Mar 31, 1995 May CRLD
>D>	IMURAN		
>D> AP	+ PROMETHEUS LABS	EQ 100MG BASE/VIAL	N17391 001 May DISC
>A>	@	EQ 100MG BASE/VIAL	N17391 001 May DISC

AZITHROMYCIN

CAPSULE; ORAL
ZITHROMAX
@ PFIZER EQ 250MG BASE N50670 001 Nov 01, 1991 Mar DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN

AT	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50416 002 Mar CRLD
AT	+ BAUSCH AND LOMB	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64068 001 Oct 30, 1995 Mar CRLD

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC

AT	AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N65088 001 Feb 06, 2004 Feb NEWA
AT	+ BAUSCH AND LOMB	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64064 001 Oct 30, 1995 Mar CRLD
	NEOSPORIN		
AT	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50417 001 Mar CRLD

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	+ BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	N64046 001 Jan 26, 1995 Mar CRLD
	POLYSPORIN		
AT	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	N61229 001 Mar CRLD

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL
BENAZEPRIL HCL

AB	ANDRX PHARMS	5MG	N76267 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76267 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76267 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76267 004 Feb 11, 2004 Feb NEWA
AB	EON	5MG	N76402 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76402 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76402 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76402 004 Feb 11, 2004 Feb NEWA
AB	GENPHARM	5MG	N76476 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76476 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76476 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76476 004 Feb 11, 2004 Feb NEWA
AB	IVAX PHARMS	5MG	N76333 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76333 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76333 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76333 004 Feb 11, 2004 Feb NEWA
AB	KV PHARM	5MG	N76118 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76118 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76118 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76118 004 Feb 11, 2004 Feb NEWA
AB	MYLAN	5MG	N76430 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76430 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76430 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76430 004 Feb 11, 2004 Feb NEWA
AB	RANBAXY	5MG	N76344 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76344 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76344 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76344 004 Feb 11, 2004 Feb NEWA
AB	TEVA	5MG	N76211 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76211 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76211 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76211 004 Feb 11, 2004 Feb NEWA
	LOTENSIN		
AB	NOVARTIS	5MG	N19851 001 Jun 25, 1991 Feb CPTG
AB		10MG	N19851 002 Jun 25, 1991 Feb CPTG

	TABLET; ORAL LOTENSIN			
AB	NOVARTIS	20MG	N19851 003 Jun 25, 1991 Feb CPTG	
AB	+	40MG	N19851 004 Jun 25, 1991 Feb CPTG	
NEWA				
BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
CRLD				
	TABLET; ORAL BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE			
AB	ANDRX PHARMS	5MG;6.25MG	N76342 001 Feb 11, 2004 Feb NEWA	
AB		10MG;12.5MG	N76342 002 Feb 11, 2004 Feb NEWA	
AB		20MG;12.5MG	N76342 003 Feb 11, 2004 Feb NEWA	
AB		20MG;25MG	N76342 004 Feb 11, 2004 Feb NEWA	
AB	EON	5MG;6.25MG	N76631 001 Feb 11, 2004 Feb NEWA	
AB		10MG;12.5MG	N76631 002 Feb 11, 2004 Feb NEWA	
AB		20MG;12.5MG	N76631 003 Feb 11, 2004 Feb NEWA	
AB		20MG;25MG	N76631 004 Feb 11, 2004 Feb NEWA	
CRLD				
AB	GENPHARM	5MG;6.25MG	N76612 001 Feb 11, 2004 Feb NEWA	
AB		10MG;12.5MG	N76612 002 Feb 11, 2004 Feb NEWA	
AB		20MG;12.5MG	N76612 003 Feb 11, 2004 Feb NEWA	
AB		20MG;25MG	N76612 004 Feb 11, 2004 Feb NEWA	
CRDL				
AB	IVAX PHARMS	5MG;6.25MG	N76348 001 Feb 11, 2004 Feb NEWA	
AB		10MG;12.5MG	N76348 002 Feb 11, 2004 Feb NEWA	
AB		20MG;12.5MG	N76348 003 Feb 11, 2004 Feb NEWA	
AB		20MG;25MG	N76348 004 Feb 11, 2004 Feb NEWA	
AB	MYLAN	5MG;6.25MG	N76688 001 Feb 11, 2004 Feb NEWA	
AB		10MG;12.5MG	N76688 002 Feb 11, 2004 Feb NEWA	
AB		20MG;12.5MG	N76688 003 Feb 11, 2004 Feb NEWA	
AB		20MG;25MG	N76688 004 Feb 11, 2004 Feb NEWA	
NEWA				
AB	LOTENSIN HCT			
AB	NOVARTIS	5MG;6.25MG	N20033 001 May 19, 1992 Feb CPTG	
AB		10MG;12.5MG	N20033 002 May 19, 1992 Feb CPTG	
AB		20MG;12.5MG	N20033 004 May 19, 1992 Feb CPTG	
AB	+	20MG;25MG	N20033 003 May 19, 1992 Feb CPTG	
NEWA				
BENZOYL PEROXIDE; ERYTHROMYCIN				
NEWA				
	GEL; TOPICAL BENZAMYCIN			
AB	+	DERMIK LABS	5%;3%	N50557 001 Oct 26, 1984 Mar CFTG
AB		ERYTHROMYCIN AND BENZOYL PEROXIDE		
AB	ATRUX	5%;3%	N65112 001 Mar 29, 2004 Mar NEWA	
NEWA				
BETAMETHASONE DIPROPIONATE				
NEWA				
	CREAM, AUGMENTED; TOPICAL BETAMETHASONE DIPROPIONATE			
AB	ATRUX	EQ 0.05% BASE	N76603 001 Jan 23, 2004 Jan NEWA	
NEWA				
BETAMETHASONE SODIUM PHOSPHATE				
NEWA				
	INJECTABLE; INJECTION BETAMETHASONE SODIUM PHOSPHATE			
NEWA	@ STERIS	EQ 3MG BASE/ML	N85738 001 Feb DISC	
NEWA	CELESTONE			
NEWA	@ SCHERING	EQ 3MG BASE/ML	N17561 001 Feb DISC	
NEWA				
NEWA				
CPTG				
CPTG				

>A> BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
 >A> FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL
 >A> HALFLYTELY
 >A> + BRAINTREE 5MG;210GM;0.74GM;2.86GM;5.6GM N21551 001 May 10, 2004 May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
 BRETYLIUM TOSYLATE

>D> AP + ABBOTT	50MG/ML	N19033 001 Apr 29, 1986 May CAHN
>A> AP + HOSPIRA	50MG/ML	N19033 001 Apr 29, 1986 May CAHN
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER		
>D> AP + ABBOTT	200MG/100ML	N19008 002 Apr 29, 1986 May CAHN
>D> AP +	400MG/100ML	N19008 003 Apr 29, 1986 May CAHN
>D> @	800MG/100ML	N19008 001 Apr 29, 1986 May CAHN
>A> AP + HOSPIRA	200MG/100ML	N19008 002 Apr 29, 1986 May CAHN
>A> AP +	400MG/100ML	N19008 003 Apr 29, 1986 May CAHN
>A> @	800MG/100ML	N19008 001 Apr 29, 1986 May CAHN
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER		
>D> AP + ABBOTT	50MG/ML	N19030 001 Apr 29, 1986 May CAHN
>A> AP + HOSPIRA	50MG/ML	N19030 001 Apr 29, 1986 May CAHN

BUMETANIDE

INJECTABLE; INJECTION
 BUMETANIDE

>D> AP ABBOTT	0.25MG/ML	N74160 001 Oct 30, 1997 May CAHN
>D> AP	0.25MG/ML	N74332 001 Oct 31, 1994 May CAHN
>A> AP HOSPIRA	0.25MG/ML	N74160 001 Oct 30, 1997 May CAHN
>A> AP	0.25MG/ML	N74332 001 Oct 31, 1994 May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
 BUPIVACAINE HCL

>D> AP ABBOTT	0.25%	N18053 002 May CAHN
>D> AP	0.25%	N70583 001 Feb 17, 1987 May CAHN
>D> AP	0.25%	N70586 001 Mar 03, 1987 May CAHN
>D> AP	0.25%	N70590 001 Feb 17, 1987 May CAHN
>D> AP	0.5%	N18053 001 May CAHN
>D> AP	0.5%	N70584 001 Feb 17, 1986 May CAHN
>D> AP	0.5%	N70597 001 Mar 03, 1987 May CAHN
>D> AP	0.5%	N70609 001 Mar 03, 1987 May CAHN
>D> AP	0.75%	N18053 003 May CAHN
>D> AP	0.75%	N70585 001 Mar 03, 1987 May CAHN
>D> AP	0.75%	N70587 001 Mar 03, 1987 May CAHN
>A> AP HOSPIRA	0.25%	N18053 002 May CAHN
>A> AP	0.25%	N70583 001 Feb 17, 1987 May CAHN
>A> AP	0.25%	N70586 001 Mar 03, 1987 May CAHN
>A> AP	0.25%	N70590 001 Feb 17, 1987 May CAHN
>A> AP	0.5%	N18053 001 May CAHN
>A> AP	0.5%	N70584 001 Feb 17, 1986 May CAHN
>A> AP	0.5%	N70597 001 Mar 03, 1987 May CAHN
>A> AP	0.5%	N70609 001 Mar 03, 1987 May CAHN
>A> AP	0.75%	N18053 003 May CAHN
>A> AP	0.75%	N70585 001 Mar 03, 1987 May CAHN
>A> AP	0.75%	N70587 001 Mar 03, 1987 May CAHN

INJECTABLE; INJECTION

BUPIVACAINE HCL KIT

>D>	@ ABBOTT	0.075%	N19978 001 Sep 03, 1992 May CAHN
>D>	@	0.114%	N19978 002 Sep 03, 1992 May CAHN
>D>	@	0.23%	N19978 003 Sep 03, 1992 May CAHN
>A>	@ HOSPIRA	0.075%	N19978 001 Sep 03, 1992 May CAHN
>A>	@	0.114%	N19978 002 Sep 03, 1992 May CAHN
>A>	@	0.23%	N19978 003 Sep 03, 1992 May CAHN

MARCaine HCL

>D> AP + ABBOTT	0.25%	N16964 001 May CAHN
>D> AP +	0.5%	N16964 006 May CAHN
>A> AP + HOSPIRA	0.25%	N16964 001 May CAHN
>A> AP +	0.5%	N16964 006 May CAHN

MARCaine HCL PRESERVATIVE FREE

>D> AP + ABBOTT	0.25%	N16964 012 May CAHN
>D> AP +	0.5%	N16964 005 May CAHN
>D> AP +	0.75%	N16964 009 May CAHN
>A> AP + HOSPIRA	0.25%	N16964 012 May CAHN
>A> AP +	0.5%	N16964 005 May CAHN
>A> AP +	0.75%	N16964 009 May CAHN

INJECTABLE; SPINAL

BUPIVACAINE

>D> AP ABBOTT	0.75%	N71810 001 Dec 11, 1987 May CAHN
>A> AP HOSPIRA	0.75%	N71810 001 Dec 11, 1987 May CAHN

MARCaine

>D> AP + ABBOTT	0.75%	N18692 001 May 04, 1984 May CAHN
>A> AP + HOSPIRA	0.75%	N18692 001 May 04, 1984 May CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

>D> + ABBOTT	0.25%;0.005MG/ML	N71165 001 Jun 16, 1988 May CAHN
>D>	0.25%;0.005MG/ML	N71166 001 Jun 16, 1988 May CAHN
>D>	0.25%;0.005MG/ML	N71167 001 Jun 16, 1988 May CAHN
>D> +	0.5%;0.005MG/ML	N71168 001 Jun 16, 1988 May CAHN
>D>	0.5%;0.005MG/ML	N71169 001 Jun 16, 1988 May CAHN
>D>	0.5%;0.005MG/ML	N71170 001 Jun 16, 1988 May CAHN
>D> +	0.75%;0.005MG/ML	N71171 001 Jun 16, 1988 May CAHN
>A> + HOSPIRA	0.25%;0.005MG/ML	N71165 001 Jun 16, 1988 May CAHN
>A>	0.25%;0.005MG/ML	N71166 001 Jun 16, 1988 May CAHN
>A>	0.25%;0.005MG/ML	N71167 001 Jun 16, 1988 May CAHN
>A> +	0.5%;0.005MG/ML	N71168 001 Jun 16, 1988 May CAHN
>A>	0.5%;0.005MG/ML	N71169 001 Jun 16, 1988 May CAHN
>A>	0.5%;0.005MG/ML	N71170 001 Jun 16, 1988 May CAHN
>A> +	0.75%;0.005MG/ML	N71171 001 Jun 16, 1988 May CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCaine HCL W/ EPINEPHRINE

>D> AP + ABBOTT	0.25%;0.0091MG/ML	N16964 004 May CAHN
>D> AP +	0.5%;0.0091MG/ML	N16964 008 May CAHN
>A> AP + HOSPIRA	0.25%;0.0091MG/ML	N16964 004 May CAHN
>A> AP +	0.5%;0.0091MG/ML	N16964 008 May CAHN

MARCaine HCL W/ EPINEPHRINE PRESERVATIVE FREE

>D> AP + ABBOTT	0.25%;0.0091MG/ML	N16964 013 May CAHN
>D> AP +	0.5%;0.0091MG/ML	N16964 007 May CAHN

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE

>D>	AP	+	ABBOTT	0.75%;0.0091MG/ML	N16964 010	May	CAHN
>A>	AP	+	HOSPIRA	0.25%;0.0091MG/ML	N16964 013	May	CAHN
>A>	AP	+		0.5%;0.0091MG/ML	N16964 007	May	CAHN
>A>	AP	+		0.75%;0.0091MG/ML	N16964 010	May	CAHN

BUPRENORPHINE HYDROCHLORIDEINJECTABLE; INJECTION

BUPRENORPHINE HCL

>D>	AP	ABBOTT	EQ 0.3MG BASE/ML	N74137 001 Jun 03, 1996 May CAHN
>A>	AP	HOSPIRA	EQ 0.3MG BASE/ML	N74137 001 Jun 03, 1996 May CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

>D>	AB	EON	100MG	N75932 001 Nov 25, 2003 May CPTG
>A>	AB1		100MG	N75932 001 Nov 25, 2003 May CPTG
>D>	AB		150MG	N75932 002 Mar 22, 2004 May CTEC
>A>	AB1		150MG	N75932 002 Mar 22, 2004 May CTEC
	AB		150MG	N75932 002 Mar 22, 2004 Mar NEWA
>D>	AB	IMPAK LABS	100MG	N75913 001 Jan 28, 2004 May CTEC
>A>	AB1		100MG	N75913 001 Jan 28, 2004 May CTEC
	AB		100MG	N75913 001 Jan 28, 2004 Jan NEWA
>D>	AB		150MG	N75913 002 Mar 22, 2004 May CTEC
>A>	AB1		150MG	N75913 002 Mar 22, 2004 May CTEC
	AB		150MG	N75913 002 Mar 22, 2004 Mar NEWA
>A>	AB2		150MG	N75914 001 May 27, 2004 May NEWA
	WELLBUTRIN SR			
>D>	AB	GLAXOSMITHKLINE	100MG	N20358 002 Oct 04, 1996 May CTEC
>A>	AB		100MG	N20358 002 Oct 04, 1996 May CTEC
>D>	AB	+	150MG	N20358 003 Oct 04, 1996 May CTEC
>A>	AB	+	150MG	N20358 003 Oct 04, 1996 May CTEC
	AB	+	150MG	N20358 003 Oct 04, 1996 Mar CPTG
	ZYBAN			
>D>	+	GLAXOSMITHKLINE	150MG	N20711 003 May 14, 1997 May CPTG
>A>	AB	+	150MG	N20711 003 May 14, 1997 May CPTG

BUSPIRONE HYDROCHLORIDETABLET; ORAL

BUSPIRONE HCL

AB	TEVA	30MG	N75022 004 Mar 25, 2004 Mar NEWA
----	------	------	----------------------------------

BUTORPHANOL TARTRATEINJECTABLE; INJECTION

BUTORPHANOL TARTRATE

>D>	AP	ABBOTT	1MG/ML	N75559 001 Mar 20, 2000 May CAHN
>D>	AP		2MG/ML	N75559 002 Mar 20, 2000 May CAHN
>A>	AP	HOSPIRA	1MG/ML	N75559 001 Mar 20, 2000 May CAHN
>A>	AP		2MG/ML	N75559 002 Mar 20, 2000 May CAHN

BUTORPHANOL TARTRATE PRESERVATIVE FREE

>D>	AP	ABBOTT	1MG/ML	N74620 001 Jan 22, 1997 May CAHN
>D>	AP		1MG/ML	N74626 001 Jan 23, 1997 May CAHN
>D>	AP		2MG/ML	N74620 002 Jan 22, 1997 May CAHN
>D>	AP		2MG/ML	N74626 002 Jan 23, 1997 May CAHN
>A>	AP	HOSPIRA	1MG/ML	N74620 001 Jan 22, 1997 May CAHN

INJECTABLE; INJECTIONBUTORPHANOL TARTRATE PRESERVATIVE FREE

>A>	AP	HOSPIRA	1MG/ML	N74626 001 Jan 23, 1997 May CAHN
>A>	AP		2MG/ML	N74620 002 Jan 22, 1997 May CAHN
>A>	AP		2MG/ML	N74626 002 Jan 23, 1997 May CAHN

CALCITRIOLINJECTABLE; INJECTIONCALCITRIOL

AP	MAYNE PHARMA USA	0.001MG/ML	N75816 001 Jan 16, 2004 Jan NEWA
AP		0.002MG/ML	N75816 002 Jan 16, 2004 Jan NEWA

CALCIUM CHLORIDEINJECTABLE; INJECTIONCALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

>D>	+	ABBOTT	100MG/ML	N21117 001 Jan 28, 2000 May CAHN
>A>	+	HOSPIRA	100MG/ML	N21117 001 Jan 28, 2000 May CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONDEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

>D>	AP	ABBOTT	33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML	N18254 001	May CAHN
>A>	AP	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML	N18254 001	May CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATEINJECTABLE; INJECTIONDEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	AP	ABBOTT	20MG/100ML;5GM/100ML;30MG/100ML;6 00MG/100ML;310MG/100ML	N17608 001	May CAHN
>A>	AP	HOSPIRA	20MG/100ML;5GM/100ML;30MG/100ML;6 00MG/100ML;310MG/100ML	N17608 001	May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	⑨ ABBOTT	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML	N19685 005	Oct 17, 1988 May CAHN
>D>	⑨	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 006	Oct 17, 1988 May CAHN

>A>	⑨ HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML	N19685 005	Oct 17, 1988 May CAHN
>A>	⑨	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 006	Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	⑨ ABBOTT	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685 007	Oct 17, 1988 May CAHN
>A>	⑨ HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685 007	Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	AP	ABBOTT	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 002	Oct 17, 1988 May CAHN
>D>	AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 008	Oct 17, 1988 May CAHN

>A>	AP	HOSPIRA	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 002	Oct 17, 1988 May CAHN
>A>	AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 008	Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	⑨ ABBOTT	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685 003	Oct 17, 1988 May CAHN
>A>	⑨ HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685 003	Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	AP	ABBOTT	20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 004	Oct 17, 1988 May CAHN
-----	----	--------	--	------------	-----------------------

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
>A> AP HOSPIRA 20MG/100ML;5GM/100ML;328MG/100ML; N19685 004 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
>D> @ ABBOTT 20MG/100ML;5GM/100ML;104MG/100ML; N19685 001 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

>A> @ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; N19685 001 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TPN ELECTROLYTES IN PLASTIC CONTAINER
>D> ABBOTT 16.5MG/ML;25.4MG/ML;74.6MG/ML;121 N18895 001 Jul 20, 1984 May CAHN
MG/ML;16.1MG/ML

>A> HOSPIRA 16.5MG/ML;25.4MG/ML;74.6MG/ML;121 N18895 001 Jul 20, 1984 May CAHN
MG/ML;16.1MG/ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER
>D> AT + ABBOTT 17.6MG/100ML;325.3MG/100ML;119.3M N18608 001 Feb 26, 1982 May CAHN
G/100ML;643MG/100ML

>A> AT + HOSPIRA 17.6MG/100ML;325.3MG/100ML;119.3M N18608 001 Feb 26, 1982 May CAHN
G/100ML;643MG/100ML

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER
>D> AP ABBOTT 33MG/100ML;30MG/100ML;860MG/100ML N18251 001 May CAHN

>A> AP HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N18251 001 May CAHN

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER
>D> AT ABBOTT 33MG/100ML;30MG/100ML;860MG/100ML N17635 001 May CAHN

>A> AT HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N17635 001 May CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
>D> AP ABBOTT 20MG/100ML;30MG/100ML;600MG/100ML N17641 001 May CAHN
;310MG/100ML

>A> AP HOSPIRA 20MG/100ML;30MG/100ML;600MG/100ML N17641 001 May CAHN
;310MG/100ML

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER
>D> AT ABBOTT 20MG/100ML;30MG/100ML;600MG/100ML N19416 001 Jan 17, 1986 May CAHN
;310MG/100ML

>A> AT HOSPIRA 20MG/100ML;30MG/100ML;600MG/100ML N19416 001 Jan 17, 1986 May CAHN
;310MG/100ML

CAPTOPRIL

TABLET; ORAL
Captopril
>A> AB DURAMED PHARMS BARR 12.5MG N74477 001 Feb 13, 1996 May CAHN
>A> AB 25MG N74477 002 Feb 13, 1996 May CAHN
>A> AB 50MG N74477 003 Feb 13, 1996 May CAHN
>A> AB 100MG N74477 004 Feb 13, 1996 May CAHN
>D> AB HALLMARK PHARMS 12.5MG N74477 001 Feb 13, 1996 May CAHN
>D> AB 25MG N74477 002 Feb 13, 1996 May CAHN
>D> AB 50MG N74477 003 Feb 13, 1996 May CAHN
>D> AB 100MG N74477 004 Feb 13, 1996 May CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
 CARBATROL
 SHIRE PHARM 100MG N20712 003 Sep 30, 1997 Mar CRLD
 200MG N20712 001 Sep 30, 1997 Mar CRLD

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
 CARBIDOPA AND LEVODOPA
 >A> AB IMPAX LABS 25MG;100MG N76521 001 May 14, 2004 May NEWA
 >A> AB 50MG;200MG N76521 002 May 14, 2004 May NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)
 PARAPLATIN
 + BRISTOL MYERS SQUIBB EQ 600MG /60ML(10MG/ML) N20452 004 Jan 15, 2004 Jan NEWA

CEFACLOR

CAPSULE; ORAL
 CEFACLOR
 AB CARLSBAD EQ 250MG BASE N65146 001 Jan 22, 2004 Jan NEWA
 AB EQ 500MG BASE N65146 002 Jan 22, 2004 Jan NEWA

FOR SUSPENSION; ORAL

CECLR

>A> AB CEPH INTL	EQ 125MG BASE/5ML	N62206 001	May	CAHN
>A> AB	EQ 187MG BASE/5ML	N62206 003	Apr 20,	1988 May CAHN
>A> AB	EQ 250MG BASE/5ML	N62206 002	May	CAHN
>A> AB +	EQ 375MG BASE/5ML	N62206 004	Apr 20,	1988 May CAHN
>D> AB LILLY	EQ 125MG BASE/5ML	N62206 001	May	CAHN
>D> AB	EQ 187MG BASE/5ML	N62206 003	Apr 20,	1988 May CAHN
>D> AB	EQ 250MG BASE/5ML	N62206 002	May	CAHN
>D> AB +	EQ 375MG BASE/5ML	N62206 004	Apr 20,	1988 May CAHN

CEFIXIME

SUSPENSION; ORAL
 SUPRAX
 + LUPIN 100MG/5ML N65129 001 Feb 23, 2004 Feb NEWA
 TABLET; ORAL
 SUPRAX
 + LUPIN 400MG N65130 001 Feb 12, 2004 Feb NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP ACS DOBFAR	500MG/VIAL	N62640 001	Nov 20,	1985 Apr CTNA
AP	1GM/VIAL	N62640 002	Nov 20,	1985 Apr CTNA
AP	2GM/VIAL	N62640 003	Nov 20,	1985 Apr CTNA
TAZICEF				
>D> AP ABBOTT	500MG/VIAL	N62662 001	Mar 06,	1986 May CAHN
>D> AP	1GM/VIAL	N62662 002	Mar 06,	1986 May CAHN
>D> AP	1GM/VIAL	N64032 001	Oct 31,	1993 May CAHN
>D> AP	2GM/VIAL	N62662 003	Mar 06,	1986 May CAHN
>D> AP	2GM/VIAL	N64032 002	Oct 31,	1993 May CAHN
>D> AP	6GM/VIAL	N62662 004	Mar 06,	1986 May CAHN
>A> AP HOSPIRA	500MG/VIAL	N62662 001	Mar 06,	1986 May CAHN

INJECTABLE; INJECTION

TAZICEF

>A>	AP	HOSPIRA	1GM/VIAL	N62662 002 Mar 06, 1986 May CAHN
>A>	AP		1GM/VIAL	N64032 001 Oct 31, 1993 May CAHN
>A>	AP		2GM/VIAL	N62662 003 Mar 06, 1986 May CAHN
>A>	AP		2GM/VIAL	N64032 002 Oct 31, 1993 May CAHN
>A>	AP		6GM/VIAL	N62662 004 Mar 06, 1986 May CAHN
		TAZIDIME		
	@ LILLY		1GM/VIAL	N62655 001 Nov 20, 1985 Apr DISC
	@		2GM/VIAL	N62655 002 Nov 20, 1985 Apr DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

AB		HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	N65048 001 Jan 09, 2004 Jan NEWA
		INJECTABLE; INJECTION		
		CEFUROXIME		
AP		HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048 002 Jan 09, 2004 Jan NEWA
AP			EQ 7.5GM BASE/VIAL	N65046 001 Jan 09, 2004 Jan NEWA

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

ZYRTEC

PFIZER		5MG	N21621 001 Mar 16, 2004 Mar NEWA
+		10MG	N21621 002 Mar 16, 2004 Mar NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT		MORTON GROVE	0.12%	N75006 001 Mar 03, 2004 Mar NEWA
----	--	--------------	-------	----------------------------------

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HCL

>D>	AP	ABBOTT	2%	N87447 001 Apr 16, 1982 May CAHN
>D>	AP		3%	N87446 001 Apr 16, 1982 May CAHN
>A>	AP	HOSPIRA	2%	N87447 001 Apr 16, 1982 May CAHN
>A>	AP		3%	N87446 001 Apr 16, 1982 May CAHN

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

>D>		SERONO INC	0.25MG/VIAL	N21149 001 Sep 20, 2000 May DISC
>A>	+	@	0.25MG/VIAL	N21149 001 Sep 20, 2000 May DISC

INJECTABLE; SUBCUTANEOUS

OVIDREL

+	SERONO INC	EQ 0.25MG / 0.5ML	N21149 002 Oct 06, 2003 Apr CPOT
---	------------	-------------------	----------------------------------

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

>D>	+	ABBOTT	EQ 0.004MG CHROMIUM/ML	N18961 001 Jun 26, 1986 May CAHN
>A>	+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N18961 001 Jun 26, 1986 May CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

>D>	AP	ABBOTT	EQ 300MG BASE/2ML	N74296 001 Mar 28, 1997 May CAHN
>D>	AP		EQ 300MG BASE/2ML	N74344 001 Jan 31, 1995 May CAHN
>D>	AP		EQ 300MG BASE/2ML	N74345 001 Jan 31, 1995 May CAHN
>D>	AP		EQ 300MG BASE/2ML	N74412 001 Mar 28, 1997 May CAHN
>D>	AP		EQ 300MG BASE/2ML	N74422 001 Jan 31, 1995 May CAHN
>A>	AP	HOSPIRA	EQ 300MG BASE/2ML	N74296 001 Mar 28, 1997 May CAHN
>A>	AP		EQ 300MG BASE/2ML	N74344 001 Jan 31, 1995 May CAHN
>A>	AP		EQ 300MG BASE/2ML	N74345 001 Jan 31, 1995 May CAHN
>A>	AP		EQ 300MG BASE/2ML	N74412 001 Mar 28, 1997 May CAHN
>A>	AP		EQ 300MG BASE/2ML	N74422 001 Jan 31, 1995 May CAHN
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
>D>	AP	ABBOTT	EQ 6MG BASE/ML	N74269 001 Dec 27, 1994 May CAHN
>D>	+		EQ 90MG BASE/100ML	N74468 005 Dec 29, 1994 May CAHN
>D>	+		EQ 120MG BASE/100ML	N74468 006 Dec 29, 1994 May CAHN
>D>	+		EQ 180MG BASE/100ML	N74468 003 Dec 29, 1994 May CAHN
>D>	+		EQ 240MG BASE/100ML	N74468 004 Dec 29, 1994 May CAHN
>D>	+		EQ 360MG BASE/100ML	N74468 001 Dec 29, 1994 May CAHN
>D>	+		EQ 480MG BASE/100ML	N74468 002 Dec 29, 1994 May CAHN
>A>	AP	HOSPIRA	EQ 6MG BASE/ML	N74269 001 Dec 27, 1994 May CAHN
>A>	+		EQ 90MG BASE/100ML	N74468 005 Dec 29, 1994 May CAHN
>A>	+		EQ 120MG BASE/100ML	N74468 006 Dec 29, 1994 May CAHN
>A>	+		EQ 180MG BASE/100ML	N74468 003 Dec 29, 1994 May CAHN
>A>	+		EQ 240MG BASE/100ML	N74468 004 Dec 29, 1994 May CAHN
>A>	+		EQ 360MG BASE/100ML	N74468 001 Dec 29, 1994 May CAHN
>A>	+		EQ 480MG BASE/100ML	N74468 002 Dec 29, 1994 May CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

EQ 30MG BASE

N21688 001 Mar 08, 2004 Mar NEWA

EQ 60MG BASE

N21688 002 Mar 08, 2004 Mar NEWA

+

EQ 90MG BASE

N21688 003 Mar 08, 2004 Mar NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

+ BAYER PHARMS

425.2MG;EQ 574.9MG BASE

N21473 002 Aug 28, 2003 Feb CDFR

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

UROLOGIC G IN PLASTIC CONTAINER

>D>	AT	ABBOTT	3.24GM/100ML;380MG/100ML;430MG/10 OML	N18904 001 May 27, 1983 May CAHN
>A>	AT	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/10 OML	N18904 001 May 27, 1983 May CAHN

CLADRBINE

INJECTABLE; INJECTION

CLADRBINE

AP AM PHARM

1MG/ML

N76571 001 Apr 22, 2004 Apr NEWA

CLARITHROMYCIN

TABLET; ORAL
BIAXIN

>D>	+	ABBOTT	250MG	N50662 001 Oct 31, 1991 May CPTG
>A>	AB	+	250MG	N50662 001 Oct 31, 1991 May CPTG
>D>		+	500MG	N50662 002 Oct 31, 1991 May CPTG
>A>	AB	+	500MG	N50662 002 Oct 31, 1991 May CPTG
>A>		CLARITHROMYCIN		
>A>	AB	ROXANE	250MG	N65178 002 May 25, 2004 May NEWA
>A>	AB		500MG	N65178 001 May 25, 2004 May NEWA

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE

AB	+	TEVA	2.68MG	N73283 001 Jan 31, 1992 Mar CRLD
		TAVIST		
		@ NOVARTIS	2.68MG	N17661 001 Mar DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL

AB		COREPHARMA	EQ 150MG BASE	N65194 001 Mar 22, 2004 Mar NEWA
AB			EQ 300MG BASE	N65194 002 Mar 22, 2004 Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN

>D>		PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N62644 001 Apr 07, 1986 May CRLD
>A>	+		EQ 75MG BASE/5ML	N62644 001 Apr 07, 1986 May CRLD

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

>D>	AP	ABBOTT	EQ 150MG BASE/ML	N62800 001 Jul 24, 1987 May CAHN
>D>	AP		EQ 150MG BASE/ML	N62801 001 Jul 24, 1987 May CAHN
>D>		@	EQ 150MG BASE/ML	N62943 001 Sep 29, 1988 May CAHN
>A>	AP	HOSPIRA	EQ 150MG BASE/ML	N62800 001 Jul 24, 1987 May CAHN
>A>	AP		EQ 150MG BASE/ML	N62801 001 Jul 24, 1987 May CAHN
>A>		@	EQ 150MG BASE/ML	N62943 001 Sep 29, 1988 May CAHN
		SOLUTION; TOPICAL		
		CLINDAMYCIN PHOSPHATE		
AT		TARO PHARM IND'S	EQ 1% BASE	N65184 001 Mar 31, 2004 Mar NEWA

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL
CLOBEK

+	GALDERMA LABS	0.05%	N21644 001 Feb 05, 2004 Feb NEWA
---	---------------	-------	----------------------------------

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
FAZACLO

	ALAMO PHARMS	25MG	N21590 001 Feb 10, 2004 Feb NEWA
+		100MG	N21590 002 Feb 10, 2004 Feb NEWA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP PADDOCK EQ 150MG BASE/VIAL N65177 001 Mar 19, 2004 Mar NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

+ KING PHARMS 0.8MG/INH

N18887 001 Dec 05, 1985 Jan CAHN

SOLUTION; INHALATION

INTAL

AN + KING PHARMS 10MG/ML N18596 001 May 28, 1982 Jan CAHN

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

>D> + ABBOTT EQ 0.4MG COPPER/ML N18960 001 Jun 26, 1986 May CAHN

>A> + HOSPIRA EQ 0.4MG COPPER/ML N18960 001 Jun 26, 1986 May CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP BIONICHE ANIM HLTH 1MG/ML N40451 001 Sep 23, 2003 Apr CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP AM PHARM 100MG/ML N76512 001 Jan 15, 2004 Jan NEWA

AP + MAYNE PHARMA USA 100MG/ML N75383 001 Nov 22, 1999 Jan CFTG

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

>D> AP ABBOTT 500MG/VIAL N76019 001 Mar 17, 2004 May CAHN

AP 500MG/VIAL N76019 001 Mar 17, 2004 Mar NEWA

>D> AP 2GM/VIAL N76019 002 Mar 17, 2004 May CAHN

AP 2GM/VIAL N76019 002 Mar 17, 2004 Mar NEWA

>A> AP HOSPIRA 500MG/VIAL N76019 001 Mar 17, 2004 May CAHN

AP 2GM/VIAL N76019 002 Mar 17, 2004 May CAHN

DESFERAL

AP + NOVARTIS 500MG/VIAL N16267 001 Mar CFTG

AP + 2GM/VIAL N16267 002 May 25, 2000 Mar CFTG

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

AB ESP PHARMA 150MG N50261 002 Mar CFTG

AB + 300MG N50261 003 Mar CFTG

DEMECLOCYCLINE HCL

AB IMPAX LABS 150MG N65094 001 Mar 22, 2004 Mar NEWA

AB 300MG N65094 002 Mar 22, 2004 Mar NEWA

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

IPRIVASK
+ CANYON

15MG/VIAL

N21271 001 Apr 04, 2003 Apr CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

>D> AP ABBOTT 0.004MG/ML N75220 001 Aug 28, 2000 May CAHN
>A> AP HOSPIRA 0.004MG/ML N75220 001 Aug 28, 2000 May CAHNDESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

CYCLESSA

AB + ORGANON USA INC 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.02 5MG, 0.025MG N21090 001 Dec 20, 2000 Feb CFTG

VELIVET

AB DURAMED PHARMS BARR 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.02 5MG, 0.025MG N76455 001 Feb 24, 2004 Feb NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

@ NOVARTIS

0.1%; EQ 3.5MG BASE/ML; 10,000

UNITS/ML

N62544 001 Oct 29, 1984 Apr DISC

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX

>D> + ABBOTT EQ 100UGM BASE/ML N21038 001 Dec 17, 1999 May CAHN
>A> + HOSPIRA EQ 100UGM BASE/ML N21038 001 Dec 17, 1999 May CAHNDEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

>D> AP ABBOTT 10GM/100ML N18080 001 May CAHN
>A> AP HOSPIRA 10GM/100ML N18080 001 May CAHN

DEXTROSE 2.5% IN PLASTIC CONTAINER

>D> B BRAUN 2.5GM/100ML N18358 001 May DISC
>A> @ 2.5GM/100ML N18358 001 May DISC

DEXTROSE 20% IN PLASTIC CONTAINER

>D> AP ABBOTT 20GM/100ML N18564 001 Mar 23, 1982 May CAHN
>A> AP HOSPIRA 20GM/100ML N18564 001 Mar 23, 1982 May CAHN

DEXTROSE 25%

>D> ABBOTT 250MG/ML N19445 002 Nov 23, 1998 May CAHN
>A> HOSPIRA 250MG/ML N19445 002 Nov 23, 1998 May CAHN

DEXTROSE 30% IN PLASTIC CONTAINER

>D> AP ABBOTT 30GM/100ML N19345 001 Jan 26, 1985 May CAHN
>A> AP HOSPIRA 30GM/100ML N19345 001 Jan 26, 1985 May CAHN

DEXTROSE 40% IN PLASTIC CONTAINER

>D> AP ABBOTT 40GM/100ML N18562 001 Mar 23, 1982 May CAHN
>A> AP HOSPIRA 40GM/100ML N18562 001 Mar 23, 1982 May CAHN

DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP ABBOTT 50MG/ML N16367 002 May CAHN
>D> AP 50MG/ML N19222 001 Jul 13, 1984 May CAHN
>D> AP 5GM/100ML N19466 001 Jul 15, 1985 May CAHN
>D> AP 5GM/100ML N19479 001 Sep 17, 1985 May CAHN

INJECTABLE; INJECTIONDEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP	HOSPIRA	50MG/ML	N16367 002	May	CAHN	
>A>	AP		50MG/ML	N19222 001	Jul 13, 1984	May	CAHN
>A>	AP		5GM/100ML	N19466 001	Jul 15, 1985	May	CAHN
>A>	AP		5GM/100ML	N19479 001	Sep 17, 1985	May	CAHN
DEXTROSE 50% IN PLASTIC CONTAINER							
>D>		@ ABBOTT	500MG/ML	N19445 001	Jun 03, 1986	May	CAHN
>D>	AP		50GM/100ML	N18563 001	Mar 23, 1982	May	CAHN
>D>	AP		50GM/100ML	N19894 001	Dec 26, 1989	May	CAHN
>A>		@ HOSPIRA	500MG/ML	N19445 001	Jun 03, 1986	May	CAHN
>A>	AP		50GM/100ML	N18563 001	Mar 23, 1982	May	CAHN
>A>	AP		50GM/100ML	N19894 001	Dec 26, 1989	May	CAHN
DEXTROSE 60% IN PLASTIC CONTAINER							
>D>	AP	ABBOTT	60GM/100ML	N19346 001	Jan 25, 1985	May	CAHN
>A>	AP	HOSPIRA	60GM/100ML	N19346 001	Jan 25, 1985	May	CAHN
DEXTROSE 70% IN PLASTIC CONTAINER							
>D>	AP	ABBOTT	70GM/100ML	N18561 001	Mar 23, 1982	May	CAHN
>D>	AP		70GM/100ML	N19893 001	Dec 26, 1989	May	CAHN
>A>	AP	HOSPIRA	70GM/100ML	N18561 001	Mar 23, 1982	May	CAHN
>A>	AP		70GM/100ML	N19893 001	Dec 26, 1989	May	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTIONNORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>		ABBOTT	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610 001	May	CAHN
>A>		HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610 001	May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATEINJECTABLE; INJECTION

>D>		ISOLYTE P W/ DEXTROSE 5%	IN PLASTIC CONTAINER				
>D>		B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19025 001	Dec 27, 1984	May	DISC
>A>		@	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19025 001	Dec 27, 1984	May	DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE; INJECTIONIONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>		ABBOTT	5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100 ML;16MG/100ML	N19515 001	May 08, 1986	May	CAHN
>A>		HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100 ML;16MG/100ML	N19515 001	May 08, 1986	May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE; INJECTIONIONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>		ABBOTT	5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML	N19513 001	May 08, 1986	May	CAHN
>A>		HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML	N19513 001	May 08, 1986	May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;2 20MG/100ML;140MG/100ML	N18273 001	May	DISC
>A>	@	5GM/100ML;30MG/100ML;97MG/100ML;2 20MG/100ML;140MG/100ML	N18273 001	May	DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	ABBOTT	5GM/100ML;30MG/100ML;37MG/100ML;2 22MG/100ML;526MG/100ML;502MG/100M L	N17609 001	May	CAHN
>A>	HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;2 22MG/100ML;526MG/100ML;502MG/100M L	N17609 001	May	CAHN

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	ABBOTT	5GM/100ML;149MG/100ML	N18371 001	May	CAHN
>A>	HOSPIRA	5GM/100ML;149MG/100ML	N18371 001	May	CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D> AP	ABBOTT	5GM/100ML;224MG/100ML	N18371 003	May	CAHN
>A> AP	HOSPIRA	5GM/100ML;224MG/100ML	N18371 003	May	CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	ABBOTT	5GM/100ML;298MG/100ML	N18371 002	May	CAHN
>A>	HOSPIRA	5GM/100ML;298MG/100ML	N18371 002	May	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	ABBOTT	5GM/100ML;111MG/100ML;256MG/100ML ;146MG/100ML;207MG/100ML	N19514 001	May 08, 1986	May CAHN
>A>	HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML ;146MG/100ML;207MG/100ML	N19514 001	May 08, 1986	May CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML ;280MG/100ML;91MG/100ML	N18270 001	May	DISC
>A>	@	5GM/100ML;150MG/100ML;130MG/100ML ;280MG/100ML;91MG/100ML	N18270 001	May	DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	ABBOTT	5GM/100ML;74.5MG/100ML;225MG/100M L	N18365 002	Jul 05, 1983	May CAHN
>D>		5GM/100ML;149MG/100ML;225MG/100ML	N18365 006	Mar 28, 1988	May CAHN
>A>	HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100M L	N18365 002	Jul 05, 1983	May CAHN
>A>		5GM/100ML;149MG/100ML;225MG/100ML	N18365 006	Mar 28, 1988	May CAHN
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
>D>	ABBOTT	5GM/100ML;74.5MG/100ML;300MG/100M L	N18876 001	Jan 17, 1986	May CAHN
>D>		5GM/100ML;149MG/100ML;300MG/100ML	N18876 006	Mar 28, 1988	May CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>A> HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100M N18876 001 Jan 17, 1986 May CAHN
L

>A> 5GM/100ML;149MG/100ML;300MG/100ML N18876 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D> AP ABBOTT 5GM/100ML;74.5MG/100ML;450MG/100M N18362 005 Mar 28, 1988 May CAHN
L

>D> AP 5GM/100ML;74.5MG/100ML;450MG/100M N18362 009 Jul 05, 1983 May CAHN
L

>A> AP HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100M N18362 005 Mar 28, 1988 May CAHN
L

>A> AP 5GM/100ML;74.5MG/100ML;450MG/100M N18362 009 Jul 05, 1983 May CAHN
L

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP ABBOTT 5GM/100ML;74.5MG/100ML;900MG/100M N19691 002 Mar 24, 1988 May CAHN
L

>D> AP 5GM/100ML;149MG/100ML;900MG/100ML N19691 004 Mar 24, 1988 May CAHN

>A> AP HOSPIRA 5GM/100ML;74.5MG/100ML;900MG/100M N19691 002 Mar 24, 1988 May CAHN
L

>A> AP 5GM/100ML;149MG/100ML;900MG/100ML N19691 004 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D> ABBOTT 5GM/100ML;224MG/100ML;225MG/100M N18365 008 Mar 28, 1988 May CAHN

>A> HOSPIRA 5GM/100ML;224MG/100ML;225MG/100M N18365 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>D> ABBOTT 5GM/100ML;224MG/100ML;300MG/100M N18876 007 Mar 28, 1988 May CAHN

>A> HOSPIRA 5GM/100ML;224MG/100ML;300MG/100M N18876 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D> AP ABBOTT 5GM/100ML;224MG/100ML;450MG/100M N18362 006 Mar 28, 1988 May CAHN

>A> AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100M N18362 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP ABBOTT 5GM/100ML;224MG/100ML;900MG/100M N19691 006 Mar 24, 1988 May CAHN

>A> AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100M N19691 006 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D> ABBOTT 5GM/100ML;149MG/100ML;225MG/100M N18365 001 May CAHN

>D> 5GM/100ML;298MG/100ML;225MG/100M N18365 009 Mar 28, 1988 May CAHN

>A> HOSPIRA 5GM/100ML;149MG/100ML;225MG/100M N18365 001 May CAHN

>A> 5GM/100ML;298MG/100ML;225MG/100M N18365 009 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>D> ABBOTT 5GM/100ML;298MG/100ML;300MG/100M N18876 008 Mar 28, 1988 May CAHN

>A> HOSPIRA 5GM/100ML;298MG/100ML;300MG/100M N18876 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D> AP ABBOTT 5GM/100ML;149MG/100ML;450MG/100M N18362 010 Jul 05, 1983 May CAHN

>D> AP 5GM/100ML;298MG/100ML;450MG/100M N18362 007 Mar 28, 1988 May CAHN

>A> AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100M N18362 010 Jul 05, 1983 May CAHN

>A> AP 5GM/100ML;298MG/100ML;450MG/100M N18362 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP ABBOTT 5GM/100ML;149MG/100ML;900MG/100M N19691 005 Mar 24, 1988 May CAHN

>D> AP 5GM/100ML;298MG/100ML;900MG/100M N19691 008 Mar 24, 1988 May CAHN

>A> AP HOSPIRA 5GM/100ML;149MG/100ML;900MG/100M N19691 005 Mar 24, 1988 May CAHN

>A> AP 5GM/100ML;298MG/100ML;900MG/100M N19691 008 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>D> ABBOTT 5GM/100ML;149MG/100ML;300MG/100M N18876 002 Jan 17, 1986 May CAHN

>A> HOSPIRA 5GM/100ML;149MG/100ML;300MG/100M N18876 002 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D> ABBOTT 5GM/100ML;224MG/100ML;225MG/100M N18365 003 Jul 05, 1983 May CAHN

>A> HOSPIRA 5GM/100ML;224MG/100ML;225MG/100M N18365 003 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>D> ABBOTT 5GM/100ML;224MG/100ML;300MG/100M N18876 003 Jan 17, 1986 May CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
>A> HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 003 Jan 17, 1986 May CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;224MG/100ML;450MG/100ML N18362 002 May CAHN
>A> AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 002 May CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;224MG/100ML;900MG/100ML N19691 007 Mar 24, 1988 May CAHN
>A> AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100ML N19691 007 Mar 24, 1988 May CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;298MG/100ML;225MG/100ML N18365 004 Jul 05, 1983 May CAHN
>A> HOSPIRA 5GM/100ML;298MG/100ML;225MG/100ML N18365 004 Jul 05, 1983 May CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;298MG/100ML;300MG/100ML N18876 004 Mar 28, 1988 May CAHN
>A> HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N18876 004 Mar 28, 1988 May CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;298MG/100ML;450MG/100ML N18362 003 May CAHN
>A> AP HOSPIRA 5GM/100ML;298MG/100ML;450MG/100ML N18362 003 May CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;298MG/100ML;900MG/100ML N19691 009 Mar 24, 1988 May CAHN
>A> AP HOSPIRA 5GM/100ML;298MG/100ML;900MG/100ML N19691 009 Mar 24, 1988 May CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;74.5MG/100ML;225MG/100M N18365 005 Mar 28, 1988 May CAHN
L
>D> HOSPIRA 5GM/100ML;149MG/100ML;225MG/100ML N18365 007 Mar 28, 1988 May CAHN
>A> HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100M N18365 005 Mar 28, 1988 May CAHN
L
>A> HOSPIRA 5GM/100ML;149MG/100ML;225MG/100ML N18365 007 Mar 28, 1988 May CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;74.5MG/100ML;300MG/100M N18876 005 Mar 28, 1988 May CAHN
L
>D> HOSPIRA 5GM/100ML;149MG/100ML;300MG/100ML N18876 009 Mar 28, 1988 May CAHN
>A> HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100M N18876 005 Mar 28, 1988 May CAHN
L
>A> HOSPIRA 5GM/100ML;149MG/100ML;300MG/100ML N18876 009 Mar 28, 1988 May CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;74.5MG/100ML;450MG/100M N18362 008 Mar 28, 1988 May CAHN
L
>D> AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100ML N18362 004 Mar 28, 1988 May CAHN
>A> AP HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100M N18362 008 Mar 28, 1988 May CAHN
L
>A> AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100ML N18362 004 Mar 28, 1988 May CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;74.5MG/100ML;900MG/100M N19691 001 Mar 24, 1988 May CAHN
L
>D> AP HOSPIRA 5GM/100ML;149MG/100ML;900MG/100ML N19691 003 Mar 24, 1988 May CAHN
>A> AP HOSPIRA 5GM/100ML;74.5MG/100ML;900MG/100M N19691 001 Mar 24, 1988 May CAHN
L
>A> AP HOSPIRA 5GM/100ML;149MG/100ML;900MG/100ML N19691 003 Mar 24, 1988 May CAHN

DEXTROSE; SODIUM CHLORIDEINJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
>D> AP ABBOTT 2.5GM/100ML;450MG/100ML N18096 001 May CAHN
>A> AP HOSPIRA 2.5GM/100ML;450MG/100ML N18096 001 May CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;225MG/100ML N17606 001 May CAHN
>A> AP HOSPIRA 5GM/100ML;225MG/100ML N17606 001 May CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
>D> AP ABBOTT 5GM/100ML;300MG/100ML N17799 001 May CAHN

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>A>	HOSPIRA	5GM/100ML;300MG/100ML	N17799 001	May CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
>D> AP	ABBOTT	5GM/100ML;450MG/100ML	N17607 001	May CAHN
>A> AP	HOSPIRA	5GM/100ML;450MG/100ML	N17607 001	May CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
>D> AP	ABBOTT	5GM/100ML;900MG/100ML	N17585 001	May CAHN
>A> AP		5GM/100ML;900MG/100ML	N17585 001	May CAHN

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION				
HYPAQUE				
>D> AP	+ AMERSHAM HLTH	30%	N16403 002	May DISC
>A>	@ GE HEALTHCARE	30%	N16403 002	May DISC
RENO-DIP				
>D> AP	+ BRACCO	30%	N10040 012	May CRLD
>A>	+	30%	N10040 012	May CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION				
HYPAQUE-76				
>D> AP	AMERSHAM HLTH	66%;10%	N86505 001	May DISC
>A>	@ GE HEALTHCARE	66%;10%	N86505 001	May DISC

DIAZEPAM

INJECTABLE; INJECTION			
DIAZEPAM			
>D> AP	+ ABBOTT	5MG/ML	N71583 001 Oct 13, 1987 May CAHN
>D> AP		5MG/ML	N71584 001 Oct 13, 1987 May CAHN
>D> AP		5MG/ML	N72079 001 Dec 20, 1988 May CAHN
>A> AP	+ HOSPIRA	5MG/ML	N71583 001 Oct 13, 1987 May CAHN
>A> AP		5MG/ML	N71584 001 Oct 13, 1987 May CAHN
>A> AP		5MG/ML	N72079 001 Dec 20, 1988 May CAHN
AP	PARENTA PHARMS	5MG/ML	N76815 001 Apr 15, 2004 Apr NEWA

DICLOFENAC POTASSIUM

TABLET; ORAL			
DICLOFENAC POTASSIUM			
AB	TORPHARM	50MG	N76561 001 Mar 18, 2004 Mar NEWA

DICLOXACILLIN SODIUM

CAPSULE; ORAL				
DICLOXACILLIN SODIUM				
AB	SANDOZ	EQ 125MG BASE	N61454 002	Mar CAHN
AB		EQ 250MG BASE	N61454 001	Mar CAHN
AB	+	EQ 500MG BASE	N61454 003	Mar CAHN

DIGOXIN

INJECTABLE; INJECTION			
DIGOXIN			
>D> AP	ABBOTT	0.25MG/ML	N40093 001 May 16, 1996 May CAHN
>D> AP		0.25MG/ML	N40206 001 Aug 28, 1998 May CAHN
>A> AP	HOSPIRA	0.25MG/ML	N40093 001 May 16, 1996 May CAHN
>A> AP		0.25MG/ML	N40206 001 Aug 28, 1998 May CAHN

INJECTABLE; INJECTION

DIGOXIN PEDIATRIC

>D>	AP	ABBOTT	0.1MG/ML	N40092 001 Apr 25, 1996 May CAHN
>A>	AP	HOSPIRA	0.1MG/ML	N40092 001 Apr 25, 1996 May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILT-CD

>A>	AB3	TORPHARM	120MG	N76151 001 May 20, 2004 May NEWA
>A>	AB3		180MG	N76151 002 May 20, 2004 May NEWA
>A>	AB3		240MG	N76151 003 May 20, 2004 May NEWA
>A>	AB3		300MG	N76151 004 May 20, 2004 May NEWA

INJECTABLE; INJECTION

DILTIAZEM HCL

>D>	AP	ABBOTT	5MG/ML	N74941 001 Apr 15, 1998 May CAHN
>D>	AP		5MG/ML	N75004 001 Feb 16, 2000 May CAHN
>D>	AP		100MG/VIAL	N75853 001 Dec 17, 2002 May CAHN
>A>	AP	HOSPIRA	5MG/ML	N74941 001 Apr 15, 1998 May CAHN
>A>	AP		5MG/ML	N75004 001 Feb 16, 2000 May CAHN
>A>	AP		100MG/VIAL	N75853 001 Dec 17, 2002 May CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

BIOVAIL	120MG	N21392 001 Feb 06, 2003 Jan CRLD
	180MG	N21392 002 Feb 06, 2003 Jan CRLD
	240MG	N21392 003 Feb 06, 2003 Jan CRLD
	300MG	N21392 004 Feb 06, 2003 Jan CRLD
	360MG	N21392 005 Feb 06, 2003 Jan CRLD

DIMYRISTOYL LECITHIN; PERPLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+ IMCOR PH	0.92MG/VIAL;0.092MG/VIAL	N21191 001 May 31, 2002 Feb CAHN
------------	--------------------------	----------------------------------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

>D>	AP	ABBOTT	50MG/ML	N40140 001 Nov 20, 1998 May CAHN
>A>	AP	HOSPIRA	50MG/ML	N40140 001 Nov 20, 1998 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>D>	AP	ABBOTT	5MG/ML	N74601 001 Dec 19, 1997 May CAHN
>A>	AP	HOSPIRA	5MG/ML	N74601 001 Dec 19, 1997 May CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

ABBOTT	EQ 125MG VALPROIC ACID	N18723 003 Oct 26, 1984 Jan CRLD
	EQ 250MG VALPROIC ACID	N18723 001 Mar 10, 1983 Jan CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

>D>	AP	ABBOTT	EQ 12.5MG BASE/ML	N74086 001 Nov 29, 1993 May CAHN
>D>	AP		EQ 12.5MG BASE/ML	N74292 001 Feb 16, 1995 May CAHN

INJECTABLE; INJECTION

DOBUTAMINE HCL

>D>	AP	ABBOTT	EQ 1.25GM BASE/100ML	N74634 001 Sep 27, 1996 May CAHN
>A>	AP	HOSPIRA	EQ 12.5MG BASE/ML	N74086 001 Nov 29, 1993 May CAHN
>A>	AP		EQ 12.5MG BASE/ML	N74292 001 Feb 16, 1995 May CAHN
>A>	AP		EQ 1.25GM BASE/100ML	N74634 001 Sep 27, 1996 May CAHN
DOBUTAMINE HCL IN DEXTROSE 5%				
>D>	AP	+ ABBOTT	EQ 50MG BASE/100ML	N20269 001 Oct 19, 1993 May CAHN
>D>	AP	+	EQ 100MG BASE/100ML	N20269 002 Oct 19, 1993 May CAHN
>D>	AP	+	EQ 200MG BASE/100ML	N20269 003 Oct 19, 1993 May CAHN
>A>	AP	+ HOSPIRA	EQ 50MG BASE/100ML	N20269 001 Oct 19, 1993 May CAHN
>A>	AP	+	EQ 100MG BASE/100ML	N20269 002 Oct 19, 1993 May CAHN
>A>	AP	+	EQ 200MG BASE/100ML	N20269 003 Oct 19, 1993 May CAHN
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER				
>D>	AP	+ ABBOTT	EQ 50MG BASE/100ML	N20201 003 Oct 19, 1993 May CAHN
>D>	AP	+	EQ 100MG BASE/100ML	N20201 002 Oct 19, 1993 May CAHN
>D>	AP	+	EQ 200MG BASE/100ML	N20201 001 Oct 19, 1993 May CAHN
>D>	AP	+	EQ 400MG BASE/100ML	N20201 006 Jul 07, 1994 May CAHN
>A>	AP	+ HOSPIRA	EQ 50MG BASE/100ML	N20201 003 Oct 19, 1993 May CAHN
>A>	AP	+	EQ 100MG BASE/100ML	N20201 002 Oct 19, 1993 May CAHN
>A>	AP	+	EQ 200MG BASE/100ML	N20201 001 Oct 19, 1993 May CAHN
>A>	AP	+	EQ 400MG BASE/100ML	N20201 006 Jul 07, 1994 May CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

>D>	AP	+ ABBOTT	40MG/ML	N18132 001 May CAHN
>D>	AP		40MG/ML	N74403 001 May 23, 1996 May CAHN
>D>	AP	+	80MG/100ML	N18132 002 Feb 04, 1982 May CAHN
>D>	AP	+	80MG/ML	N18132 004 Jul 09, 1982 May CAHN
>D>	AP	+	160MG/100ML	N18132 003 Feb 04, 1982 May CAHN
>A>	AP	+ HOSPIRA	40MG/ML	N18132 001 May CAHN
>A>	AP		40MG/ML	N74403 001 May 23, 1996 May CAHN
>A>	AP	+	80MG/100ML	N18132 002 Feb 04, 1982 May CAHN
>A>	AP	+	80MG/ML	N18132 004 Jul 09, 1982 May CAHN
>A>	AP	+	160MG/100ML	N18132 003 Feb 04, 1982 May CAHN
DOPAMINE HCL IN DEXTROSE 5%				
>D>	AP	+ ABBOTT	1.6MG/ML	N20542 001 Aug 30, 1995 May CAHN
>A>	AP	+ HOSPIRA	1.6MG/ML	N20542 001 Aug 30, 1995 May CAHN
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER				
>D>	AP	+ ABBOTT	80MG/100ML	N18826 001 Sep 30, 1983 May CAHN
>D>	AP	+	160MG/100ML	N18826 002 Sep 30, 1983 May CAHN
>D>	AP	+	320MG/100ML	N18826 003 Sep 30, 1983 May CAHN
>A>	AP	+ HOSPIRA	80MG/100ML	N18826 001 Sep 30, 1983 May CAHN
>A>	AP	+	160MG/100ML	N18826 002 Sep 30, 1983 May CAHN
>A>	AP	+	320MG/100ML	N18826 003 Sep 30, 1983 May CAHN

DOXEPEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPEPIN HCL

AA	PHARM ASSOC	EQ 10MG BASE/ML	N75924 001 Jan 15, 2004 Jan NEWA
----	-------------	-----------------	----------------------------------

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

BONE CARE

0.5UG/ML

N20862 002 Apr 23, 2004 Apr NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	WATSON LABS	EQ 50MG BASE	N65041 001 Apr 28, 2000 Apr CAHN
AB		EQ 100MG BASE	N65041 002 Apr 28, 2000 Apr CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	WATSON LABS	EQ 50MG BASE	N61717 001 Apr CAHN
AB		EQ 100MG BASE	N61717 002 Apr CAHN

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

>D>	AP	ABBOTT	2.5MG/ML	N71981 001 Feb 29, 1988 May CAHN
>D>	AP		2.5MG/ML	N72272 001 Aug 31, 1995 May CAHN
>A>	AP	HOSPIRA	2.5MG/ML	N71981 001 Feb 29, 1988 May CAHN
>A>	AP		2.5MG/ML	N72272 001 Aug 31, 1995 May CAHN

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

>D>	+	ABBOTT	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001 May 04, 1988 May CAHN
>A>	+	HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001 May 04, 1988 May CAHN

EDETATE DISODIUM

INJECTABLE; INJECTION

EDNTRATE

>D>	AP	+	ABBOTT	150MG/ML	N11355 001 May CAHN
>A>	AP	+	HOSPIRA	150MG/ML	N11355 001 May CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

>D>	AP	ABBOTT	10MG/ML	N40131 001 Feb 24, 1998 May CAHN
>A>	AP	HOSPIRA	10MG/ML	N40131 001 Feb 24, 1998 May CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

>D>	AP	ABBOTT	1.25MG/ML	N75456 001 Aug 22, 2000 May CAHN
>D>	AP		1.25MG/ML	N75458 001 Aug 22, 2000 May CAHN
>A>	AP	HOSPIRA	1.25MG/ML	N75456 001 Aug 22, 2000 May CAHN
>A>	AP		1.25MG/ML	N75458 001 Aug 22, 2000 May CAHN

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

>A>	+	HOLLISTER STIER LABS	EQ 0.15MG /DELIVERY	N20800 002 May 28, 2004 May NEWA
-----	---	----------------------	---------------------	----------------------------------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

>D>	AP	ABBOTT	0.005MG/ML;0.5%	N89635 001 Jun 21, 1988 May CAHN
-----	----	--------	-----------------	----------------------------------

INJECTABLE; INJECTIONLIDOCAINE HCL AND EPINEPHRINE

>D>	AP	ABBOTT	0.005MG/ML;1%	N89649 001 Jun 21, 1988 May CAHN
>D>	AP		0.005MG/ML;1.5%	N88571 001 Sep 13, 1985 May CAHN
>D>	AP		0.005MG/ML;1.5%	N89645 001 Jun 21, 1988 May CAHN
>D>	AP		0.005MG/ML;1.5%	N89650 001 Jun 21, 1988 May CAHN
>D>	AP		0.005MG/ML;2%	N89651 001 Jun 21, 1988 May CAHN
>D>	AP		0.01MG/ML;1%	N89644 001 Jun 21, 1988 May CAHN
>D>	AP		0.01MG/ML;2%	N89646 001 Jun 21, 1988 May CAHN
>A>	AP	HOSPIRA	0.005MG/ML;0.5%	N89635 001 Jun 21, 1988 May CAHN
>A>	AP		0.005MG/ML;1%	N89649 001 Jun 21, 1988 May CAHN
>A>	AP		0.005MG/ML;1.5%	N88571 001 Sep 13, 1985 May CAHN
>A>	AP		0.005MG/ML;1.5%	N89645 001 Jun 21, 1988 May CAHN
>A>	AP		0.005MG/ML;1.5%	N89650 001 Jun 21, 1988 May CAHN
>A>	AP		0.005MG/ML;2%	N89651 001 Jun 21, 1988 May CAHN
>A>	AP		0.01MG/ML;1%	N89644 001 Jun 21, 1988 May CAHN
>A>	AP		0.01MG/ML;2%	N89646 001 Jun 21, 1988 May CAHN
>A>	PATCH; IONTOPHORESIS			
>A>	LIDOSITE TOPICAL SYSTEM KIT			
>A>	+ VYTERIS	1.05MG/PATCH;100MG/PATCH		N21504 001 May 06, 2004 May NEWA

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS; ORAL
ERYC

AB	WARNER CHILCOTT	250MG	N62338 001	Jan CMFD
----	-----------------	-------	------------	----------

ERYTHROMYCIN ESTOLATESUSPENSION; ORALERYTHROMYCIN ESTOLATE

ALPHARMA	EQ 125MG BASE/5ML	N62353 001 Nov 18, 1982 Jan CTEC
+	EQ 250MG BASE/5ML	N62409 001 Dec 16, 1982 Jan CRLD
ILOSONE		
@ LILLY	EQ 125MG BASE/5ML	N50010 001 Jan DISC
@	EQ 250MG BASE/5ML	N50010 002 Jan DISC

ERYTHROMYCIN LACTOBIONATEINJECTABLE; INJECTIONERYTHROCIN

>D>	AP	+	ABBOTT	EQ 500MG BASE/VIAL	N50182 002 May CAHN
>D>	AP			EQ 500MG BASE/VIAL	N50609 001 Sep 24, 1986 May CAHN
>D>	AP			EQ 500MG BASE/VIAL	N62638 001 Oct 31, 1986 May CAHN
>D>	AP	+		EQ 1GM BASE/VIAL	N50182 003 May CAHN
>D>	AP			EQ 1GM BASE/VIAL	N50609 002 Sep 24, 1986 May CAHN
>D>	AP			EQ 1GM BASE/VIAL	N62638 002 Oct 31, 1986 May CAHN
>A>	AP	+	HOSPIRA	EQ 500MG BASE/VIAL	N50182 002 May CAHN
>A>	AP			EQ 500MG BASE/VIAL	N50609 001 Sep 24, 1986 May CAHN
>A>	AP			EQ 500MG BASE/VIAL	N62638 001 Oct 31, 1986 May CAHN
>A>	AP	+		EQ 1GM BASE/VIAL	N50182 003 May CAHN
>A>	AP			EQ 1GM BASE/VIAL	N50609 002 Sep 24, 1986 May CAHN
>A>	AP			EQ 1GM BASE/VIAL	N62638 002 Oct 31, 1986 May CAHN

ESCITALOPRAM OXALATETABLET; ORALLEXAPRO

FOREST LABS

5MG

N21323 001 Aug 14, 2002 Apr CMFD

ESTRADIOL

GEL, METERED; TOPICAL ESTROGEL SOLVAY	0.06%	N21166 002 Feb 09, 2004 Feb NEWA
GEL; TOPICAL ESTROGEL + SOLVAY	0.06% 0.06%	N21166 001 Feb 09, 2004 Mar CRLD N21166 001 Feb 09, 2004 Feb NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL FEMRING >D> GALEN LTD	0.05MG/24HR	N21367 001 Mar 20, 2003 May CPOT
>A>	EQ 0.05MG BASE/24HR	N21367 001 Mar 20, 2003 May CPOT
>D> +	0.1MG/24HR	N21367 002 Mar 20, 2003 May CPOT
>A> +	EQ 0.1MG BASE/24HR	N21367 002 Mar 20, 2003 May CPOT

ESTROGENS, CONJUGATED

TABLET; ORAL PREMARIN >D> WYETH PHARMS INC	2.5MG	N04782 002 May DISC
>A> @	2.5MG	N04782 002 May DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL CENESTIN DURAMED	0.45MG	N20992 005 Feb 05, 2004 Feb NEWA
-------------------------------------	--------	----------------------------------

>A> ESTROGENS, CONJUGATED SYNTHETIC B
 >A> TABLET; ORAL
 >A> ENJUVIA
 >A> DURAMED 0.625MG N21443 003 May 10, 2004 May NEWA
 >A> + 1.25MG N21443 004 May 10, 2004 May NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL MYAMBUTOL >D> @ ELAN PHARMS	100MG	N16320 001 May CMFD
@	100MG	N16320 001 Feb CAHN
>D> @	200MG	N16320 002 May CAHN
@	200MG	N16320 002 Feb CAHN
>D> @	400MG	N16320 003 May CMFD
@	400MG	N16320 003 Feb CAHN
>D> @	500MG	N16320 004 May CAHN
@	500MG	N16320 004 Feb CAHN
>A> AB STAT TRADE	100MG	N16320 001 May CMFD
>A> @	200MG	N16320 002 May CAHN
>A> AB	400MG	N16320 003 May CMFD
>A> @	500MG	N16320 004 May CAHN

ETHINYL ESTRADIOL

TABLET; ORAL ESTINYL @ SCHERING	0.02MG	N05292 001 Apr DISC
@	0.05MG	N05292 002 Apr DISC

TABLET; ORAL

ESTINYL

@ SCHERING

0.5MG

N05292 003

Apr DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

PREVEN EMERGENCY CONTRACEPTIVE KIT

+ DURAMED

0.05MG;0.25MG

N20946 001 Sep 01, 1998 Feb CAHN

TABLET; ORAL-21

LEVYLITE

>D> AB + BERLEX

0.02MG;0.1MG

N20860 001 Jul 13, 1998 May CTEC

>A> AB2 +

0.02MG;0.1MG

N20860 001 Jul 13, 1998 May CTEC

TABLET; ORAL-28

LESSINA-28

>D> AB BARR

0.02MG;0.1MG

N75803 002 Mar 20, 2002 May CTEC

>A> AB2

0.02MG;0.1MG

N75803 002 Mar 20, 2002 May CTEC

LEVYLITE

>D> AB BERLEX

0.02MG;0.1MG

N20860 002 Jul 13, 1998 May CTEC

>A> AB2

0.02MG;0.1MG

N20860 002 Jul 13, 1998 May CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

AB BARR

0.035MG;0.4MG

N76198 001 Apr 22, 2004 Apr NEWA

OVCON-35

AB + WARNER CHILCOTT

0.035MG;0.4MG

N18127 001 Apr CPTG

TABLET; ORAL-28

BALZIVA-28

AB BARR

0.035MG;0.4MG

N76238 001 Apr 22, 2004 Apr NEWA

ORTHO-NOVUM 1/35-28

AB + ORTHO MCNEIL PHARM

0.035MG;1MG

N17919 002 Mar CRLD

OVCON-35

AB + WARNER CHILCOTT

0.035MG;0.4MG

N17716 001 Apr CPTG

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

PREVIFEM

AB ANDRX PHARMS

0.035MG;0.25MG

N76334 001 Jan 09, 2004 Jan NEWA

TRI-PREVIFEM

AB ANDRX PHARMS

0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG N76335 001 Mar 26, 2004 Mar NEWA

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

>D> AB + WYETH PHARMS INC

400MG

N20584 001 Oct 25, 1996 May CRLD

>A> AB 400MG

N20584 001 Oct 25, 1996 May CRLD

>D> AB + 500MG

N20584 003 Jan 20, 1998 May CRLD

>A> AB 500MG

N20584 003 Jan 20, 1998 May CRLD

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

>D> AP + ABBOTT

2MG/ML

N18227 001 Sep 07, 1982 May CAHN

>A> AP + HOSPIRA

2MG/ML

N18227 001 Sep 07, 1982 May CAHN

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

>D>	AP	ABBOTT	20MG/ML	N74320 001 Aug 30, 1995 May CAHN
>D>	AP		20MG/ML	N74351 001 Aug 30, 1995 May CAHN
>A>	AP	HOSPIRA	20MG/ML	N74320 001 Aug 30, 1995 May CAHN
>A>	AP		20MG/ML	N74351 001 Aug 30, 1995 May CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D>	AP	ABBOTT	10MG/ML	N75870 001 Nov 23, 2001 May CAHN
>D>	AP		10MG/ML	N75905 001 Nov 23, 2001 May CAHN
>A>	AP	HOSPIRA	10MG/ML	N75870 001 Nov 23, 2001 May CAHN
>A>	AP		10MG/ML	N75905 001 Nov 23, 2001 May CAHN

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CROLOPAM

>D>	AP	+	ABBOTT	EQ 10MG BASE/ML	N19922 001 Sep 23, 1997 May CAHN
>A>	AP	+	HOSPIRA	EQ 10MG BASE/ML	N19922 001 Sep 23, 1997 May CAHN

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

>D>	AP	ABBOTT	EQ 0.05MG BASE/ML	N19115 001 Jan 12, 1985 May CAHN	
>A>	AP	HOSPIRA	EQ 0.05MG BASE/ML	N19115 001 Jan 12, 1985 May CAHN	
FENTANYL CITRATE PRESERVATIVE FREE					
>D>	AP	ABBOTT	EQ 0.05MG BASE/ML	N72786 001 Sep 24, 1991 May CAHN	
>A>	AP	HOSPIRA	EQ 0.05MG BASE/ML	N72786 001 Sep 24, 1991 May CAHN	

TROCHE/LOZENGE; ORAL

ACTIQ

CEPHALON

		EQ 0.2MG BASE	N20747 001 Nov 04, 1998 Feb CAHN
		EQ 0.4MG BASE	N20747 002 Nov 04, 1998 Feb CAHN
		EQ 0.6MG BASE	N20747 003 Nov 04, 1998 Feb CAHN
		EQ 0.8MG BASE	N20747 004 Nov 04, 1998 Feb CAHN
		EQ 1.2MG BASE	N20747 005 Nov 04, 1998 Feb CAHN
+		EQ 1.6MG BASE	N20747 006 Nov 04, 1998 Feb CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

+	GENSIA SICOR PHARMS	50MG/2ML (25MG/ML)	N76661 001 Apr 28, 2004 Apr NEWA
---	---------------------	--------------------	----------------------------------

>D> FLUDEOXYGLUCOSE, F-18

>D> INJECTABLE; INJECTION

>D> FLUDEOXYGLUCOSE F 18

>D> + DOWNSTATE CLINCL

4-90mCi/ML

N20306 002 Sep 25, 2001 May DISC

>A>

@

4-90mCi/ML

N20306 002 Sep 25, 2001 May DISC

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE HCL

>A>	AA	PAR PHARM	EQ 20MG BASE/5ML	N76458 001 May 14, 2004 May NEWA
-----	----	-----------	------------------	----------------------------------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ MAYNE PHARMA USA 25MG/ML

N74966 001 Apr 16, 1998 Apr CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

>A> GLAXOSMITHKLINE 0.044MG/INH
>A> + 0.11MG/INH
>A> + 0.22MG/INHN21433 003 May 14, 2004 May NEWA
N21433 002 May 14, 2004 May NEWA
N21433 001 May 14, 2004 May NEWA

CREAM; TOPICAL

CUTIVATE

>D> + GLAXOSMITHKLINE 0.05%

N19958 001 Dec 18, 1990 May CFTG

>A> AB + 0.05%

N19958 001 Dec 18, 1990 May CFTG

>A> FLUTICASONE PROPIONATE

>A> AB ALTANA 0.05%

N76451 001 May 14, 2004 May NEWA

>A> AB ATRIX 0.05%

N76633 001 May 14, 2004 May NEWA

>A> AB CLAY PARK 0.05%

N76793 001 May 14, 2004 May NEWA

OINTMENT; TOPICAL

CUTIVATE

>D> + GLAXOSMITHKLINE 0.005%

N19957 001 Dec 14, 1990 May CFTG

>A> AB + 0.005%

N19957 001 Dec 14, 1990 May CFTG

>A> FLUTICASONE PROPIONATE

>A> AB ALTANA 0.005%

N76300 001 May 14, 2004 May NEWA

>A> AB CLAY PARK 0.005%

N76668 001 May 14, 2004 May NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC

FOLLISTIM

BX ORGANON USA INC 75 IU/VIAL

N20582 001 Sep 29, 1997 Mar CDFR

BX + 150 IU/VIAL

N20582 002 Sep 29, 1997 Mar CDFR

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC 300 IU/0.525ML

N21211 001 Mar 23, 2004 Mar NEWA

+ 600 IU/0.885ML

N21211 002 Mar 23, 2004 Mar NEWA

GONAL-F

>D> SERONO INC 37.5 IU/VIAL

N21765 001 Mar 25, 2004 May DISC

>A> @ 37.5 IU/VIAL

N21765 001 Mar 25, 2004 May DISC

37.5 IU/VIAL

N21765 001 Mar 25, 2004 Mar NEWA

BX 75 IU/VIAL

N20378 001 Sep 29, 1997 Mar CDFR

75 IU/VIAL

N21765 002 Mar 25, 2004 Mar NEWA

BX 150 IU/VIAL

N20378 002 Sep 29, 1997 Mar CDFR

+ 150 IU/VIAL

N21765 003 Mar 25, 2004 May DISC

>A> @ 150 IU/VIAL

N21765 003 Mar 25, 2004 May DISC

+ 150 IU/VIAL

N21765 003 Mar 25, 2004 Mar NEWA

450 IU/VIAL

N20378 005 Mar 26, 2004 Mar NEWA

+ 1,050 IU/VIAL

N20378 004 Feb 28, 2001 Apr CPOT

+ 1,200 IU/VIAL

N20378 004 Feb 28, 2001 Mar CAIN

>A> GONAL-F RFF PEN

>A> SERONO INC 300 IU/0.5ML

N21684 001 May 25, 2004 May NEWA

>A> + 450 IU/0.75ML

N21684 002 May 25, 2004 May NEWA

>A> + 900 IU/1.5ML

N21684 003 May 25, 2004 May NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE
+ NOVARTIS 6.6MG/ML

N20961 001 Aug 26, 1998 Jan CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS
ARIXTRA
>A> + FONDA BV 5MG/0.4ML
>A> + 7.5MG/0.6ML
>A> + 10MG/0.8ML

N21345 002 May 28, 2004 May NEWA
N21345 003 May 28, 2004 May NEWA
N21345 004 May 28, 2004 May NEWA

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM
AB EON 10MG
AB 20MG
AB 40MG
AB RANBAXY 10MG
AB 20MG
AB 40MG

N76483 001 Apr 23, 2004 Apr NEWA
N76483 002 Apr 23, 2004 Apr NEWA
N76483 003 Apr 23, 2004 Apr NEWA
N76580 001 Apr 23, 2004 Apr NEWA
N76580 002 Apr 23, 2004 Apr NEWA
N76580 003 Apr 23, 2004 Apr NEWA

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVA
>D> + ELAN PHARMS EQ 2.5MG BASE
>A> + VERNALIS EQ 2.5MG BASE

N21006 001 Nov 08, 2001 May CAHN
N21006 001 Nov 08, 2001 May CAHN

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
>D> AP ABBOTT 10MG/ML
>D> AP 10MG/ML
>D> AP 10MG/ML
>D> AP 10MG/ML
>D> AP 10MG/ML
>A> AP HOSPIRA 10MG/ML
>A> AP 10MG/ML
>A> AP 10MG/ML
>A> AP 10MG/ML
>A> AP 10MG/ML

N18667 001 May 28, 1982 May CAHN
N70578 001 Jul 08, 1987 May CAHN
N72080 001 Aug 13, 1991 May CAHN
N74337 001 Oct 31, 1994 May CAHN
N75241 001 May 28, 1999 May CAHN
N18667 001 May 28, 1982 May CAHN
N70578 001 Jul 08, 1987 May CAHN
N72080 001 Aug 13, 1991 May CAHN
N74337 001 Oct 31, 1994 May CAHN
N75241 001 May 28, 1999 May CAHN

TABLET; ORAL
FUROSEMIDE

AB	VINTAGE PHARMS	20MG	N76796 001 Mar 26, 2004 Mar NEWA
AB		40MG	N76796 002 Mar 26, 2004 Mar NEWA
AB		80MG	N76796 003 Mar 26, 2004 Mar NEWA

GABAPENTIN

TABLET; ORAL
GABAPENTIN
IVAX PHARMS 100MG
300MG
400MG

N76017 001 Apr 28, 2004 Apr NEWA
N76017 002 Apr 28, 2004 Apr NEWA
N76017 003 Apr 28, 2004 Apr NEWA

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ OSCIENT

EQ 320MG BASE

N21158 001 Apr 04, 2003 Apr CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

>D>	AP	ABBOTT	EQ 10MG BASE/ML	N62420 001 Aug 15, 1983 May CAHN
>D>	AP		EQ 10MG BASE/ML	N62612 004 Feb 20, 1986 May CAHN
>D>	AP		EQ 40MG BASE/ML	N62420 002 Aug 15, 1983 May CAHN
>A>	AP	HOSPIRA	EQ 10MG BASE/ML	N62420 001 Aug 15, 1983 May CAHN
>A>	AP		EQ 10MG BASE/ML	N62612 004 Feb 20, 1986 May CAHN
>A>	AP		EQ 40MG BASE/ML	N62420 002 Aug 15, 1983 May CAHN
			GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
>D>	AP	ABBOTT	EQ 1.2MG BASE/ML	N62414 001 Aug 15, 1983 May CAHN
>D>		@	EQ 1.2MG BASE/ML	N62588 001 Jan 06, 1986 May CAHN
>D>	AP		EQ 1.4MG BASE/ML	N62414 002 Aug 15, 1983 May CAHN
>D>		@	EQ 1.4MG BASE/ML	N62588 002 Jan 06, 1986 May CAHN
>D>	AP		EQ 1.6MG BASE/ML	N62414 003 Aug 15, 1983 May CAHN
>D>		@	EQ 1.6MG BASE/ML	N62588 003 Jan 06, 1986 May CAHN
>D>	AP		EQ 1.8MG BASE/ML	N62414 004 Aug 15, 1983 May CAHN
>D>		@	EQ 1.8MG BASE/ML	N62588 004 Jan 06, 1986 May CAHN
>D>	AP		EQ 2MG BASE/ML	N62414 005 Aug 15, 1983 May CAHN
>D>		@	EQ 2MG BASE/ML	N62588 005 Jan 06, 1986 May CAHN
>D>	AP		EQ 60MG BASE/100ML	N62414 006 Aug 15, 1983 May CAHN
>D>		@	EQ 60MG BASE/100ML	N62588 006 Jan 06, 1986 May CAHN
>D>	AP		EQ 70MG BASE/100ML	N62414 007 Aug 15, 1983 May CAHN
>D>		@	EQ 70MG BASE/100ML	N62588 007 Jan 06, 1986 May CAHN
>D>	AP		EQ 80MG BASE/100ML	N62414 008 Aug 15, 1983 May CAHN
>D>		@	EQ 80MG BASE/100ML	N62588 008 Jan 06, 1986 May CAHN
>D>	AP		EQ 90MG BASE/100ML	N62414 009 Aug 15, 1983 May CAHN
>D>		@	EQ 90MG BASE/100ML	N62588 009 Jan 06, 1986 May CAHN
>D>	AP		EQ 100MG BASE/100ML	N62414 010 Aug 15, 1983 May CAHN
>D>		@	EQ 100MG BASE/100ML	N62588 010 Jan 06, 1986 May CAHN
>A>	AP	HOSPIRA	EQ 1.2MG BASE/ML	N62414 001 Aug 15, 1983 May CAHN
>A>		@	EQ 1.2MG BASE/ML	N62588 001 Jan 06, 1986 May CAHN
>A>	AP		EQ 1.4MG BASE/ML	N62414 002 Aug 15, 1983 May CAHN
>A>		@	EQ 1.4MG BASE/ML	N62588 002 Jan 06, 1986 May CAHN
>A>	AP		EQ 1.6MG BASE/ML	N62414 003 Aug 15, 1983 May CAHN
>A>		@	EQ 1.6MG BASE/ML	N62588 003 Jan 06, 1986 May CAHN
>A>	AP		EQ 1.8MG BASE/ML	N62414 004 Aug 15, 1983 May CAHN
>A>		@	EQ 1.8MG BASE/ML	N62588 004 Jan 06, 1986 May CAHN
>A>	AP		EQ 2MG BASE/ML	N62414 005 Aug 15, 1983 May CAHN
>A>		@	EQ 2MG BASE/ML	N62588 005 Jan 06, 1986 May CAHN
>A>	AP		EQ 60MG BASE/100ML	N62414 006 Aug 15, 1983 May CAHN
>A>		@	EQ 60MG BASE/100ML	N62588 006 Jan 06, 1986 May CAHN
>A>	AP		EQ 70MG BASE/100ML	N62414 007 Aug 15, 1983 May CAHN
>A>		@	EQ 70MG BASE/100ML	N62588 007 Jan 06, 1986 May CAHN
>A>	AP		EQ 80MG BASE/100ML	N62414 008 Aug 15, 1983 May CAHN
>A>		@	EQ 80MG BASE/100ML	N62588 008 Jan 06, 1986 May CAHN
>A>	AP		EQ 90MG BASE/100ML	N62414 009 Aug 15, 1983 May CAHN
>A>		@	EQ 90MG BASE/100ML	N62588 009 Jan 06, 1986 May CAHN
>A>	AP		EQ 100MG BASE/100ML	N62414 010 Aug 15, 1983 May CAHN
>A>		@	EQ 100MG BASE/100ML	N62588 010 Jan 06, 1986 May CAHN

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

AT + SCHERING	EQ 0.3% BASE	N50039 002	Jan	CDFR
	GENTAMICIN SULFATE			
AT ALTANA	EQ 3% BASE	N65121 001	Jan 30, 2004	Jan NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

AB BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001	Jul 31, 2000	Feb CFTG
AB	2.5MG;500MG	N21178 002	Jul 31, 2000	Feb CFTG
AB +	5MG;500MG	N21178 003	Jul 31, 2000	Feb CFTG
	GLYBURIDE AND METFORMIN HCL			
AB IVAX PHARMS	1.25MG;250MG	N76345 001	Feb 18, 2004	Feb NEWA
AB	2.5MG;500MG	N76345 002	Feb 18, 2004	Feb NEWA
AB	5MG;500MG	N76345 003	Feb 18, 2004	Feb NEWA

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

>D> AT ABBOTT	1.5GM/100ML	N17633 001	May	CAHN
>D> AT	1.5GM/100ML	N18315 001	May	CAHN
>A> AT HOSPIRA	1.5GM/100ML	N17633 001	May	CAHN
>A> AT	1.5GM/100ML	N18315 001	May	CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>D> @ ABBOTT	0.2MG/ML	N89393 001	Jun 15, 1988	May CAHN
>A> @ HOSPIRA	0.2MG/ML	N89393 001	Jun 15, 1988	May CAHN

HALAZEPAM

TABLET; ORAL

PAXIPAM

@ SCHERING	20MG	N17736 003	Apr	DISC
@	40MG	N17736 004	Apr	DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176 001	Feb 09, 2000	Apr CAHN
@	EQ 100MG BASE/ML	N75176 002	Feb 09, 2000	Apr CAHN

HALOTHANE

LIQUID; INHALATION

HALOTHANE

>D> AN + ABBOTT	99.99%	N83254 001	May	CAHN
>A> AN + HOSPIRA	99.99%	N83254 001	May	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

>D> AP ABBOTT	10 UNITS/ML	N05264 001	May	CAHN
>D> AP	10 UNITS/ML	N40082 001	Feb 28, 1995	May CAHN
>D> AP	10 UNITS/ML	N88097 001	Apr 28, 1983	May CAHN
>D> AP	10 UNITS/ML	N88346 001	May 18, 1983	May CAHN

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

>D>	ABBOTT	100 UNITS/ML	N05264 010	May	CAHN	
>D>	AP	100 UNITS/ML	N40082 002	Feb 28, 1995	May CAHN	
>D>	AP	100 UNITS/ML	N88098 001	Apr 28, 1983	May CAHN	
>D>	AP	100 UNITS/ML	N88347 001	May 18, 1983	May CAHN	
>A>	HOSPIRA	10 UNITS/ML	N05264 001		May CAHN	
>A>	AP	10 UNITS/ML	N40082 001	Feb 28, 1995	May CAHN	
>A>	AP	10 UNITS/ML	N88097 001	Apr 28, 1983	May CAHN	
>A>	AP	10 UNITS/ML	N88346 001	May 18, 1983	May CAHN	
>A>	@	100 UNITS/ML	N05264 010		May CAHN	
>A>	AP	100 UNITS/ML	N40082 002	Feb 28, 1995	May CAHN	
>A>	AP	100 UNITS/ML	N88098 001	Apr 28, 1983	May CAHN	
>A>	AP	100 UNITS/ML	N88347 001	May 18, 1983	May CAHN	
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER						
>D>	AP	ABBOTT	10 UNITS/ML	N05264 015	May 21, 1985	May CAHN
>D>	AP		100 UNITS/ML	N05264 016	May 21, 1985	May CAHN
>A>	AP	HOSPIRA	10 UNITS/ML	N05264 015	May 21, 1985	May CAHN
>A>	AP		100 UNITS/ML	N05264 016	May 21, 1985	May CAHN
HEPARIN SODIUM						
>D>	AP	+ ABBOTT	2,500 UNITS/ML	N88099 001	Apr 28, 1983	May CAHN
>D>	AP		5,000 UNITS/ML	N88100 001	Apr 28, 1983	May CAHN
>D>		@	10,000 UNITS/ML	N40095 001	Jul 26, 1996	May CAHN
>A>	AP	+ HOSPIRA	2,500 UNITS/ML	N88099 001	Apr 28, 1983	May CAHN
>A>	AP		5,000 UNITS/ML	N88100 001	Apr 28, 1983	May CAHN
>A>		@	10,000 UNITS/ML	N40095 001	Jul 26, 1996	May CAHN
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>D>	AP	ABBOTT	200 UNITS/100ML	N18916 010	Jun 23, 1989	May CAHN
>A>	AP	HOSPIRA	200 UNITS/100ML	N18916 010	Jun 23, 1989	May CAHN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%						
>D>		@ ABBOTT	10,000 UNITS/100ML	N18911 006	Jan 30, 1985	May CAHN
>A>		@ HOSPIRA	10,000 UNITS/100ML	N18911 006	Jan 30, 1985	May CAHN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	ABBOTT	10,000 UNITS/100ML	N19339 003	Mar 27, 1985	May CAHN
>A>	AP	HOSPIRA	10,000 UNITS/100ML	N19339 003	Mar 27, 1985	May CAHN
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%						
>D>		@ ABBOTT	10,000 UNITS/100ML	N18911 001	Jan 30, 1985	May CAHN
>D>		@	10,000 UNITS/100ML	N18916 005	Jan 31, 1984	May CAHN
>A>		@ HOSPIRA	10,000 UNITS/100ML	N18911 001	Jan 30, 1985	May CAHN
>A>		@	10,000 UNITS/100ML	N18916 005	Jan 31, 1984	May CAHN
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%						
>D>		@ ABBOTT	10,000 UNITS/100ML	N18911 003	Jan 30, 1985	May CAHN
>D>		@	10,000 UNITS/100ML	N18916 002	Jan 31, 1984	May CAHN
>A>		@ HOSPIRA	10,000 UNITS/100ML	N18911 003	Jan 30, 1985	May CAHN
>A>		@	10,000 UNITS/100ML	N18916 002	Jan 31, 1984	May CAHN
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%						
>D>		@ ABBOTT	5,000 UNITS/100ML	N18911 007	Jan 30, 1985	May CAHN
>A>		@ HOSPIRA	5,000 UNITS/100ML	N18911 007	Jan 30, 1985	May CAHN
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>		ABBOTT	5,000 UNITS/100ML	N19339 001	Mar 27, 1985	May CAHN
>A>		HOSPIRA	5,000 UNITS/100ML	N19339 001	Mar 27, 1985	May CAHN
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
>D>		ABBOTT	5,000 UNITS/100ML	N18916 006	Jan 31, 1984	May CAHN
>A>		HOSPIRA	5,000 UNITS/100ML	N18916 006	Jan 31, 1984	May CAHN
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%						
>D>		@ ABBOTT	5,000 UNITS/100ML	N18911 005	Jan 30, 1985	May CAHN

INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

>D>	# ABBOTT	5,000 UNITS/100ML	N18916 003 Jan 31, 1984 May CAHN
>A>	# HOSPIRA	5,000 UNITS/100ML	N18911 005 Jan 30, 1985 May CAHN
>A>	#	5,000 UNITS/100ML	N18916 003 Jan 31, 1984 May CAHN

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP	ABBOTT	200 UNITS/100ML	N18916 011 Jun 23, 1989 May CAHN
>A> AP	HOSPIRA	200 UNITS/100ML	N18916 011 Jun 23, 1989 May CAHN

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP	ABBOTT	4,000 UNITS/100ML	N19805 001 Jan 25, 1989 May CAHN
>A> AP	HOSPIRA	4,000 UNITS/100ML	N19805 001 Jan 25, 1989 May CAHN

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

>D>	# ABBOTT	5,000 UNITS/100ML	N18911 009 Jan 30, 1985 May CAHN
>D>	#	10,000 UNITS/100ML	N18911 008 Jan 30, 1985 May CAHN
>A>	# HOSPIRA	5,000 UNITS/100ML	N18911 009 Jan 30, 1985 May CAHN
>A>	#	10,000 UNITS/100ML	N18911 008 Jan 30, 1985 May CAHN

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP	ABBOTT	5,000 UNITS/100ML	N19339 004 Mar 27, 1985 May CAHN
>D> AP		5,000 UNITS/100ML	N19805 002 Jan 25, 1989 May CAHN
>D> AP		10,000 UNITS/100ML	N19339 002 Mar 27, 1985 May CAHN
>A> AP	HOSPIRA	5,000 UNITS/100ML	N19339 004 Mar 27, 1985 May CAHN
>A> AP		5,000 UNITS/100ML	N19805 002 Jan 25, 1989 May CAHN
>A> AP		10,000 UNITS/100ML	N19339 002 Mar 27, 1985 May CAHN

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	ABBOTT	5,000 UNITS/100ML	N18916 007 Jan 31, 1984 May CAHN
>D>		10,000 UNITS/100ML	N18916 008 Jan 31, 1984 May CAHN
>A>	HOSPIRA	5,000 UNITS/100ML	N18916 007 Jan 31, 1984 May CAHN
>A>		10,000 UNITS/100ML	N18916 008 Jan 31, 1984 May CAHN

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%

>D>	# ABBOTT	5,000 UNITS/100ML	N18911 004 Jan 30, 1985 May CAHN
>A>	# HOSPIRA	5,000 UNITS/100ML	N18911 004 Jan 30, 1985 May CAHN

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	# ABBOTT	5,000 UNITS/100ML	N18916 009 Jan 31, 1984 May CAHN
>A>	# HOSPIRA	5,000 UNITS/100ML	N18916 009 Jan 31, 1984 May CAHN

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%

>D>	# ABBOTT	100 UNITS/ML	N18911 002 Jan 30, 1985 May CAHN
>D>	#	100 UNITS/ML	N18916 004 Jan 31, 1984 May CAHN
>A>	# HOSPIRA	100 UNITS/ML	N18911 002 Jan 30, 1985 May CAHN
>A>	#	100 UNITS/ML	N18916 004 Jan 31, 1984 May CAHN

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%

>D>	# ABBOTT	1,000 UNITS/100ML	N18916 001 Jan 31, 1984 May CAHN
>A>	# HOSPIRA	1,000 UNITS/100ML	N18916 001 Jan 31, 1984 May CAHN

HEPARIN SODIUM PRESERVATIVE FREE

>D>	+ ABBOTT	2,000 UNITS/ML	N05264 013 Apr 07, 1986 May CAHN
>D> AP	+	2,500 UNITS/ML	N05264 014 Apr 07, 1986 May CAHN
>D> AP	+	10,000 UNITS/ML	N89522 001 May 04, 1987 May CAHN
>A>	+ HOSPIRA	2,000 UNITS/ML	N05264 013 Apr 07, 1986 May CAHN
>A> AP	+	2,500 UNITS/ML	N05264 014 Apr 07, 1986 May CAHN
>A> AP	+	10,000 UNITS/ML	N89522 001 May 04, 1987 May CAHN

PANHEPRIN

>D>	# ABBOTT	1,000 UNITS/ML	N05264 004 May CAHN
>D>	#	5,000 UNITS/ML	N05264 006 May CAHN
>D>	#	10,000 UNITS/ML	N05264 007 May CAHN
>D>	#	20,000 UNITS/ML	N05264 008 May CAHN
>D>	#	40,000 UNITS/ML	N05264 009 May CAHN
>A>	# HOSPIRA	1,000 UNITS/ML	N05264 004 May CAHN

INJECTABLE; INJECTION

PANHEPRIN				
>A> # HOSPIRA	5,000 UNITS/ML	N05264 006	May	CAHN
>A> #	10,000 UNITS/ML	N05264 007	May	CAHN
>A> #	20,000 UNITS/ML	N05264 008	May	CAHN
>A> #	40,000 UNITS/ML	N05264 009	May	CAHN

HYALURONIDASE

>A>	INJECTABLE; INJECTION			
>A>	VITRASE			
>A> + ISTA PHARMS	6,200 UNITS/VIAL	N21640 001	May 05, 2004	May NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL				
ACCURETIC				
AB PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125 001	Dec 28, 1999	Mar CFTG
AB	12.5MG;EQ 20MG BASE	N20125 002	Dec 28, 1999	Mar CFTG
AB +	25MG;EQ 20MG BASE	N20125 003	Dec 28, 1999	Mar CFTG
QUINARETIC				
AB AMIDE PHARM	12.5MG;EQ 10MG BASE	N76374 001	Mar 31, 2004	Mar NEWA
AB	12.5MG;EQ 20MG BASE	N76374 002	Mar 31, 2004	Mar NEWA
AB	25MG;EQ 20MG BASE	N76374 003	Mar 31, 2004	Mar NEWA

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL				
MICARDIS HCT				
>D> + BOEHRINGER INGELHEIM	12.5MG;80MG	N21162 002	Nov 17, 2000	May CRLD
>A>	12.5MG;80MG	N21162 002	Nov 17, 2000	May CRLD
>A> +	25MG;80MG	N21162 003	Apr 19, 2004	May NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL				
HYDROCODONE BITARTRATE AND IBUPROFEN				
+ INTERPHARM	5MG;200MG	N76642 002	Mar 18, 2004	Mar NEWA

HYDROCORTISONE

CREAM; TOPICAL				
HYDROCORTISONE				
AT VINTAGE PHARMS	2.5%	N40503 001	Mar 12, 2004	Mar NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL				
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%				
BX BOCA PHARMA	1%;1%	N89440 001	May 17, 1988	Apr CAHN

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL				
HYDROCORTISONE BUTYRATE				
AT TARO PHARM IND	0.1%	N76364 001	Jan 14, 2004	Jan NEWA
LOCOID				
AT + FERNDALE LABS	0.1%	N19116 001	Feb 25, 1987	Jan CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION				
A-HYDROCORT				
>D> AP ABBOTT	EQ 100MG BASE/VIAL	N85929 001		May CAHN

INJECTABLE; INJECTIONA-HYDROCORT

>D>	AP	ABBOTT	EQ 250MG BASE/VIAL	N85930 001	May	CAHN
>D>	AP		EQ 500MG BASE/VIAL	N85931 001	May	CAHN
>D>	AP		EQ 1GM BASE/VIAL	N85932 001	May	CAHN
>A>	AP	HOSPIRA	EQ 100MG BASE/VIAL	N85929 001	May	CAHN
>A>	AP		EQ 250MG BASE/VIAL	N85930 001	May	CAHN
>A>	AP		EQ 500MG BASE/VIAL	N85931 001	May	CAHN
>A>	AP		EQ 1GM BASE/VIAL	N85932 001	May	CAHN

HYDROMORPHONE HYDROCHLORIDEINJECTABLE; INJECTIONHYDROMORPHONE HCL

>D>	AP	ABBOTT	10MG/ML	N74598 001	Jun 19, 1997	May	CAHN
>A>	AP	HOSPIRA	10MG/ML	N74598 001	Jun 19, 1997	May	CAHN

HYDROXYZINE HYDROCHLORIDEINJECTABLE; INJECTIONHYDROXYZINE HCL

>D>	AP	ABBOTT	25MG/ML	N87416 001	May	CAHN
>D>		@	50MG/ML	N86821 001	May	CAHN
>D>	AP		50MG/ML	N87546 001	May	CAHN
>A>	AP	HOSPIRA	25MG/ML	N87416 001	May	CAHN
>A>		@	50MG/ML	N86821 001	May	CAHN
>A>	AP		50MG/ML	N87546 001	May	CAHN

IDARUBICIN HYDROCHLORIDEINJECTABLE; INJECTIONIDARUBICIN HCL

+ GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	May 01, 2002	Feb	CTEC
-----------------------	----------	------------	--------------	-----	------

INAMRINONE LACTATEINJECTABLE; INJECTIONAMRINONE

>D>	AP	+ ABBOTT	EQ 5MG BASE/ML	N74616 001	Aug 03, 1998	May	CAHN
>A>	AP	+ HOSPIRA	EQ 5MG BASE/ML	N74616 001	Aug 03, 1998	May	CAHN

INSULIN ASPARTINJECTABLE; SUBCUTANEOUSNOVOLOG

>D>		+ NOVO NORDISK	100 UNITS/ML	N20986 001	Jun 07, 2000	May	CAIN
-----	--	----------------	--------------	------------	--------------	-----	------

INSULIN ASPART RECOMBINANTINJECTABLE; SUBCUTANEOUSNOVOLOG

>A>		+ NOVO NORDISK	100 UNITS/ML	N20986 001	Jun 07, 2000	May	CAIN
-----	--	----------------	--------------	------------	--------------	-----	------

INSULIN GLARGINEINJECTABLE; INJECTIONLANTUS

>D>		+ AVENTIS PHARMS	100 UNITS/ML	N21081 001	Apr 20, 2000	May	CAIN
-----	--	------------------	--------------	------------	--------------	-----	------

INSULIN GLARGINE RECOMBINANTINJECTABLE; INJECTIONLANTUS

>A>		+ AVENTIS PHARMS	100 UNITS/ML	N21081 001	Apr 20, 2000	May	CAIN
-----	--	------------------	--------------	------------	--------------	-----	------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

+ AVENTIS PHARMS 100 UNITS/ML

N21629 001 Apr 16, 2004 Apr NEWA

>D> INSULIN LISPRO

INJECTABLE; INJECTION

HUMALOG

+ LILLY 100 UNITS/ML

N20563 001 Jun 14, 1996 May CAIN

HUMALOG PEN

+ LILLY 100 UNITS/ML

N20563 002 Aug 06, 1998 May CAIN

>A> INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

>A> INJECTABLE; INJECTION

HUMALOG MIX 50/50

>A> + LILLY 50 UNITS/ML;50 UNITS/ML

N21018 001 Dec 22, 1999 May CAIN

>A> HUMALOG MIX 75/25

>A> + LILLY 75 UNITS/ML;25 UNITS/ML

N21017 001 Dec 22, 1999 May CAIN

>A> INSULIN LISPRO RECOMBINANT

>A> INJECTABLE; INJECTION

HUMALOG

>A> + LILLY 100 UNITS/ML

N20563 001 Jun 14, 1996 May CAIN

>A> HUMALOG PEN

>A> + LILLY 100 UNITS/ML

N20563 002 Aug 06, 1998 May CAIN

>D> INSULIN LISPRO; INSULIN LISPRO PROTAMINE

>D> INJECTABLE; INJECTION

HUMALOG MIX 50/50

>D> + LILLY 50 UNITS/ML;50 UNITS/ML

N21018 001 Dec 22, 1999 May CAIN

>D> HUMALOG MIX 75/25

>D> + LILLY 25 UNITS/ML;75 UNITS/ML

N21017 001 Dec 22, 1999 May CAIN

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

>D> AP ABBOTT 41%

N74898 001 Dec 30, 1997 May CAHN

>A> AP HOSPIRA 41%

N74898 001 Dec 30, 1997 May CAHN

IOPAMIDOL-200 IN PLASTIC CONTAINER

>D> AP ABBOTT 41%

N74636 001 Dec 30, 1997 May CAHN

>A> AP HOSPIRA 41%

N74636 001 Dec 30, 1997 May CAHN

IOPAMIDOL-250

>D> AP ABBOTT 51%

N74898 002 Dec 30, 1997 May CAHN

>D> AP 51%

N75005 001 Feb 24, 1998 May CAHN

>A> AP HOSPIRA 51%

N74898 002 Dec 30, 1997 May CAHN

>A> AP 51%

N75005 001 Feb 24, 1998 May CAHN

IOPAMIDOL-250 IN PLASTIC CONTAINER

>D> AP ABBOTT 51%

N74636 002 Dec 30, 1997 May CAHN

>A> AP HOSPIRA 51%

N74636 002 Dec 30, 1997 May CAHN

IOPAMIDOL-300

>D> AP ABBOTT 61%

N74898 003 Dec 30, 1997 May CAHN

>D> AP 61%

N75005 002 Feb 24, 1998 May CAHN

>A> AP HOSPIRA 61%

N74898 003 Dec 30, 1997 May CAHN

>A> AP 61%

N75005 002 Feb 24, 1998 May CAHN

INJECTABLE; INJECTIONIOPAMIDOL-300 IN PLASTIC CONTAINER

>D>	AP	ABBOTT	61%	N74636 003	Dec 30, 1997	May	CAHN
>D>	AP		61%	N74637 001	Apr 03, 1997	May	CAHN
>A>	AP	HOSPIRA	61%	N74636 003	Dec 30, 1997	May	CAHN
>A>	AP		61%	N74637 001	Apr 03, 1997	May	CAHN
<u>IOPAMIDOL-370</u>							
>D>	AP	ABBOTT	76%	N74898 004	Dec 30, 1997	May	CAHN
>D>	AP		76%	N75005 003	Feb 24, 1998	May	CAHN
>A>	AP	HOSPIRA	76%	N74898 004	Dec 30, 1997	May	CAHN
>A>	AP		76%	N75005 003	Feb 24, 1998	May	CAHN
<u>IOPAMIDOL-370 IN PLASTIC CONTAINER</u>							
>D>	AP	ABBOTT	76%	N74636 004	Dec 30, 1997	May	CAHN
>A>	AP	HOSPIRA	76%	N74636 004	Dec 30, 1997	May	CAHN

IOPANOIC ACID

>D>		TABLET; ORAL					
>D>		TELEPAQUE					
>D>	+	AMERSHAM HLTH	500MG	N08032 001		May	DISC
>A>	0	GE HEALTHCARE	500MG	N08032 001		May	DISC

IOPROMIDEINJECTABLE; INJECTIONULTRAVIST (PHARMACY BULK)

+	BERLEX	49.9%	N21425 003	Mar 12, 2004	Mar	NEWA
+		62.3%	N21425 001	Sep 20, 2002	Mar	CPOT
+		76.9%	N21425 002	Sep 20, 2002	Mar	CPOT

IPRATROPIUM BROMIDESOLUTION; INHALATIONIPRATROPIUM BROMIDE

AN	HOLOPACK INTL	0.02%	N75693 001	Jan 26, 2001	Apr	CAHN
----	---------------	-------	------------	--------------	-----	------

ISOFLURANELIQUID; INHALATIONISOFLURANE

>D>	AN	ABBOTT	99.9%	N74097 001	Jan 25, 1993	May	CAHN
>A>	AN	HOSPIRA	99.9%	N74097 001	Jan 25, 1993	May	CAHN

ISONIAZIDINJECTABLE; INJECTIONNYDRAZID

+	SANDOZ	100MG/ML	N08662 001		Feb	CAHN
---	--------	----------	------------	--	-----	------

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTIONISOPROTERENOL HCL

>D>		ABBOTT	0.02MG/ML	N83283 001		May	CAHN	
>D>	AP		0.2MG/ML	N83346 001		May	CAHN	
>A>		HOSPIRA	0.02MG/ML	N83283 001		May	CAHN	
>A>	AP		0.2MG/ML	N83346 001		May	CAHN	
<u>ISUPREL</u>								
>D>	AP	+	ABBOTT	0.2MG/ML	N10515 001		May	CAHN
>A>	AP	+	HOSPIRA	0.2MG/ML	N10515 001		May	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR

AB	SCHERING PLOUGH	30MG	N20225 001 Aug 12, 1993 Apr CRLD
AB		60MG	N20225 002 Aug 12, 1993 Apr CRLD

ITRACONAZOLE

CAPSULE; ORAL

>A>	ITRACONAZOLE		
>A> AB	EON	100MG	N76104 001 May 28, 2004 May NEWA
	SPORANOX		
>D>	+ JANSSEN PHARMA	100MG	N20083 001 Sep 11, 1992 May CPTG
>A> AB	+	100MG	N20083 001 Sep 11, 1992 May CPTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

>D> AP	ABBOTT	EQ 50MG BASE/ML	N74549 001 Jun 27, 1996 May CAHN
>D> AP		EQ 100MG BASE/ML	N74549 002 Jun 27, 1996 May CAHN
>A> AP	HOSPIRA	EQ 50MG BASE/ML	N74549 001 Jun 27, 1996 May CAHN
>A> AP		EQ 100MG BASE/ML	N74549 002 Jun 27, 1996 May CAHN

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	ALTANA	2%	N76294 001 Apr 28, 2004 Apr NEWA
AB	+ TEVA	2%	N75581 001 Apr 25, 2000 Apr CRLD
	NIZORAL		
	@ JANSSEN PHARMA	2%	N19084 001 Dec 31, 1985 Apr DISC
	SHAMPOO; TOPICAL		
	KETOCONAZOLE		
AB	CLAY PARK	2%	N76419 001 Jan 07, 2004 Jan NEWA
	NIZORAL		
AB	+ MCNEIL CONS SPECLT	2%	N19927 001 Aug 31, 1990 Jan CPTG

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>D>	@ ABBOTT	15MG/ML	N74801 001 Jun 05, 1997 May CAHN
>D> AP		15MG/ML	N74802 001 Jun 05, 1997 May CAHN
>D> AP		15MG/ML	N74993 001 Jan 27, 1999 May CAHN
>D>	@	30MG/ML	N74801 002 Jun 05, 1997 May CAHN
>D> AP		30MG/ML	N74802 002 Jun 05, 1997 May CAHN
>D> AP		30MG/ML	N74993 002 Jan 27, 1999 May CAHN
	AP + BEDFORD	15MG/ML	N75222 001 Apr 26, 1999 Jan CRLD
	AP +	30MG/ML	N75222 002 Apr 26, 1999 Jan CRLD
>A>	@ HOSPIRA	15MG/ML	N74801 001 Jun 05, 1997 May CAHN
>A> AP		15MG/ML	N74802 001 Jun 05, 1997 May CAHN
>A> AP		15MG/ML	N74993 001 Jan 27, 1999 May CAHN
>A>	@	30MG/ML	N74801 002 Jun 05, 1997 May CAHN
>A> AP		30MG/ML	N74802 002 Jun 05, 1997 May CAHN
>A> AP		30MG/ML	N74993 002 Jan 27, 1999 May CAHN
	TORADOL		
	@ ROCHE PALO	15MG/ML	N19698 001 Nov 30, 1989 Jan DISC
	@	30MG/ML	N19698 002 Nov 30, 1989 Jan DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+ NOVARTIS

EQ 0.025% BASE

N21066 001 Jul 02, 1999 Feb CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

>D> AP ABBOTT

5MG/ML

N75239 001 Nov 29, 1999 May CAHN

>D> AP

5MG/ML

N75240 001 Nov 29, 1999 May CAHN

>A> AP HOSPIRA

5MG/ML

N75239 001 Nov 29, 1999 May CAHN

>A> AP

5MG/ML

N75240 001 Nov 29, 1999 May CAHN

LAMIVUDINE

TABLET; ORAL

EPIVIR

>D> + GLAXOSMITHKLINE 150MG

N20564 001 Nov 17, 1995 May CRLD

>A>

150MG

N20564 001 Nov 17, 1995 May CRLD

>D>

300MG

N20564 003 Jun 24, 2002 May CRLD

>A> +

300MG

N20564 003 Jun 24, 2002 May CRLD

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

+ GLAXOSMITHKLINE 25MG

N20241 005 Dec 27, 1994 Apr CRLD

200MG

N20241 003 Dec 27, 1994 Apr CRLD

LANSOPRAZOLE

>A> INJECTABLE; INTRAVENOUS

>A> PREVACID IV

>A> + TAP PHARM 30MG/VIAL

N21566 001 May 27, 2004 May NEWA

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>D> AP + ABBOTT EQ 10MG BASE/ML

N40147 001 Jun 25, 1997 May CAHN

>A> AP + HOSPIRA EQ 10MG BASE/ML

N40147 001 Jun 25, 1997 May CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

>D> INJECTABLE; INJECTION

>D> CHIROCAINE

>D> PURDUE PHARMA LP EQ 2.5MG BASE/ML

N20997 001 Aug 05, 1999 May DISC

>A> @ EQ 2.5MG BASE/ML

N20997 001 Aug 05, 1999 May DISC

>D> @ EQ 5MG BASE/ML

N20997 002 Aug 05, 1999 May DISC

>A> @ EQ 5MG BASE/ML

N20997 002 Aug 05, 1999 May DISC

>D> + EQ 7.5MG BASE/ML

N20997 003 Aug 05, 1999 May DISC

>A> @ EQ 7.5MG BASE/ML

N20997 003 Aug 05, 1999 May DISC

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

+ NOVARTIS

EQ 0.05% BASE

N20219 001 Nov 10, 1993 Feb CAHN

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
IQUIX

+ SANTEN 1.5%

N21571 001 Mar 01, 2004 Mar NEWA

LEVONORGESTREL

TABLET; ORAL
PLAN B

+ DURAMED 0.75MG

N21045 001 Jul 28, 1999 Feb CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

>D>	AP	ABBOTT	0.5%	N88328 001 May 17, 1984 May CAHN
>D>	AP		1%	N40013 001 Jun 23, 1995 May CAHN
>D>	AP		1%	N83158 001 May CAHN
>D>	AP		1%	N88329 001 May 17, 1984 May CAHN
>D>		0	1.5%	N88330 001 May 17, 1984 May CAHN
>D>	AP		2%	N40078 001 Jun 23, 1995 May CAHN
>D>	AP		2%	N83158 002 May CAHN
>D>	AP		2%	N88294 001 May 17, 1984 May CAHN
>D>	AP		2%	N88331 001 May 17, 1984 May CAHN
>D>	AP		20%	N83158 003 May CAHN
>A>	AP	HOSPIRA	0.5%	N88328 001 May 17, 1984 May CAHN
>A>	AP		1%	N40013 001 Jun 23, 1995 May CAHN
>A>	AP		1%	N83158 001 May CAHN
>A>	AP		1%	N88329 001 May 17, 1984 May CAHN
>A>		0	1.5%	N88330 001 May 17, 1984 May CAHN
>A>	AP		2%	N40078 001 Jun 23, 1995 May CAHN
>A>	AP		2%	N83158 002 May CAHN
>A>	AP		2%	N88294 001 May 17, 1984 May CAHN
>A>	AP		2%	N88331 001 May 17, 1984 May CAHN
>A>	AP		20%	N83158 003 May CAHN
		LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER		
		0 B BRAUN	200MG/100ML	N18967 001 Mar 30, 1984 Apr DISC
		LIDOCAINE HCL 0.2% IN DEXTROSE 5%		
>D>	AP	ABBOTT	200MG/100ML	N83158 005 May CAHN
>A>	AP	HOSPIRA	200MG/100ML	N83158 005 May CAHN
		LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER		
>D>	AP	ABBOTT	200MG/100ML	N18388 001 May CAHN
>A>	AP	HOSPIRA	200MG/100ML	N18388 001 May CAHN
		LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER		
		0 B BRAUN	400MG/100ML	N18967 002 Mar 30, 1984 Apr DISC
		LIDOCAINE HCL 0.4% IN DEXTROSE 5%		
>D>	AP	ABBOTT	400MG/100ML	N83158 006 May CAHN
>A>	AP	HOSPIRA	400MG/100ML	N83158 006 May CAHN
		LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER		
>D>	AP	ABBOTT	400MG/100ML	N18388 002 May CAHN
>A>	AP	HOSPIRA	400MG/100ML	N18388 002 May CAHN
		LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER		
		0 B BRAUN	800MG/100ML	N18967 003 Mar 30, 1984 Apr DISC
		LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER		
>D>	AP	ABBOTT	800MG/100ML	N18388 003 Nov 05, 1982 May CAHN
>A>	AP	HOSPIRA	800MG/100ML	N18388 003 Nov 05, 1982 May CAHN

INJECTABLE; INJECTIONLIDOCAINE HCL IN PLASTIC CONTAINER

>D>	AP	ABBOTT	0.5%	N88325 001 Jul 31, 1984 May CAHN
>D>	AP		1%	N88299 001 Jul 31, 1984 May CAHN
>D>	AP		1.5%	N88326 001 Jul 31, 1984 May CAHN
>D>	AP		2%	N88327 001 Jul 31, 1984 May CAHN
>D>	AP		10%	N88367 001 Jul 31, 1984 May CAHN
>D>	AP		20%	N88368 001 Jul 31, 1984 May CAHN
>A>	AP	HOSPIRA	0.5%	N88325 001 Jul 31, 1984 May CAHN
>A>	AP		1%	N88299 001 Jul 31, 1984 May CAHN
>A>	AP		1.5%	N88326 001 Jul 31, 1984 May CAHN
>A>	AP		2%	N88327 001 Jul 31, 1984 May CAHN
>A>	AP		10%	N88367 001 Jul 31, 1984 May CAHN
>A>	AP		20%	N88368 001 Jul 31, 1984 May CAHN

LIDOCAINE HCL PRESERVATIVE FREE

>D>	AP	ABBOTT	1%	N80408 001 May CAHN
>D>	AP		1.5%	N80408 002 May CAHN
>D>	AP		4%	N88295 001 May 17, 1984 May CAHN
>A>	AP	HOSPIRA	1%	N80408 001 May CAHN
>A>	AP		1.5%	N80408 002 May CAHN
>A>	AP		4%	N88295 001 May 17, 1984 May CAHN

LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER

>D>	AP	ABBOTT	1%	N40302 001 Sep 28, 1998 May CAHN
>D>	AP		2%	N40302 002 Sep 28, 1998 May CAHN
>A>	AP	HOSPIRA	1%	N40302 001 Sep 28, 1998 May CAHN
>A>	AP		2%	N40302 002 Sep 28, 1998 May CAHN

INJECTABLE; SPINALLIDOCAINE HCL 5% AND DEXTROSE 7.5%

>D>	+	ABBOTT	5%	N83914 001 May CAHN
>A>	+	HOSPIRA	5%	N83914 001 May CAHN

SOLUTION; TOPICALLTA II KIT

>D>	AT	ABBOTT	4%	N80409 001 May CAHN
>D>	AT		4%	N88542 001 Jul 31, 1984 May CAHN
>A>	AT	HOSPIRA	4%	N80409 001 May CAHN
>A>	AT		4%	N88542 001 Jul 31, 1984 May CAHN

PEDIATRIC LTA KIT

>D>	AT	ABBOTT	2%	N85995 001 May CAHN
>A>	AT	HOSPIRA	2%	N85995 001 May CAHN

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINEINJECTABLE; INJECTIONTERRAMYCIN

+	PFIZER	2%;50MG/ML	N60567 001 Feb CRLD
+		2%;125MG/ML	N60567 002 Feb CRLD

LITHIUM CARBONATETABLET, EXTENDED RELEASE; ORALLITHIUM CARBONATE

AB	ROXANE	450MG	N76691 001 Jan 05, 2004 Jan NEWA
----	--------	-------	----------------------------------

LORAZEPAMINJECTABLE; INJECTIONLORAZEPAM

>D>	AP	ABBOTT	2MG/ML	N74243 001 Apr 12, 1994 May CAHN
>D>	AP		2MG/ML	N74280 001 May 27, 1994 May CAHN

INJECTABLE; INJECTIONLORAZEPAM

>D>	AP	ABBOTT	2MG/ML	N74282 001 May 27, 1994 May CAHN
>D>	AP		2MG/ML	N74300 001 Apr 12, 1994 May CAHN
>D>	AP		4MG/ML	N74243 002 Apr 12, 1994 May CAHN
>D>	AP		4MG/ML	N74280 002 May 27, 1994 May CAHN
>D>	AP		4MG/ML	N74282 002 May 27, 1994 May CAHN
>D>	AP		4MG/ML	N74300 003 Mar 19, 1997 May CAHN
>A>	AP	HOSPIRA	2MG/ML	N74243 001 Apr 12, 1994 May CAHN
>A>	AP		2MG/ML	N74280 001 May 27, 1994 May CAHN
>A>	AP		2MG/ML	N74282 001 May 27, 1994 May CAHN
>A>	AP		2MG/ML	N74300 001 Apr 12, 1994 May CAHN
>A>	AP		4MG/ML	N74243 002 Apr 12, 1994 May CAHN
>A>	AP		4MG/ML	N74280 002 May 27, 1994 May CAHN
>A>	AP		4MG/ML	N74282 002 May 27, 1994 May CAHN
>A>	AP		4MG/ML	N74300 003 Mar 19, 1997 May CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+ KOS	20MG;500MG	N21249 001 Dec 17, 2001 Feb CRLD
+	20MG;750MG	N21249 002 Dec 17, 2001 Feb CRLD

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATEINJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

>D>	ABBOTT	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586 001	May CAHN
>A>	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586 001	May CAHN

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

>D>	@ ABBOTT	14MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 001	May CAHN
>D>		30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17637 002 Jul 08, 1982 May CAHN	
>A>	@ HOSPIRA	14MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 001	May CAHN
>A>		30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17637 002 Jul 08, 1982 May CAHN	

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

>D>	ABBOTT	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 002 Jul 08, 1982 May CAHN
>A>	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 002 Jul 08, 1982 May CAHN

MAGNESIUM SULFATEINJECTABLE; INJECTION

MAGNESIUM SULFATE

>D>	AP	ABBOTT	500MG/ML	N75151 001 Apr 25, 2000 May CAHN
>A>	AP	HOSPIRA	500MG/ML	N75151 001 Apr 25, 2000 May CAHN

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	+	ABBOTT	1GM/100ML	N20488 001 Jul 11, 1995 May CAHN
>D>	+		2GM/100ML	N20488 002 Jul 11, 1995 May CAHN
>A>	+	HOSPIRA	1GM/100ML	N20488 001 Jul 11, 1995 May CAHN
>A>	+		2GM/100ML	N20488 002 Jul 11, 1995 May CAHN

MAGNESIUM SULFATE IN PLASTIC CONTAINER

>D>	+	ABBOTT	80MG/ML	N20309 002 Jun 24, 1994 May CAHN
>D>	+		4GM/100ML	N20309 001 Jun 24, 1994 May CAHN
>A>	+	HOSPIRA	80MG/ML	N20309 002 Jun 24, 1994 May CAHN

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

>A> + HOSPIRA 4GM/100ML N20309 001 Jun 24, 1994 May CAHN

MANGANESE CHLORIDE

INJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER

>D> ABBOTT EQ 0.1MG MANGANESE/ML N18962 001 Jun 26, 1986 May CAHN
>A> HOSPIRA EQ 0.1MG MANGANESE/ML N18962 001 Jun 26, 1986 May CAHN

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

>D> @ ABBOTT 10GM/100ML N16269 002 May CAHN
>A> @ HOSPIRA 10GM/100ML N16269 002 May CAHN

MANNITOL 10% IN PLASTIC CONTAINER

>D> AP ABBOTT 10GM/100ML N19603 002 Jan 08, 1987 May CAHN
>A> AP HOSPIRA 10GM/100ML N19603 002 Jan 08, 1987 May CAHN

MANNITOL 15%

>D> @ ABBOTT 15GM/100ML N16269 003 May CAHN
>A> @ HOSPIRA 15GM/100ML N16269 003 May CAHN

MANNITOL 15% IN PLASTIC CONTAINER

>D> AP ABBOTT 15GM/100ML N19603 003 Jan 08, 1990 May CAHN
>A> AP HOSPIRA 15GM/100ML N19603 003 Jan 08, 1990 May CAHN

MANNITOL 20%

>D> @ ABBOTT 20GM/100ML N16269 004 May CAHN
>A> @ HOSPIRA 20GM/100ML N16269 004 May CAHN

MANNITOL 20% IN PLASTIC CONTAINER

>D> AP ABBOTT 20GM/100ML N19603 004 Jan 08, 1990 May CAHN
>A> AP HOSPIRA 20GM/100ML N19603 004 Jan 08, 1990 May CAHN

MANNITOL 25%

>D> @ ABBOTT 12.5GM/50ML N16269 005 May CAHN
>D> AP 12.5GM/50ML N16269 006 Aug 25, 1994 May CAHN

@ HOSPIRA 12.5GM/50ML N16269 005 May CAHN

>A> AP 12.5GM/50ML N16269 006 Aug 25, 1994 May CAHN

MANNITOL 5%

>D> @ ABBOTT 5GM/100ML N16269 001 May CAHN
>A> @ HOSPIRA 5GM/100ML N16269 001 May CAHN

MANNITOL 5% IN PLASTIC CONTAINER

>D> AP ABBOTT 5GM/100ML N19603 001 Jan 08, 1987 May CAHN
>A> AP HOSPIRA 5GM/100ML N19603 001 Jan 08, 1987 May CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

>D> @ ABBOTT 540MG/100ML;2.7GM/100ML N80224 001 May CAHN
>A> @ HOSPIRA 540MG/100ML;2.7GM/100ML N80224 001 May CAHN

SORBITOL-MANNITOL IN PLASTIC CONTAINER

>D> AT ABBOTT 540MG/100ML;2.7GM/100ML N17636 001 May CAHN
>D> AT 540MG/100ML;2.7GM/100ML N18316 001 May CAHN
>A> AT HOSPIRA 540MG/100ML;2.7GM/100ML N17636 001 May CAHN
>A> AT 540MG/100ML;2.7GM/100ML N18316 001 May CAHN

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

>D>	PERGONAL				
>D> BX	+	SERONO	75 IU/AMP;75 IU/AMP	N17646 001	May DISC
>A>	@		75 IU/AMP;75 IU/AMP	N17646 001	May DISC
	REPRONEX				
>D> BX	+	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	Aug 27, 1999 May CTEC
>A>	+		75 IU/VIAL;75 IU/VIAL	N21047 001	Aug 27, 1999 May CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

>D> AP	+	ABBOTT	25MG/ML	N21171 001	May CAHN
>D> AP	+		50MG/ML	N21171 002	May CAHN
>D> AP	+		75MG/ML	N21171 003	May CAHN
>D> AP	+		100MG/ML	N21171 004	May CAHN
>A> AP	+	HOSPIRA	25MG/ML	N21171 001	May CAHN
>A> AP	+		50MG/ML	N21171 002	May CAHN
>A> AP	+		75MG/ML	N21171 003	May CAHN
>A> AP	+		100MG/ML	N21171 004	May CAHN
	MEPERIDINE HCL PRESERVATIVE FREE				
>D> AP	+	ABBOTT	10MG/ML	N88432 001	Aug 16, 1984 May CAHN
>A> AP	+	HOSPIRA	10MG/ML	N88432 001	Aug 16, 1984 May CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

>A> AP	+	HOSPIRA	1%	N12250 001	May CAHN
>A> AP	+		1.5%	N12250 005	May CAHN
>A> AP	+		2%	N12250 002	May CAHN
>D> AP	+	STERLING WINTHROP	1%	N12250 001	May CAHN
>D> AP	+		1.5%	N12250 005	May CAHN
>D> AP	+		2%	N12250 002	May CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB	PROMETHEUS LABS	50MG	N40461 001	Feb 11, 2004 Feb NEWA	
AB	ROXANE	50MG	N40528 001	Feb 13, 2004 Feb NEWA	
	PURINETHOL				
AB	+	TEVA	50MG	N09053 002	Feb CFTG

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	BEDFORD	100MG/ML	N75739 001	Jan 09, 2004 Jan NEWA
----	---------	----------	------------	-----------------------

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

>D>	+	NOVARTIS	EQ 25MG BASE/ML	N16997 001	May DISC
>A>	@		EQ 25MG BASE/ML	N16997 001	May DISC
>D>	TABLET; ORAL				
>D>	SERENTIL				
>D>	NOVARTIS		EQ 25MG BASE	N16774 002	May DISC

>D>	TABLET; ORAL				
>D>	SERENTIL				
>A>	# NOVARTIS	EQ 25MG BASE	N16774 002	May	DISC
>D>	+	EQ 100MG BASE	N16774 004	May	DISC
>A>	@	EQ 100MG BASE	N16774 004	May	DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL					
FORTAMET					
BX	ANDRX	500MG	N21574 001	Apr 27, 2004	Apr NEWA
	+	1GM	N21574 002	Apr 27, 2004	Apr NEWA
GLUCOPHAGE XR					
AB	BRISTOL MYERS SQUIBB	500MG	N21202 001	Oct 13, 2000	Jan CFTG
METFORMIN HCL					
AB	IVAX PHARMS	500MG	N76545 001	Dec 01, 2003	Jan NEWA

METHADONE HYDROCHLORIDE

TABLET; ORAL					
METHADONE HCL					
AA	MALLINCKRODT	5MG	N40517 001	Apr 27, 2004	Apr NEWA
AA		10MG	N40517 002	Apr 27, 2004	Apr NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL					
DESOXYN					
AB	+	OVATION PHARMS	5MG	N05378 002	Feb CFTG
METHAMPHETAMINE HCL					
AB	ABLE	5MG	N40529 001	Feb 25, 2004	Feb NEWA

METHIMAZOLE

TABLET; ORAL					
TAPAZOLE					
AB	KING PHARMS	5MG	N07517 002	Mar CAHN	
AB		10MG	N07517 004	Mar CAHN	

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION					
METHYLDOPATE HCL					
>D>	AP	ABBOTT	50MG/ML	N70698 001	Jun 15, 1987 May CAHN
>D>	AP		50MG/ML	N70699 001	Jun 15, 1987 May CAHN
>A>	AP	HOSPIRA	50MG/ML	N70698 001	Jun 15, 1987 May CAHN
>A>	AP		50MG/ML	N70699 001	Jun 15, 1987 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
METADATE CD					
>D>		CELLTECH PHARMS	10MG	N21259 003	May 27, 2003 May CTEC
>A>	BX		10MG	N21259 003	May 27, 2003 May CTEC
RITALIN LA					
>D>		NOVARTIS	10MG	N21284 004	Apr 10, 2004 May CTEC
>A>	BX		10MG	N21284 004	Apr 10, 2004 May CTEC
			10MG	N21284 004	Apr 10, 2004 Apr NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

>D>	AP	ABBOTT	EQ 40MG BASE/VIAL	N85853 001	May	CAHN	
>D>	AP		EQ 125MG BASE/VIAL	N85855 001	May	CAHN	
>D>	AP		EQ 500MG BASE/VIAL	N85854 001	May	CAHN	
>D>	AP		EQ 500MG BASE/VIAL	N89173 001	Aug 18, 1987	May	CAHN
>D>	AP		EQ 1GM BASE/VIAL	N85852 001		May	CAHN
>D>	AP		EQ 1GM BASE/VIAL	N89174 001	Aug 18, 1987	May	CAHN
>A>	AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853 001		May	CAHN
>A>	AP		EQ 125MG BASE/VIAL	N85855 001		May	CAHN
>A>	AP		EQ 500MG BASE/VIAL	N85854 001		May	CAHN
>A>	AP		EQ 500MG BASE/VIAL	N89173 001	Aug 18, 1987	May	CAHN
>A>	AP		EQ 1GM BASE/VIAL	N85852 001		May	CAHN
>A>	AP		EQ 1GM BASE/VIAL	N89174 001	Aug 18, 1987	May	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

>D>	AP	ABBOTT	EQ 5MG BASE/ML	N70505 001	Jun 23, 1989	May	CAHN
>D>		@	EQ 5MG BASE/ML	N70506 001	Jun 22, 1989	May	CAHN
>D>	AP		EQ 5MG BASE/ML	N73117 001	Jan 17, 1991	May	CAHN
>D>	AP		EQ 5MG BASE/ML	N73118 001	Jan 17, 1991	May	CAHN
>D>	AP		EQ 5MG BASE/ML	N74147 001	Aug 02, 1996	May	CAHN
>A>	AP	HOSPIRA	EQ 5MG BASE/ML	N70505 001	Jun 23, 1989	May	CAHN
>A>		@	EQ 5MG BASE/ML	N70506 001	Jun 22, 1989	May	CAHN
>A>	AP		EQ 5MG BASE/ML	N73117 001	Jan 17, 1991	May	CAHN
>A>	AP		EQ 5MG BASE/ML	N73118 001	Jan 17, 1991	May	CAHN
>A>	AP		EQ 5MG BASE/ML	N74147 001	Aug 02, 1996	May	CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	ROXANE	10MG	N76482 002	Apr 29, 2004	Apr	NEWA
AB	TEVA	2.5MG	N76600 001	Jan 06, 2004	Jan	NEWA
AB		5MG	N76833 001	Mar 01, 2004	Mar	NEWA
	MYKROX					
	@ CELLTECH PHARMS	0.5MG	N19532 001	Oct 30, 1987	Jan	DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

>D>	AP	ABBOTT	1MG/ML	N74133 001	Dec 21, 1993	May	CAHN
>D>	AP		1MG/ML	N75160 001	Jul 06, 1998	May	CAHN
>A>	AP	HOSPIRA	1MG/ML	N74133 001	Dec 21, 1993	May	CAHN
>A>	AP		1MG/ML	N75160 001	Jul 06, 1998	May	CAHN

TABLET; ORAL

LOPRESSOR

AB	NOVARTIS	100MG	N17963 002		Mar	CRLD
	METOPROLOL TARTRATE					
AB	CARACO	25MG	N76670 001	Jan 15, 2004	Mar	CTEC
		25MG	N76670 001	Jan 15, 2004	Jan	NEWA
+	MYLAN	25MG	N76704 001	Jan 16, 2004	Jan	NEWA
AB		25MG	N76704 001	Jan 16, 2004	Mar	CTEC
AB		50MG	N76704 002	Jan 16, 2004	Jan	NEWA

TABLET; ORAL

METOPROLOL TARTRATE

AB	MYLAN	100MG	N76704 003 Jan 16, 2004 Jan NEWA
AB	+	100MG	N76704 003 Jan 16, 2004 Mar CRLD

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

AB	KALI LABS	375MG	N76522 001 Jan 29, 2004 Jan NEWA
----	-----------	-------	----------------------------------

CREAM; TOPICAL

METROCREAM

>D>	+	GALDERMA LABS LP	0.75%	N20531 001 Sep 20, 1995 May CFTG
>A>	AB	+	0.75%	N20531 001 Sep 20, 1995 May CFTG

>A>	+	METRONIDAZOLE		N76408 001 May 28, 2004 May NEWA
>A>	AB	ALTANA	0.75%	

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

>D>	AP	+	ABBOTT	500MG/100ML	N18890 002 Nov 18, 1983 May CAHN
>A>	AP	+	HOSPIRA	500MG/100ML	N18890 002 Nov 18, 1983 May CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

>D>	AP	+	ABBOTT	EQ 1MG BASE/ML	N75293 001 Jun 20, 2000 May DISC
>D>	AP			EQ 1MG BASE/ML	N75409 002 Jun 20, 2000 May CAHN
>D>	AP			EQ 1MG BASE/ML	N75857 001 Jul 22, 2002 May CAHN
>D>	AP	+		EQ 5MG BASE/ML	N75293 002 Jun 20, 2000 May DISC
>D>	AP			EQ 5MG BASE/ML	N75409 001 Jun 20, 2000 May CAHN
>D>	AP			EQ 5MG BASE/ML	N75857 002 Jul 22, 2002 May CAHN
>A>		@ HOSPIRA		EQ 1MG BASE/ML	N75293 001 Jun 20, 2000 May DISC
>A>	AP			EQ 1MG BASE/ML	N75409 002 Jun 20, 2000 May CAHN
>A>	AP			EQ 1MG BASE/ML	N75856 001 Jun 13, 2002 May CAHN
>A>	AP	+		EQ 1MG BASE/ML	N75857 001 Jul 22, 2002 May CAHN
>A>		@		EQ 5MG BASE/ML	N75293 002 Jun 20, 2000 May DISC
>A>	AP			EQ 5MG BASE/ML	N75409 001 Jun 20, 2000 May CAHN
>A>	AP			EQ 5MG BASE/ML	N75856 002 Jun 13, 2002 May CAHN
>A>	AP	+		EQ 5MG BASE/ML	N75857 002 Jul 22, 2002 May CAHN
>D>	AP	ROSS LABS		EQ 1MG BASE/ML	N75856 001 Jun 13, 2002 May CAHN
>D>	AP			EQ 5MG BASE/ML	N75856 002 Jun 13, 2002 May CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HCL

>A>	AB	IMPAX PHARMS	2.5MG	N76449 001 May 27, 2004 May NEWA
>A>	AB		5MG	N76449 002 May 27, 2004 May NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>D>	AP	HOSPIRA	EQ 1MG BASE/ML	N75884 001 May 28, 2002 May CAHN
>A>	AP		EQ 1MG BASE/ML	N75884 001 May 28, 2002 May CAHN
>D>	AP	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER		
>D>	AP	ABBOTT	EQ 20MG BASE/100ML	N75885 001 May 28, 2002 May CAHN
>A>	AP	HOSPIRA	EQ 20MG BASE/100ML	N75885 001 May 28, 2002 May CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL			
MINOCYCLINE HCL			
AB	MEDICIS	EQ 50MG BASE	N65131 001 Apr 16, 2003 Jan CFTG
AB		EQ 75MG BASE	N65131 002 Apr 16, 2003 Jan CFTG
AB	+	EQ 100MG BASE	N65131 003 Apr 16, 2003 Jan CFTG
AB	RANBAXY	EQ 50MG BASE	N65156 001 Jan 06, 2004 Jan NEWA
AB		EQ 75MG BASE	N65156 002 Jan 06, 2004 Jan NEWA
AB		EQ 100MG BASE	N65156 003 Jan 06, 2004 Jan NEWA

MIRTAZAPINE

TABLET; ORAL			
MIRTAZAPINE			
	CARACO	7.5MG	N76541 004 Apr 22, 2004 Apr NEWA
AB		15MG	N76541 001 Apr 22, 2004 Apr NEWA
AB		30MG	N76541 002 Apr 22, 2004 Apr NEWA
AB		45MG	N76541 003 Apr 22, 2004 Apr NEWA

MOLINDONE HYDROCHLORIDE

>D>	CONCENTRATE; ORAL				
>D>	MOBAN				
>D>	+	ENDO PHARMS	20MG/ML	N17938 001	May DISC
>A>			20MG/ML	N17938 001	May DISC
>D>	TABLET; ORAL				
>D>	MOBAN				
>D>	+	ENDO PHARMS	100MG	N17111 008	May DISC
>A>			100MG	N17111 008	May DISC

MORPHINE SULFATE

>A>	INJECTABLE, LIPOSOMAL; EPIDURAL				
>A>	DEPODUR				
>A>		SKYEPHARMA	10MG/ML	N21671 001 May 18, 2004 May NEWA	
>A>			15MG/1.5ML(10MG/ML)	N21671 002 May 18, 2004 May NEWA	
>A>	+		20MG/2ML(10MG/ML)	N21671 003 May 18, 2004 May NEWA	
INJECTABLE; INJECTION					
MORPHINE SULFATE					
>D>	AP	+	ABBOTT	0.5MG/ML	N19917 001 Oct 30, 1992 May CAHN
>D>	AP			0.5MG/ML	N71849 001 May 11, 1988 May CAHN
>D>	AP			0.5MG/ML	N73509 001 Sep 30, 1992 May CAHN
>D>	AP	+		1MG/ML	N19916 001 Oct 30, 1992 May CAHN
>D>	AP			1MG/ML	N71850 001 May 11, 1988 May CAHN
>D>	AP			1MG/ML	N73510 001 Sep 30, 1992 May CAHN
>A>	AP	+	HOSPIRA	0.5MG/ML	N19917 001 Oct 30, 1992 May CAHN
>A>	AP			0.5MG/ML	N71849 001 May 11, 1988 May CAHN
>A>	AP			0.5MG/ML	N73509 001 Sep 30, 1992 May CAHN
>A>	AP	+		1IMG/ML	N19916 001 Oct 30, 1992 May CAHN
>A>	AP			1IMG/ML	N71850 001 May 11, 1988 May CAHN
>A>	AP			1IMG/ML	N73510 001 Sep 30, 1992 May CAHN
TABLET, EXTENDED RELEASE; ORAL					
MORPHINE SULFATE					
>A>	AB		KV PHARM	15MG	N76733 001 May 19, 2004 May NEWA
>A>	AB			60MG	N76720 001 May 19, 2004 May NEWA
ORAMORPH SR					
BC	+	AAIPHARMA	60MG	N19977 002 Aug 15, 1991 Mar CRLD	

MYCOPHENOLIC ACID

TABLET, EXTENDED RELEASE; ORAL

MYFORTIC

NOVARTIS

+

180MG

360MG

N50791 001 Feb 27, 2004 Feb NEWA
N50791 002 Feb 27, 2004 Feb NEWANABILONE

CAPSULE; ORAL

CESAMET

@ VALEANT

1MG

N18677 001 Dec 26, 1985 Jan CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

>D> AP ABBOTT

10MG/ML

N70914 001 Feb 03, 1989 May CAHN

>D> AP

10MG/ML

N70915 001 Feb 03, 1989 May CAHN

>D> AP

20MG/ML

N70916 001 Feb 03, 1989 May CAHN

>D> AP

20MG/ML

N70918 001 Feb 03, 1989 May CAHN

>A> AP HOSPIRA

10MG/ML

N70914 001 Feb 03, 1989 May CAHN

>A> AP

10MG/ML

N70915 001 Feb 03, 1989 May CAHN

>A> AP

20MG/ML

N70916 001 Feb 03, 1989 May CAHN

>A> AP

20MG/ML

N70918 001 Feb 03, 1989 May CAHN

@ KING PHARMS

10MG/ML

N74471 001 Mar 19, 1998 Mar DISC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

>D> AP ABBOTT

0.02MG/ML

N70171 001 Sep 24, 1986 May CAHN

>D> AP

0.02MG/ML

N70252 001 Jan 16, 1987 May CAHN

>D> AP

0.02MG/ML

N70253 001 Jan 16, 1987 May CAHN

>D> @

0.4MG/ML

N70172 001 Sep 24, 1986 May CAHN

>D> AP

0.4MG/ML

N70254 001 Jan 07, 1987 May CAHN

>D> AP

0.4MG/ML

N70255 001 Jan 07, 1987 May CAHN

>D> AP

0.4MG/ML

N70256 001 Jan 07, 1987 May CAHN

>D> AP

0.4MG/ML

N70257 001 Jan 07, 1987 May CAHN

>A> AP HOSPIRA

0.02MG/ML

N70171 001 Sep 24, 1986 May CAHN

>A> AP

0.02MG/ML

N70252 001 Jan 16, 1987 May CAHN

>A> AP

0.02MG/ML

N70253 001 Jan 16, 1987 May CAHN

>A> @

0.4MG/ML

N70172 001 Sep 24, 1986 May CAHN

>A> AP

0.4MG/ML

N70254 001 Jan 07, 1987 May CAHN

>A> AP

0.4MG/ML

N70255 001 Jan 07, 1987 May CAHN

>A> AP

0.4MG/ML

N70256 001 Jan 07, 1987 May CAHN

>A> AP

0.4MG/ML

N70257 001 Jan 07, 1987 May CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB WESTWARD

250MG

N76494 001 Jan 14, 2004 Jan NEWA

AB

375MG

N76494 002 Jan 14, 2004 Jan NEWA

AB

500MG

N76494 003 Jan 14, 2004 Jan NEWA

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

+ KING PHARMS

1.75MG/INH

N19660 001 Dec 30, 1992 Jan CAHN

NIACIN

TABLET; ORAL			
NIACIN			
# MK LABS	500MG	N83525 001	Feb DISC
# TABLICAPS	500MG	N84237 001	Feb DISC
NIACOR			
AA + UPSHER SMITH	500MG	N40378 001	May 03, 2000 Feb CRLD

NIFEDIPIINE

TABLET, EXTENDED RELEASE; ORAL			
NIFEDIPIINE			
AB2 MARTEC	90MG	N75414 003	Mar 23, 2004 Mar NEWA
AB2 + PIZER	90MG	N19684 003	Sep 06, 1989 Mar CFTG

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL			
MACROBID			
AB + PROCTER AND GAMBLE	75MG;25MG	N20064 001	Dec 24, 1991 Mar CFTG
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)			
AB MYLAN	EQ 75MG BASE;25MG	N76648 001	Mar 22, 2004 Mar NEWA
AB	75MG;25MG	N76648 001	Mar 22, 2004 Apr CPOT

NITROGLYCERIN

INJECTABLE; INJECTION			
NITROGLYCERIN			
>D> AP + ABBOTT	5MG/ML	N18531 001	May CAHN
>A> AP + HOSPIRA	5MG/ML	N18531 001	May CAHN
NITROGLYCERIN IN DEXTROSE 5%			
>D> AP ABBOTT	0.1MG/ML	N74083 001	Oct 26, 1994 May CAHN
>D> AP	10MG/100ML	N71846 001	Aug 31, 1990 May CAHN
>D> AP	20MG/100ML	N71847 001	Aug 31, 1990 May CAHN
>D> AP	40MG/100ML	N71848 001	Aug 31, 1990 May CAHN
>A> AP HOSPIRA	0.1MG/ML	N74083 001	Oct 26, 1994 May CAHN
>A> AP	10MG/100ML	N71846 001	Aug 31, 1990 May CAHN
>A> AP	20MG/100ML	N71847 001	Aug 31, 1990 May CAHN
>A> AP	40MG/100ML	N71848 001	Aug 31, 1990 May CAHN

NIZATIDINE

>A>	SOLUTION; ORAL		
>A>	AXID		
>A> + RELIANT PHARMS	15MG/ML	N21494 001	May 25, 2004 May NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION			
LEVOPHED			
>D> AP + ABBOTT	EQ 1MG BASE/ML	N07513 001	May CAHN
>A> AP + HOSPIRA	EQ 1MG BASE/ML	N07513 001	May CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC			
OCUFLOX			
>D> + ALLERGAN	0.3%	N19921 001	Jul 30, 1993 May CFTG
>A> AT +	0.3%	N19921 001	Jul 30, 1993 May CFTG

<u>SOLUTION/DROPS; OPHTHALMIC</u>			
>A>	OFLOXACIN		
>A> AT	ALCON	0.3%	N76231 001 May 14, 2004 May NEWA
>A> AT	BAUSCH AND LOMB	0.3%	N76622 001 May 14, 2004 May NEWA
>A> AT	HI TECH PHARMA	0.3%	N76615 001 May 14, 2004 May NEWA
>A> AT	NOVEX	0.3%	N76513 001 May 14, 2004 May NEWA
<u>OLANZAPINE</u>			
INJECTABLE; INTRAMUSCULAR			
ZYPREXA			
+ LILLY		10MG/VIAL	N21253 001 Mar 29, 2004 Mar NEWA
<u>OXACILLIN SODIUM</u>			
INJECTABLE; INJECTION			
OXACILLIN SODIUM			
AP +	APOTHECON	EQ 250MG BASE/VIAL	N61490 001 Mar CRLD
AP +		EQ 2GM BASE/VIAL	N61490 004 Mar NEWA
AP		EQ 2GM BASE/VIAL	N62737 002 Dec 23, 1986 Mar CRLD
<u>OXAMNIQUINE</u>			
CAPSULE; ORAL			
VANSIL			
@ PFIZER		250MG	N18069 001 Mar DISC
<u>OXYCODONE HYDROCHLORIDE</u>			
TABLET, EXTENDED RELEASE; ORAL			
OXYCODONE HCL			
AB ENDO PHARMS		10MG	N75923 001 Mar 23, 2004 Mar NEWA
AB		20MG	N75923 002 Mar 23, 2004 Mar NEWA
AB		40MG	N75923 003 Mar 23, 2004 Mar NEWA
AB TEVA		80MG	N76168 001 Mar 23, 2004 Mar NEWA
OXYCONTIN			
AB PURDUE PHARMA LP		10MG	N20553 001 Dec 12, 1995 Mar CFTG
AB		20MG	N20553 002 Dec 12, 1995 Mar CPTG
AB +		40MG	N20553 003 Dec 12, 1995 Mar CFTG
AB +		80MG	N20553 004 Jan 06, 1997 Mar CFTG
TABLET; ORAL			
OXYCODONE HCL			
AB AMIDE PHARM		15MG	N76636 001 Feb 06, 2004 Feb NEWA
AB		30MG	N76636 002 Feb 06, 2004 Feb NEWA
ROXICODONE			
AB + AAIPHARMA		15MG	N21011 001 Aug 31, 2000 Feb CFTG
AB		30MG	N21011 002 Aug 31, 2000 Feb CFTG
<u>PANCURONIUM BROMIDE</u>			
INJECTABLE; INJECTION			
PANCURONIUM BROMIDE			
>D> AP ABBOTT		1MG/ML	N72320 001 Jan 19, 1989 May CAHN
>D> AP		2MG/ML	N72321 001 Jan 19, 1989 May CAHN
>A> AP HOSPIRA		1MG/ML	N72320 001 Jan 19, 1989 May CAHN
>A> AP		2MG/ML	N72321 001 Jan 19, 1989 May CAHN
<u>PARICALCITOL</u>			
INJECTABLE; INJECTION			
ZEMPLAR			
ABBOTT		0.002MG/ML	N20819 002 Feb 01, 2000 Mar NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAROXETINE HCL

AB	ALPHAPHARM	EQ 10MG BASE	N75716 001 Mar 08, 2004 Mar NEWA
AB		EQ 20MG BASE	N75716 002 Mar 08, 2004 Mar NEWA
AB		EQ 30MG BASE	N75716 003 Mar 08, 2004 Mar NEWA
AB		EQ 40MG BASE	N75716 004 Mar 08, 2004 Mar NEWA
AB	SANDOZ	EQ 10MG BASE	N75566 001 Mar 08, 2004 Mar NEWA
AB		EQ 20MG BASE	N75566 002 Mar 08, 2004 Mar NEWA
AB		EQ 30MG BASE	N75566 003 Mar 08, 2004 Mar NEWA
AB		EQ 40MG BASE	N75566 004 Mar 08, 2004 Mar NEWA

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+ LILLY EQ 500MG BASE/VIAL

N21462 001 Feb 04, 2004 Feb NEWA

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

>D>	AP	ABBOTT	300MG/VIAL	N73479 001 Jun 30, 1992 May CAHN
>A>	AP	HOSPIRA	300MG/VIAL	N73479 001 Jun 30, 1992 May CAHN

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

>D>	+	ABBOTT	EQ 30MG BASE/ML	N16194 001 May CAHN
>A>	+	HOSPIRA	EQ 30MG BASE/ML	N16194 001 May CAHN

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

>D>	+	OVATION PHARMS	30MG	N84095 001 May DISC
>A>	@		30MG	N84095 001 May DISC
>D>	AA	+	100MG	N83245 001 May DISC
>A>	@		100MG	N83245 001 May DISC
		SODIUM PENTOBARBITAL		
>D>	AA	VALEANT PHARM INTL	100MG	N83264 001 May CRLD
>A>	+		100MG	N83264 001 May CRLD

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB	TARO	125MG/5ML	N40521 001 Mar 08, 2004 Mar NEWA
----	------	-----------	----------------------------------

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

>D>	@	ABBOTT	50MG/ML	N89521 001 Mar 17, 1987 May CAHN
>D>	@		50MG/ML	N89744 001 Dec 18, 1987 May CAHN
>A>	@	HOSPIRA	50MG/ML	N89521 001 Mar 17, 1987 May CAHN
>A>	@		50MG/ML	N89744 001 Dec 18, 1987 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION

VITAMIN K1

>D>	BP	ABBOTT	1MG/0.5ML	N87954 001 Jul 25, 1983 May CAHN	>D>
>D>	BP		10MG/ML	N87955 001 Jul 25, 1983 May CAHN	>D>
>D>		@	10MG/ML	N87956 001 Jul 25, 1983 May CAHN	>A>
>A>	BP	HOSPIRA	1MG/0.5ML	N87954 001 Jul 25, 1983 May CAHN	>A>
>A>	BP		10MG/ML	N87955 001 Jul 25, 1983 May CAHN	>D>
>A>		@	10MG/ML	N87956 001 Jul 25, 1983 May CAHN	>A>

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 001 Apr 22, 1991 Feb CPTG	>D>
AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 002 Nov 18, 1994 Feb CPTG	>A>
AA		TRILYTE			>D>
AA		SCHWARZ PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N76491 001 Feb 05, 2004 Feb NEWA	>A>

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL

>D>	+	ABBOTT	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001 Apr 30, 1986 May CAHN	>D>
>A>	+	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001 Apr 30, 1986 May CAHN	>A>

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

>D>	+	ABBOTT	2MEQ/ML	N18896 001 Jul 20, 1984 May CAHN	>D>
>A>	+	HOSPIRA	2MEQ/ML	N18896 001 Jul 20, 1984 May CAHN	>A>

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

>D>	@	ABBOTT	1MEQ/ML	N80205 003 May CAHN	>A>
>D>	@		1MEQ/ML	N83345 003 May CAHN	>D>
>D>	+		1.5MEQ/ML	N83345 001 May CAHN	>A>
>D>	AP	+	2MEQ/ML	N80205 001 May CAHN	>D>
>D>	AP		2MEQ/ML	N83345 002 May CAHN	>A>
>D>		@	2.4MEQ/ML	N80205 004 May CAHN	
>D>		@	3.2MEQ/ML	N80205 005 May CAHN	
>A>		@ HOSPIRA	1MEQ/ML	N80205 003 May CAHN	
>A>		@	1MEQ/ML	N83345 003 May CAHN	
>A>		+	1.5MEQ/ML	N83345 001 May CAHN	>A>
>A>	AP	+	2MEQ/ML	N80205 001 May CAHN	
>A>	AP		2MEQ/ML	N83345 002 May CAHN	
>A>		@	2.4MEQ/ML	N80205 004 May CAHN	
>A>		@	3.2MEQ/ML	N80205 005 May CAHN	
			POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER		
>D>		@ ABBOTT	14.9MG/ML	N20161 005 Nov 30, 1992 May CAHN	
>D>		@	745MG/100ML	N20161 001 Nov 30, 1992 May CAHN	
>A>		@ HOSPIRA	14.9MG/ML	N20161 005 Nov 30, 1992 May CAHN	

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER			
>A>	@ HOSPIRA	745MG/100ML	N20161 001 Nov 30, 1992 May CAHN
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER			
>D> AP	+ ABBOTT	29.8MG/ML	N20161 006 Aug 11, 1998 May CAHN
>D>	@	1.49GM/100ML	N20161 002 Nov 30, 1992 May CAHN
>A> AP	+ HOSPIRA	29.8MG/ML	N20161 006 Aug 11, 1998 May CAHN
>A>	@	1.49GM/100ML	N20161 002 Nov 30, 1992 May CAHN
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER			
>D> AP	+ ABBOTT	2.24GM/100ML	N20161 003 Aug 11, 1998 May CAHN
>A> AP	+ HOSPIRA	2.24GM/100ML	N20161 003 Aug 11, 1998 May CAHN
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER			
>D> AP	+ ABBOTT	2.98GM/100ML	N20161 004 Aug 11, 1998 May CAHN
>A> AP	+ HOSPIRA	2.98GM/100ML	N20161 004 Aug 11, 1998 May CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION			
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
>D> AP	ABBOTT	149MG/100ML;900MG/100ML	N19686 001 Oct 17, 1988 May CAHN
>A> AP	HOSPIRA	149MG/100ML;900MG/100ML	N19686 001 Oct 17, 1988 May CAHN
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
>D> AP	ABBOTT	298MG/100ML;900MG/100ML	N19686 002 Oct 17, 1988 May CAHN
>A> AP	HOSPIRA	298MG/100ML;900MG/100ML	N19686 002 Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION			
THAM-E			
>D>	@ ABBOTT	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025 001 May CAHN
>A>	@ HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025 001 May CAHN

PREDNISOLONE

TABLET; ORAL			
PREDNISOLONE			
>D> BX	EVERYLIFE	2.5MG	N84439 002 May DISC
>A>	@	2.5MG	N84439 002 May DISC
>D> BX		5MG	N84439 003 May DISC
>A>	@	5MG	N84439 003 May DISC
>D>	SPERTI	1MG	N80358 001 May DISC
>A>	@	1MG	N80358 001 May DISC
>D> BX		2.5MG	N80358 002 May DISC
>A>	@	2.5MG	N80358 002 May DISC
>D> BX		5MG	N80358 003 May DISC
>A>	@	5MG	N80358 003 May DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL			
PREDNISOLONE SODIUM PHOSPHATE			
>A> AA	PADDICK	EQ 5MG BASE/5ML	N75988 001 May 25, 2004 May NEWA

PREDNISONE

TABLET; ORAL			
PREDNISONE			
AB	WEST WARD	2.5MG	N40538 001 Jan 08, 2004 Jan NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

>D>	AP	ABBOTT	100MG/ML	N89069 001	Feb 12, 1986	May	CAHN
>D>	AP		500MG/ML	N89070 001	Feb 12, 1986	May	CAHN
>D>	AP		500MG/ML	N89537 001	Aug 25, 1987	May	CAHN
>A>	AP	HOSPIRA	100MG/ML	N89069 001	Feb 12, 1986	May	CAHN
>A>	AP		500MG/ML	N89070 001	Feb 12, 1986	May	CAHN
>A>	AP		500MG/ML	N89537 001	Aug 25, 1987	May	CAHN

PROCaine HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

>D>	AP	+	ABBOTT	1%	N85362 003	May	CAHN
>D>	AP	+		2%	N85362 004	May	CAHN
>D>		+		10%	N86797 001	May	CAHN
>A>	AP	+	HOSPIRA	1%	N85362 003	May	CAHN
>A>	AP	+		2%	N85362 004	May	CAHN
>A>		+		10%	N86797 001	May	CAHN
			PROCaine HCL				
>D>	AP	ABBOTT	1%	N80416 001	May	CAHN	
>D>	AP		2%	N80416 002	May	CAHN	
>A>	AP	HOSPIRA	1%	N80416 001	May	CAHN	
>A>	AP		2%	N80416 002	May	CAHN	

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

>D>	AP	ABBOTT	EQ 5MG BASE/ML	N89703 001	Apr 07, 1988	May	CAHN
>A>	AP	BEDFORD	EQ 5MG BASE/ML	N40540 001	May 28, 2004	May	NEWA
>A>	AP	HOSPIRA	EQ 5MG BASE/ML	N89703 001	Apr 07, 1988	May	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

>D>	AP	ABBOTT	25MG/ML	N40372 001	Jun 08, 2000	May	CAHN
>D>	AP		50MG/ML	N40372 002	Jun 08, 2000	May	CAHN
>D>	AP		50MG/ML	N83838 002		May	CAHN
	AP	BEDFORD LABS	25MG/ML	N40524 001	Mar 17, 2004	Mar	NEWA
	AP		50MG/ML	N40524 002	Mar 17, 2004	Mar	NEWA
>A>	AP	HOSPIRA	25MG/ML	N40372 001	Jun 08, 2000	May	CAHN
>A>	AP		50MG/ML	N40372 002	Jun 08, 2000	May	CAHN
>A>	AP		50MG/ML	N83838 002		May	CAHN

SYRUP; ORAL

PROMETH PLAIN

ALPHARMA 6.25MG/5ML

N85953 001 Feb DISC

PROMETHAZINE HCL

>D>	AA	+	HI TECH PHARMA	6.25MG/5ML	N40026 001	Sep 25, 1998	May	CRLD
>A>	AA			6.25MG/5ML	N40026 001	Sep 25, 1998	May	CRLD
	AA	+		6.25MG/5ML	N40026 001	Sep 25, 1998	Feb	CRLD

PROMETHAZINE PLAIN

>D>	AA	MORTON GROVE	6.25MG/5ML	N87953 001	Nov 15, 1982	May	CRLD
>A>	AA	+	6.25MG/5ML	N87953 001	Nov 15, 1982	May	CRLD

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL
PROPAFENONE HCL

AB	PLIVA	150MG	N76550 001 Apr 23, 2004 Apr NEWA
AB		225MG	N76550 002 Apr 23, 2004 Apr NEWA
AB		300MG	N76550 003 Apr 23, 2004 Apr NEWA

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
PROPRANOLOL

AP	AM PHARM PARTNERS	1MG/ML	N75826 001 Aug 31, 2001 Jan NEWA
----	-------------------	--------	----------------------------------

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

+	AM PHARM PARTNERS	10MG/ML	N89454 001 Apr 07, 1987 Mar CRLD
@	LILLY	10MG/ML	N06460 002 Mar DISC

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 25

	GLAXOSMITHKLINE	EQ 25MG BASE	N20251 003 Apr 01, 2004 Apr NEWA
--	-----------------	--------------	----------------------------------

RIBAVIRIN

CAPSULE; ORAL
REBETOL

AB	+ SCHERING PLOUGH RES	200MG	N20903 002 Jul 25, 2001 Apr CFTG
AB	RIBASPHERE		N76203 001 Apr 06, 2004 Apr NEWA
AB	THREE RIVERS PHARMS	200MG	
	RIBAVIRIN		
AB	SANDOZ	200MG	N76192 001 Apr 06, 2004 Apr NEWA

>A> RIFAXIMIN

>A> TABLET; ORAL
>A> XIFAXAN

>A>	+ SALIX PHARMS	200MG	N21361 001 May 25, 2004 May NEWA
-----	----------------	-------	----------------------------------

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL

>D>	+ ABBOTT	10MG/ML	N71618 001 Feb 28, 1991 May CAHN
>D>	+	15MG/ML	N71619 001 Feb 28, 1991 May CAHN
>A>	+ HOSPIRA	10MG/ML	N71618 001 Feb 28, 1991 May CAHN
>A>	+	15MG/ML	N71619 001 Feb 28, 1991 May CAHN
	RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER		
>D>	+ ABBOTT	30MG/100ML	N71438 001 Jan 22, 1991 May CAHN
>A>	+ HOSPIRA	30MG/100ML	N71438 001 Jan 22, 1991 May CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP

>D>	+ GLAXOSMITHKLINE	EQ 5MG BASE	N20658 005 Sep 19, 1997 May CRLD
>A>		EQ 5MG BASE	N20658 005 Sep 19, 1997 May CRLD

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION
LIPOSYN II 10%

>D>	+	ABBOTT	5%;5% (5GM/100ML)	N18997 001 Aug 27, 1984 May CAHN
>A>	+	HOSPIRA	5%;5% (5GM/100ML)	N18997 001 Aug 27, 1984 May CAHN
LIPOSYN II 20%				
>D>	+	ABBOTT	10%;10% (10GM/100ML)	N18991 001 Aug 27, 1984 May CAHN
>A>	+	HOSPIRA	10%;10% (10GM/100ML)	N18991 001 Aug 27, 1984 May CAHN

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS
HUMAN SECRETIN
+ CHIRHOCLIN 16UGM/VIAL N21256 001 Apr 09, 2004 Apr NEWA

SIROLIMUS

TABLET; ORAL
RAPAMUNE
WYETH PHARMS INC 2MG N21110 002 Aug 22, 2002 Feb CRLD
+ 5MG N21110 003 Feb 23, 2004 Feb NEWA

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION
SODIUM ACETATE IN PLASTIC CONTAINER

>D>	+	ABBOTT	2MEQ/ML	N18893 001 May 04, 1983 May CAHN
>A>	+	HOSPIRA	2MEQ/ML	N18893 001 May 04, 1983 May CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	+	ABBOTT	9MG/ML	N18800 001 Oct 29, 1982 May CAHN
>A>	AP	+	HOSPIRA	9MG/ML	N18800 001 Oct 29, 1982 May CAHN
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP		ABBOTT	450MG/100ML	N18090 001 May CAHN
>D>	AP			450MG/100ML	N19759 001 Jun 08, 1988 May CAHN
>A>	AP		HOSPIRA	450MG/100ML	N18090 001 May CAHN
>A>	AP			450MG/100ML	N19759 001 Jun 08, 1988 May CAHN
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP		ABBOTT	9MG/ML	N18803 001 Oct 29, 1982 May CAHN
>D>	AP			9MG/ML	N19217 001 Jul 13, 1984 May CAHN
>D>	AP			9MG/ML	N19465 002 Jul 15, 1985 May CAHN
>D>	AP			900MG/100ML	N16366 001 May CAHN
>D>	AP			900MG/100ML	N19465 001 Jul 15, 1985 May CAHN
>D>	AP			900MG/100ML	N19480 001 Sep 17, 1985 May CAHN
>A>	AP		HOSPIRA	9MG/ML	N18803 001 Oct 29, 1982 May CAHN
>A>	AP			9MG/ML	N19217 001 Jul 13, 1984 May CAHN
>A>	AP			9MG/ML	N19465 002 Jul 15, 1985 May CAHN
>A>	AP			900MG/100ML	N16366 001 May CAHN
>A>	AP			900MG/100ML	N19465 001 Jul 15, 1985 May CAHN
>A>	AP			900MG/100ML	N19480 001 Sep 17, 1985 May CAHN
SODIUM CHLORIDE IN PLASTIC CONTAINER					
>D>			ABBOTT	2.5MEQ/ML	N18897 001 Jul 20, 1984 May CAHN
>A>			HOSPIRA	2.5MEQ/ML	N18897 001 Jul 20, 1984 May CAHN
SOLUTION; IRRIGATION					
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AT		ABBOTT	450MG/100ML	N17670 001 May CAHN

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	@ ABBOTT	450MG/100ML	N18380 001	May CAHN
>A> AT	HOSPIRA	450MG/100ML	N17670 001	May CAHN
>A>	@	450MG/100ML	N18380 001	May CAHN
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
>D> AT	ABBOTT	900MG/100ML	N17514 001	May CAHN
>D> AT		900MG/100ML	N18314 001	May CAHN
>A> AT	HOSPIRA	900MG/100ML	N17514 001	May CAHN
>A> AT		900MG/100ML	N18314 001	May CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

+ WATSON PHARMS	62.5MG/5ML	N20955 001 Feb 18, 1999 Feb CAHN
-----------------	------------	----------------------------------

SODIUM IODIDE, I-131

SOLUTION; ORAL

SODIUM IODIDE I 131

@ CIS 50mCi/ML

N17315 001 Apr DISC

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

>D> AP	ABBOTT	1.87GM/100ML	N18249 001	May CAHN
>A> AP	HOSPIRA	1.87GM/100ML	N18249 001	May CAHN
SODIUM LACTATE IN PLASTIC CONTAINER				
>D>	ABBOTT	5MEQ/ML	N18947 001 Sep 05, 1984 May CAHN	
>A>	HOSPIRA	5MEQ/ML	N18947 001 Sep 05, 1984 May CAHN	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

>D> AP	+	ABBOTT	25MG/ML	N71961 001 Aug 01, 1988 May CAHN
>D>	+		50MG/VIAL	N70566 001 Jun 09, 1986 May CAHN
>A> AP	+	HOSPIRA	25MG/ML	N71961 001 Aug 01, 1988 May CAHN
>A>	+		50MG/VIAL	N70566 001 Jun 09, 1986 May CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

>D>	ABBOTT	142MG/ML;276MG/ML	N18892 001 May 10, 1983 May CAHN
>A>	HOSPIRA	142MG/ML;276MG/ML	N18892 001 May 10, 1983 May CAHN

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

SAIZEN

>D> BX	SERONO	6MG/VIAL	N19764 001 Oct 08, 1996 May DISC
>A>	@	6MG/VIAL	N19764 001 Oct 08, 1996 May DISC
SEROSTIM			
BX	SERONO	4MG/VIAL	N20604 003 Jul 25, 1997 Jan CTEC
	@	8.8MG/VIAL	N20604 004 Sep 06, 2001 Jan DISC
ZORBTIVE			
>D> BX	SERONO INC	4MG/VIAL	N21597 001 Dec 01, 2003 May DISC
>A>	@	4MG/VIAL	N21597 001 Dec 01, 2003 May DISC
>D> BX		5MG/VIAL	N21597 002 Dec 01, 2003 May DISC

INJECTABLE; INJECTION

ZORBTIVE

>A>	@ SERONO INC	5MG/VIAL	N21597 002 Dec 01, 2003 May DISC
>D> BX		6MG/VIAL	N21597 003 Dec 01, 2003 May DISC
>A>	@	6MG/VIAL	N21597 003 Dec 01, 2003 May DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HCL

AB2	MUTUAL PHARM	80MG	N76576 001 Apr 08, 2004 Apr NEWA
AB2		120MG	N76576 002 Apr 08, 2004 Apr NEWA
AB2		160MG	N76576 003 Apr 08, 2004 Apr NEWA

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%

>D> AP + ABBOTT	10%	N18969 001 Sep 24, 1984 May CAHN
>A> AP + HOSPIRA	10%	N18969 001 Sep 24, 1984 May CAHN
LIPOSYN III 20%		
>D> AP + ABBOTT	20%	N18970 001 Sep 25, 1984 May CAHN
>A> AP + HOSPIRA	20%	N18970 001 Sep 25, 1984 May CAHN
LIPOSYN III 30%		
>D> AP + ABBOTT	30%	N20181 001 Jan 13, 1998 May CAHN
>A> AP + HOSPIRA	30%	N20181 001 Jan 13, 1998 May CAHN

SPARFLOXACIN

TABLET; ORAL

ZAGAM

@ MYLAN

200MG

N20677 001 Dec 19, 1996 Mar DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

QUELICIN

>D> AP + ABBOTT	20MG/ML	N08845 006 May CAHN
>A> AP + HOSPIRA	20MG/ML	N08845 006 May CAHN
QUELICIN PRESERVATIVE FREE		
>D> AP + ABBOTT	20MG/ML	N08845 001 May CAHN
>D> @	50MG/ML	N08845 002 May CAHN
>D> +	100MG/ML	N08845 004 May CAHN
>A> AP + HOSPIRA	20MG/ML	N08845 001 May CAHN
>A> @	50MG/ML	N08845 002 May CAHN
>A> +	100MG/ML	N08845 004 May CAHN

SUCRALFATE

TABLET; ORAL

CARAFATE

AB + AXCAN SCANDIPHARM 1GM

N18333 001 Feb CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

>D> AP ABBOTT	EQ 0.05MG BASE/ML	N74534 001 Dec 11, 1996 May CAHN
>A> AP HOSPIRA	EQ 0.05MG BASE/ML	N74534 001 Dec 11, 1996 May CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULF-10

AT NOVARTIS 10% N80025 001 Mar CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D> AP ABBOTT 80MG/ML;16MG/ML N73199 001 Sep 11, 1992 May CAHN
>A> AP HOSPIRA 80MG/ML;16MG/ML N73199 001 Sep 11, 1992 May CAHNTECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP

>A> AP + DRAXIMAGE N/A N18035 001 May CTNA
>D> TECHNESCAN MDP KIT
>D> AP + DRAXIMAGE N/A N18035 001 May CTNATELITHROMYCIN

TABLET; ORAL

KETEK

+ AVENTIS PHARMS 400MG

N21144 001 Apr 01, 2004 Apr NEWA

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS

1%

N20846 001 Apr 29, 1998 Jan CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

AP + AAIPHARMA LLC 1MG/ML N18571 001 Apr CFTG
>A> AP AM PHARM 1MG/ML N76887 001 May 26, 2004 May NEWA
AP BEDFORD 1MG/ML N76770 001 Apr 23, 2004 Apr NEWATERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

AB + ORTHO MCNEIL PHARM 0.8% N19964 001 Feb 21, 1991 Apr CFTG
TERCONAZOLE
AB TARO 0.8% N75953 001 Apr 06, 2004 Apr NEWATHEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP + ABBOTT 4MG/ML N19211 007 Dec 14, 1984 May CAHN
>D> AP + 40MG/100ML N19211 001 Dec 14, 1984 May CAHN
>D> AP + 80MG/100ML N19211 002 Dec 14, 1984 May CAHN
>D> AP + 160MG/100ML N19211 003 Dec 14, 1984 May CAHN
>D> AP + 200MG/100ML N19211 004 Dec 14, 1984 May CAHN
>D> AP + 320MG/100ML N19211 006 Jan 20, 1988 May CAHN
>D> AP + 400MG/100ML N19211 005 Dec 14, 1984 May CAHN
>A> AP + HOSPIRA 4MG/ML N19211 007 Dec 14, 1984 May CAHN
>A> AP + 40MG/100ML N19211 001 Dec 14, 1984 May CAHN

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP	+	HOSPIRA	80MG/100ML	N19211 002	Dec 14, 1984	May	CAHN
>A>	AP	+		160MG/100ML	N19211 003	Dec 14, 1984	May	CAHN
>A>	AP	+		200MG/100ML	N19211 004	Dec 14, 1984	May	CAHN
>A>	AP	+		320MG/100ML	N19211 006	Jan 20, 1988	May	CAHN
>A>	AP	+		400MG/100ML	N19211 005	Dec 14, 1984	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB	ABLE	300MG	N40548 001	Apr 30, 2004	Apr	NEWA
AB		400MG	N40543 001	Apr 27, 2004	Apr	NEWA
AB		450MG	N40546 001	Apr 30, 2004	Apr	NEWA
AB		600MG	N40539 001	Apr 27, 2004	Apr	NEWA
	UNIPHYL					
AB	+ PURDUE FREDERICK	400MG	N87571 001	Sep 01, 1982	Apr	CFTG
AB	+	600MG	N40086 001	Apr 15, 1996	Apr	CFTG

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION

THIAMINE HCL

>D>	AP	ABBOTT	100MG/ML	N40079 001	May 03, 1996	May	CAHN
>A>	AP	HOSPIRA	100MG/ML	N40079 001	May 03, 1996	May	CAHN

TINIDAZOLETABLET; ORAL

TINDAMAX

>A>	PRESUTTI LABS	250MG	N21618 001	May 17, 2004	May	NEWA
>A>	+	500MG	N21618 002	May 17, 2004	May	NEWA

TIOTROPIUM BROMIDE MONOHYDRATECAPSULE; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM EQ 0.018MG BASE

N21395 001 Jan 30, 2004 Jan NEWA

TIZANIDINE HYDROCHLORIDETABLET; ORAL

TIZANIDINE HCL

AB	TORPHARM	EQ 2MG BASE	N76533 001	Jan 16, 2004	Jan	NEWA
AB		EQ 4MG BASE	N76533 002	Jan 16, 2004	Jan	NEWA

TOBRAMYCIN SULFATEINJECTABLE; INJECTION

TOBRAMYCIN SULFATE

>D>	AP	ABBOTT	EQ 10MG BASE/ML	N63080 001	Apr 30, 1991	May	CAHN
>D>	AP		EQ 10MG BASE/ML	N63112 001	Apr 30, 1991	May	CAHN
>D>	AP		EQ 40MG BASE/ML	N63111 001	Apr 30, 1991	May	CAHN
>D>	AP	+	EQ 40MG BASE/ML	N63116 001	May 18, 1992	May	CAHN
>D>	AP		EQ 40MG BASE/ML	N63161 001	May 29, 1991	May	CAHN
>A>	AP	HOSPIRA	EQ 10MG BASE/ML	N63080 001	Apr 30, 1991	May	CAHN
>A>	AP		EQ 10MG BASE/ML	N63112 001	Apr 30, 1991	May	CAHN
>A>	AP		EQ 40MG BASE/ML	N63111 001	Apr 30, 1991	May	CAHN
>A>	AP	+	EQ 40MG BASE/ML	N63116 001	May 18, 1992	May	CAHN
>A>	AP		EQ 40MG BASE/ML	N63161 001	May 29, 1991	May	CAHN

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	+	ABBOTT	EQ 1.2MG BASE/ML	N63081 003	Jul 31, 1990	May	CAHN
>D>	+		EQ 1.6MG BASE/ML	N63081 006	Jun 02, 1993	May	CAHN

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	+ ABBOTT	EQ 80MG BASE/100ML	N63081 001 Jul 31, 1990 May CAHN
>A>	+ HOSPIRA	EQ 1.2MG BASE/ML	N63081 003 Jul 31, 1990 May CAHN
>A>	+	EQ 1.6MG BASE/ML	N63081 006 Jun 02, 1993 May CAHN
>A>	+	EQ 80MG BASE/100ML	N63081 001 Jul 31, 1990 May CAHN

TRAVOPROSTSOLUTION/DROPS; OPHTHALMICTRAVATAN

>A>	+ ALCON	0.004%	N21257 001 Mar 16, 2001 May CAHN
>D>	+ ALCON UNIVERSAL	0.004%	N21257 001 Mar 16, 2001 May CAHN

TRIAMCINOLONE ACETONIDEAEROSOL, METERED; INHALATIONAZMACORT

+ KOS	0.1MG/INH	N18117 001 Apr 23, 1982 Apr CAHN
-------	-----------	----------------------------------

SPRAY, METERED; NASALNASACORT HFA

+ AVENTIS PHARMS	0.055MG/SPRAY	N20784 001 Apr 07, 2004 Apr NEWA
------------------	---------------	----------------------------------

TRIMETHOBENZAMIDE HYDROCHLORIDEINJECTABLE; INJECTIONTRIMETHOBENZAMIDE HCL

>D> AP	ABBOTT	100MG/ML	N88804 001 Apr 03, 1987 May CAHN
>A> AP	HOSPIRA	100MG/ML	N88804 001 Apr 03, 1987 May CAHN

TROLAMINE POLYPEPTIDE OLEATE CONDENSATESOLUTION/DROPS; OTICCERUMENEX

>D>	+ PURDUE FREDERICK	10%	N11340 002 May DISC
>A>	@	10%	N11340 002 May DISC

TROMETHAMINEINJECTABLE; INJECTIONTHAM

>D>	+ ABBOTT	3.6GM/100ML	N13025 002 May CAHN
>A>	+ HOSPIRA	3.6GM/100ML	N13025 002 May CAHN

TROSPiUM CHLORIDETABLET; ORALSANCTURA

>A>	+ INDEVUS	20MG	N21595 001 May 28, 2004 May NEWA
-----	-----------	------	----------------------------------

TUBOCURARINE CHLORIDEINJECTABLE; INJECTIONTUBOCURARINE CHLORIDE

>D> AP	+ ABBOTT	3MG/ML	N06095 001 May CAHN
>A> AP	+ HOSPIRA	3MG/ML	N06095 001 May CAHN

UREAINJECTABLE; INJECTIONSTERILE UREA

>D>	@ ABBOTT	40GM/VIAL	N17698 001 May CAHN
>A>	@ HOSPIRA	40GM/VIAL	N17698 001 May CAHN

INJECTABLE; INJECTION

UREAPHIL

>D>	+	ABBOTT	40GM/VIAL	N12154 001	May CAHN
>A>	+	HOSPIRA	40GM/VIAL	N12154 001	May CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

+ GLAXOSMITHKLINE	EQ 1GM BASE	N20487 002 Jun 23, 1995 Feb CRLD
-------------------	-------------	----------------------------------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HCL

>D> AP	ABBOTT	EQ 500MG BASE/VIAL	N62911 001 Aug 04, 1988 May CAHN
>D> AP		EQ 500MG BASE/VIAL	N62931 001 Oct 29, 1992 May CAHN
>D> AP		EQ 1GM BASE/VIAL	N62912 001 Aug 04, 1988 May CAHN
>D> AP		EQ 1GM BASE/VIAL	N62933 001 Oct 29, 1992 May CAHN
>D> AP		EQ 5GM BASE/VIAL	N63076 001 Dec 21, 1990 May CAHN
>A> AP	HOSPIRA	EQ 500MG BASE/VIAL	N62911 001 Aug 04, 1988 May CAHN
>A> AP		EQ 500MG BASE/VIAL	N62931 001 Oct 29, 1992 May CAHN
>A> AP		EQ 1GM BASE/VIAL	N62912 001 Aug 04, 1988 May CAHN
>A> AP		EQ 1GM BASE/VIAL	N62933 001 Oct 29, 1992 May CAHN
>A> AP		EQ 5GM BASE/VIAL	N63076 001 Dec 21, 1990 May CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>D>	+	ABBOTT	4MG/VIAL	N75558 001 Sep 11, 2001 May CAHN
	+		4MG/VIAL	N75558 001 Sep 11, 2001 Apr CAHN
>D> AP			10MG/VIAL	N75164 001 Oct 21, 1999 May CAHN
>D> AP			20MG/VIAL	N75164 002 Oct 21, 1999 May CAHN
>A> +	HOSPIRA		4MG/VIAL	N75558 001 Sep 11, 2001 May CAHN
>A> AP			10MG/VIAL	N75164 001 Oct 21, 1999 May CAHN
>A> AP			20MG/VIAL	N75164 002 Oct 21, 1999 May CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

>D>	+	WYETH PHARMS INC	EQ 50MG BASE	N20151 003 Dec 28, 1993 May CRLD
>A>			EQ 50MG BASE	N20151 003 Dec 28, 1993 May CRLD
>D>			EQ 100MG BASE	N20151 005 Dec 28, 1993 May CRLD
>A> +			EQ 100MG BASE	N20151 005 Dec 28, 1993 May CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

>D> AP	ABBOTT	2.5MG/ML	N70577 001 Feb 02, 1987 May CAHN
>D> AP		2.5MG/ML	N70737 001 May 06, 1987 May CAHN
>D> AP		2.5MG/ML	N70738 001 May 06, 1987 May CAHN
>D> AP		2.5MG/ML	N70739 001 May 06, 1987 May CAHN
>D> AP		2.5MG/ML	N70740 001 May 06, 1987 May CAHN
>D> AP		2.5MG/ML	N75136 001 Oct 20, 1998 May CAHN
>A> AP	HOSPIRA	2.5MG/ML	N70577 001 Feb 02, 1987 May CAHN
>A> AP		2.5MG/ML	N70737 001 May 06, 1987 May CAHN
>A> AP		2.5MG/ML	N70738 001 May 06, 1987 May CAHN
>A> AP		2.5MG/ML	N70739 001 May 06, 1987 May CAHN

INJECTABLE; INJECTION
VERAPAMIL HCL

>A> AP	HOSPIRA	2.5MG/ML	N70740 001 May 06, 1987 May CAHN
>A> AP		2.5MG/ML	N75136 001 Oct 20, 1998 May CAHN
TABLET, EXTENDED RELEASE; ORAL			
VERAPAMIL HCL			
>D>	@ BARR	120MG	N75072 001 May 25, 1999 May CMFD
>A> AB		120MG	N75072 001 May 25, 1999 May CMFD
>D>	@	240MG	N75072 003 May 25, 1999 May CMFD
>A> AB		240MG	N75072 003 May 25, 1999 May CMFD

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN
@ LILLY

1MG/ML

N14103 003 Mar 07, 1984 Mar DISC

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ MAYNE PHARMA USA EQ 50,000 UNITS BASE/ML

N06823 001 Apr CAHN

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

>D> AP	ABBOTT	100%	N18802 001 Oct 27, 1982 May CAHN
>A> AP	HOSPIRA	100%	N18802 001 Oct 27, 1982 May CAHN
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER			
>D> AP	ABBOTT	100%	N18233 001 May CAHN
>D> AP		100%	N18801 001 Oct 27, 1982 May CAHN
>D> AP		100%	N19869 001 Dec 26, 1989 May CAHN
>D> AP	B BRAUN	100%	N19077 001 Mar 02, 1984 May DISC
>A>	@	100%	N19077 001 Mar 02, 1984 May DISC
>A> AP	HOSPIRA	100%	N18233 001 May CAHN
>A> AP		100%	N18801 001 Oct 27, 1982 May CAHN
>A> AP		100%	N19869 001 Dec 26, 1989 May CAHN

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

>D> AT	ABBOTT	100%	N17513 001 May CAHN
>D> AT		100%	N18313 001 May CAHN
>A> AT	HOSPIRA	100%	N17513 001 May CAHN
>A> AT		100%	N18313 001 May CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

>D>	+ ABBOTT	EQ 1MG ZINC/ML	N18959 001 Jun 26, 1986 May CAHN
>A>	+ HOSPIRA	EQ 1MG ZINC/ML	N18959 001 Jun 26, 1986 May CAHN

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

SANOFI SYNTHELABO

5MG

N19908 001 Dec 16, 1992 Apr CAHN

+

10MG

N19908 002 Dec 16, 1992 Apr CAHN

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VASOCON-A
+ NOVARTIS 0.5%;0.05% N18746 002 Jul 11, 1994 Feb CAHN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE
@ SANDOZ 12MG N70797 001 Aug 12, 1988 Apr DISC
TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 CHLORPHENIRAMINE MALEATE
+ ALZA 16MG N19746 002 Nov 18, 1994 Mar CRLD

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL
CHILDREN'S ADVIL ALLERGY SINUS
+ WYETH CONS 1MG/5ML;100MG/5ML;15MG/5ML N21587 001 Feb 24, 2004 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL
MUCINEX DM
ADAMS LABS 30MG;600MG N21620 002 Apr 29, 2004 Apr NEWA
+ 60MG;1.2GM N21620 001 Apr 29, 2004 Apr NEWA

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ELIXSURE
TARO 100MG/5ML N21604 001 Jan 07, 2004 Jan NEWA
TABLET, CHEWABLE; ORAL
IBUPROFEN
PERRIGO 50MG N76359 001 Jan 16, 2004 Jan NEWA
100MG N76359 002 Jan 16, 2004 Jan NEWA

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL
ADVIL COLD AND SINUS
+ WYETH CONS 200MG;30MG N21374 001 May 30, 2002 Mar CAIN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE
ANDRX PHARMS 5MG;120MG N76208 001 Jan 28, 2004 Jan NEWA
IMPAX LABS 10MG;240MG N75989 001 Mar 04, 2004 Mar NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MICONAZOLE 7 COMBINATION PACK
G AND W LABS 2%,100MG N76585 001 Mar 26, 2004 Mar NEWA
CREAM; TOPICAL, VAGINAL
MICONAZOLE 3 COMBINATION PACK
PERRIGO 2%,4% N76357 001 Mar 30, 2004 Mar NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL

PERRIGO

EQ 200MG BASE;120MG

N76518 001 Mar 17, 2004 Mar NEWA

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL

LAMISIL AT

+ NOVARTIS

1%

N21124 002 Mar 17, 2000 Feb NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2004

NO MAY 2004 APPROVALS

This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
May 2004

Generic Name: sodium thiosulfate	Designated Indication: Prevention of platinum-induced ototoxicity in pediatric patients
Trade Name (if present):	Sponsor Contact Information Adherex Technologies, Inc. 600 Peter Morand Crescent Ottawa, Ontario
Date Designated 3/17/2004	
Date Approved	CANADA

Generic Name: 1-Deoxygalactonojirimycin	Designated Indication: Treatment of Fabry Disease
Trade Name (if present):	Sponsor Contact Information Amicus Therapeutics, Inc. 675 US Route 1 North Brunswick NJ 08902
Date Designated 2/25/2004	
Date Approved	*****
Generic Name: Suberoylanilide Hydroxamic Acid (SAHA)	Designated Indication: Treatment of T-cell non-Hodgkin's lymphoma
Trade Name (if present):	Sponsor Contact Information Aton Pharma, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6717
Date Designated 3/16/2004	
Date Approved	*****
Generic Name: Suberoylanilide Hydroxamic Acid	Designated Indication: Treatment of mesothelioma
Trade Name (if present):	Sponsor Contact Information Aton Pharma, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6717
Date Designated 3/17/2004	
Date Approved	

Orphan Products Designations and Approvals List
May 2004

*****	Generic Name: temocillin sodium	Designated Indication: Treatment of cystic fibrosis patients with pulmonary infection caused by <i>Burkholderia cepacia</i>
Trade Name (if present): Negaban		Sponsor Contact Information Belpharma N.V. 67 Winston Churchill Avenue Brussels
Date Designated 4/21/2004 Date Approved		
BELGIUM		
*****	Generic Name: Alpha-1-acid glycoprotein	Designated Indication: Treatment of tricyclic antidepressant poisoning
Trade Name (if present):		Sponsor Contact Information Bio Products Laboratory Dagger Lane Elstree, Hertfordshire
Date Designated 3/17/2004 Date Approved		
UNITED KINGDOM		
*****	Generic Name: alpha-1-acid glycoprotein	Designated Indication: Treatment of cocaine overdose
Trade Name (if present):		Sponsor Contact Information Bio Products Laboratory Dagger Lane, Elstree Hertfordshire
Date Designated 3/5/2004 Date Approved		
UNITED KINGDOM		
*****	Generic Name: (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy- 1,4-imino-D-ribitol-hydrochloride	Designated Indication: Treatment of T-cell non-Hodgkin's lymphoma
Trade Name (if present):		Sponsor Contact Information BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham AL 35244
Date Designated 1/29/2004 Date Approved		

Generic Name: Rituximab		Designated Indication: Treatment of chronic lymphocytic leukemia
Trade Name (if present): Rituxan		Sponsor Contact Information Biogen IDEC, Inc. 3030 Callan Road San Diego CA 92121
Date Designated 1/29/2004 Date Approved		

Orphan Products Designations and Approvals List
May 2004

Generic Name: Designated Indication:
tetrahydrobiopterin For treatment of hyperphenylalaninemia

Trade Name (if present): Sponsor Contact Information
Date Designated 1/29/2004 Biomarin Pharmaceutical Inc.
Date Approved 371 Bel Marin Blvd.
Novato CA 94949

Generic Name: Designated Indication:
3-(4'aminooxindoline-1'-one)-1-piperidine-2,6-dione (CC-5013) Treatment of myelodysplastic syndromes

Trade Name (if present): Sponsor Contact Information
REVIMID Celgene Corporation
Date Designated 1/29/2004 7 Powder Horn Drive
Date Approved Warren NJ 07059

Generic Name: Designated Indication:
diethylenetriaminepentaacetate (DPTA) For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.

Trade Name (if present): Sponsor Contact Information
Date Designated 4/14/2004 CIS-US
Date Approved 10 DeAngelo Drive
Bedford MA 01730

Generic Name: Designated Indication:
recombinant human fibroblast growth factor-20 Treatment of radiation induced oral mucositis

Trade Name (if present): Sponsor Contact Information
Date Designated 1/29/2004 CuraGen Corporation
Date Approved 322 East Main Street
Branford CT 06405

Generic Name: Designated Indication:
Diethylenetriaminepentaacetate Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination

Trade Name (if present): Sponsor Contact Information
CustomCare Pharmacy

Orphan Products Designations and Approvals List
May 2004

Date Designated 2/27/2004	5710 Hoover Blvd
Date Approved	Tampa FL 33634
<hr/>	
Generic Name: chenodeoxycholic acid	Designated Indication: Treatment of cerebrotendinous xanthomatosis
Trade Name (if present): Chenofalk	Sponsor Contact Information Dr. Falk Pharma GmbH Leinenweberstrasse 5 Postfach 6529
Date Designated 1/29/2004	GERMANY
Date Approved	
<hr/>	
Generic Name: hydralazine	Designated Indication: Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure less than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy
Trade Name (if present):	Sponsor Contact Information Esp Pharma, Inc. 2035 Lincoln Hwy. Suite 2150 Edison NJ 08817
Date Designated 4/9/2004	
Date Approved	
<hr/>	
Generic Name: DEAE-rebeccamycin	Designated Indication: Treatment of bile duct tumors
Trade Name (if present):	Sponsor Contact Information Exelixis, Inc. 170 Harbor Way South San Francisco CA 94083-0511
Date Designated 3/1/2004	
Date Approved	
<hr/>	
Generic Name: Ubiquinol	Designated Indication: Treatment of Huntington's Disease
Trade Name (if present): Ubi-Q-Nol, Li-Q-Nol	Sponsor Contact Information Gel-Tec Division of Tishcon Corp P. O. Box 331 Westbury NY 11590
Date Designated 4/12/2004	
Date Approved	
<hr/>	
Generic Name: ubiquinol, coenzyme Q10, ubiquinone	Designated Indication: Treatment of pediatric congestive heart failure
Trade Name (if present): UBI-Q-NOL	Sponsor Contact Information Gel-Tec, Division of TISHCON Corporation

Orphan Products Designations and Approvals List May 2004

Date Designated	4/12/2004	30 New York Avenue
Date Approved		P.O. Box 331 Westbury NY 11590
<hr/>		
Generic Name:		Designated Indication:
Deferitriptin		For the treatment of iron overload
Trade Name (if present):		Sponsor Contact Information
		Genzyme Corporation
Date Designated	4/14/2004	153 Second Avenue
Date Approved		Waltham MA 02451
<hr/>		
Generic Name:		Designated Indication:
mepolizumab		For first-line treatment in patients with hypereosinophilic syndrome
Trade Name (if present):		Sponsor Contact Information
		GlaxoSmithKline Pharmaceuticals
Date Designated	5/28/2004	P.O. Box 7929
Date Approved		Philadelphia PA 19101
<hr/>		
Generic Name:		Designated Indication:
vapretide		Treatment of symptomatic carcinoid tumors
Trade Name (if present):		Sponsor Contact Information
Sanvar		H3 Pharma, Inc.
Date Designated	4/6/2004	666 Sherbrooke Street West Suite 1400
Date Approved		Montreal, Quebec
<hr/>		
CANADA		
<hr/>		
Generic Name:		Designated Indication:
pentetate trisodium		Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.
Trade Name (if present):		Sponsor Contact Information
diethylenetriaminepentaacetate		Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
Date Designated	4/12/2004	Goerzallee 253
Date Approved		Federal Republic of Germany
<hr/>		
GERMANY		
<hr/>		
Generic Name:		Designated Indication:
90Y-hPAMA4		Treatment of pancreatic cancer
Trade Name (if present):		Sponsor Contact Information
PAN-Cide		Immunomedics, Inc.

Orphan Products Designations and Approvals List
May 2004

Date Designated 1/29/2004
Date Approved

300 American Road
Morris Plains NJ 07950

Generic Name:
5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)

Designated Indication:
Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):
Pirfenidone

Sponsor Contact Information
InterMune, Inc.
3280 Bayshore Blvd
Brisbane CA 94005

Date Designated 3/5/2004
Date Approved

Generic Name:
Recombinant Porcine Factor VIII, B-domain

Designated Indication:
Treatment and prevention of episodic bleeding in patients with inhibitor Deleted antibodies to human coagulation factor VIII

Trade Name (if present):

Sponsor Contact Information
Ipsen Limited
190 Bath Road
Berkshire S11 3XE

UNITED KINGDOM

Generic Name:
Icatibant acetate

Designated Indication:
Treatment of burn patients hospitalized with burn-induced edema

Trade Name (if present):

Sponsor Contact Information
Jerini AG
Invalidenstr, 130
10115 Berlin

GERMANY

Generic Name:
multi-vitamin infusion without vitamin K

Designated Indication:
Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy

Trade Name (if present):
M.V.I.-12

Sponsor Contact Information
Mayne Pharma (USA) Inc.
Mack-Cali Centre II
Second Floor
Paramus NJ 07652

Generic Name:
rofecoxib

Designated Indication:
Treatment of juvenile rheumatoid arthritis

Trade Name (if present):
VIOXX

Sponsor Contact Information

Orphan Products Designations and Approvals List
May 2004

Date Designated 3/16/2004
Date Approved

MERCK & Co., Inc.
126 East Lincoln Ave.
Rahway NJ 07065

Generic Name:
Idebenone (INN)

Designated Indication:
Treatment of cardiomyopathy associated with Friedreich's ataxia

Trade Name (if present):

Sponsor Contact Information
MyoContract Ltd.
Hammerstrasse 25
CH-4410 Liestal

Date Designated 3/25/2004
Date Approved

SWITZERLAND

Generic Name:
Staphylococcus aureus Immune Globulin

Designated Indication:
Prophylaxis against Staphylococcus aureus infections in low birth weight neonates (Human)

Trade Name (if present):
Altastaph

Sponsor Contact Information
Nabi Biopharmaceuticals
12276 Wilkins Avenue
Rockville MD 20852

Date Designated 1/29/2004
Date Approved

Generic Name:
Immune Globulin (Human) containing high

Designated Indication:
Treatment of the West Nile virus infection titers of West Nile virus antibodies

Trade Name (if present):
Omr-IgG-am (tm) 5% (WNV)

Sponsor Contact Information
OMRIX Biopharmaceuticals, Ltd.
Plasma Fractionation Institute
Ramat Gan 52621
Israel

Date Designated 3/17/2004
Date Approved

Generic Name:
mannopentaose phosphate sulfate

Designated Indication:
Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor Contact Information
Progen Industries Limited
P. O. Box 28
Richlands 4077

Date Designated 4/27/2004
Date Approved

AUSTRALIA

Generic Name:
antivenin crotaline (pit-viper) equine immune
F(ab)2

Designated Indication:
Treatment of envenomation by Crotaline snakes

Orphan Products Designations and Approvals List
May 2004

Trade Name (if present):
Antivipmyn

Sponsor Contact Information
Rare Disease Therapeutics, Inc.
1101 Kermit Drive,
Suite 608
Nashville TN 37217

Date Designated 1/29/2004
Date Approved

Generic Name:
Thymosin Beta 4

Designated Indication:
Treatment of Epidermolysis Bullosa

Trade Name (if present):

Sponsor Contact Information
RegeneRx Biopharmaceuticals, Inc.
3 Bethesda Metro Center
Suite 700
Bethesda MD 20814

Date Designated 5/28/2004
Date Approved

Generic Name:
SGN-30 (anti-CD30 antibody)

Designated Indication:
For the treatment of CD30 positive T-cell lymphomas

Trade Name (if present):

Sponsor Contact Information
Seattle Genetics, Inc.
21823 30th Drive Southeast
Bothell WA 98021

Date Designated 2/18/2004
Date Approved

Generic Name:
somatropin

Designated Indication:
Treatment of patients with HIV-associated adipose redistribution
syndrome

Trade Name (if present):
Serostim

Sponsor Contact Information
Serono, Inc.
One Technology Place
Rockland MA 02370

Date Designated 3/16/2004
Date Approved

Generic Name:
rh-microplasmin

Designated Indication:
Adjunct to surgery in cases of pediatric vitrectomy

Trade Name (if present):

Sponsor Contact Information
ThromboGenics Ltd
Unit 14
Bridgecourt Office Park
Dublin 12
IRELAND

Date Designated 3/16/2004
Date Approved

Generic Name:
Dexrazoxane

Designated Indication:
Treatment of anthracycline extravasation during chemotherapy

Orphan Products Designations and Approvals List
May 2004

Trade Name (if present):

Sponsor Contact Information
Topo Target A/S
Fruebjergvej 3, 2100
Copenhagen

Date Designated 3/25/2004
Date Approved

DENMARK

Generic Name:
oral unfractionated heparin

Designated Indication:
Treatment of sickle cell disease

Trade Name (if present):

Sponsor Contact Information
TRF Technologies, Inc.
108 Eagle Trace Drive
Half Moon Bay CA 94019

Date Designated 1/29/2004
Date Approved

Generic Name:
Immune Globulin Intravenous (human)

Designated Indication:
Treatment for Guillain Barre Syndrome

Trade Name (if present):
Carimune NF

Sponsor Contact Information
ZLB Bioplasma AG
Wankdorffstrasse 10
CH-3000 Bern 22

Date Designated 5/4/2004
Date Approved

SWITZERLAND

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 2004 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021320 001	ABARELIX; PLENAXIS	5968895 6180608	DEC 11, 2016 DEC 11, 2016	DP DP	U549	
>ADD>	ACETYLCYSTEINE; ACETADOTE ALBUMIN HUMAN; OPTISON	6423686 6455499	JUN 07, 2015 JUN 07, 2015	DS	U549	
>ADD>	ALBUTEROL SULFATE; ACCUREB	5843901	DEC 01, 2015	DS	U549	
>ADD>	ALBUTEROL SULFATE; ACCUREB ALENDRONATE SODIUM; FOSAMAX	6699813	DEC 11, 2016	DP		
>ADD>	ALENDRONATE SODIUM; FOSAMAX ALITRETNINOI; PANRETIN	6273303	APR 20, 2021	DP	ODE	JAN 23, 2011
021539 001	AMLODIPINE BESTYLATE; CADUET	6702997 6702997	DEC 28, 2021 DEC 28, 2021	DP DP	U558 U558	
020839 001	AMLODIPINE BESTYLATE; CADUET	5932622 5233995*PED	AUG 03, 2016 DEC 28, 2010	DS DS	U562 U162	
020949 002	AMLODIPINE BESTYLATE; CADUET	6445574	JUN 28, 2011	NC	U552	
020560 005	AMLODIPINE BESTYLATE; CADUET	5999156*PED	AUG 11, 2018	DS	U552	
021575 001	AMLODIPINE BESTYLATE; CADUET	5666104	JUL 08, 2016	DS		
020886 001	AMLODIPINE BESTYLATE; CADUET	5666104*PED	JAN 08, 2017	DP	U213	
021540 001	AMLODIPINE BESTYLATE; CADUET	6116971	MAY 11, 2014	DP		
021540 002	AMLODIPINE BESTYLATE; CADUET	6116971*PED	JAN 19, 2013	DP		
021540 003	AMLODIPINE BESTYLATE; CADUET	4681893 4681893*PED	JUL 19, 2013 SEP 24, 2009	DS DS	DP U161	
		4681893 4681893*PED	MAR 24, 2010	DS		
		4879303 4879303*PED	MAR 25, 2007	DS		
		4879303 4879303*PED	SEP 25, 2007	DS		
		4572909 4572909*PED	JUL 31, 2006	DS	DP U3	
		4572909 4572909*PED	JAN 31, 2007	DS	DP U161	
		4681893 4681893*PED	SEP 24, 2009	DS	DP U161	
		4879303 4879303*PED	MAR 24, 2010	DS		
		4879303 4879303*PED	MAR 25, 2007	DS		
		4572909 4572909*PED	JUL 31, 2006	DS	DP U3	
		5227995 5227995*PED	JAN 31, 2007	DS	DP U162	
		5271995 5271995*PED	DEC 28, 2010	DS		
		6455574	JUN 28, 2011	DS		
		5966156	AUG 11, 2018	DS	U552	
		5966156*PED	JUL 08, 2016	DS		
		5681104	JAN 08, 2017	DP	U213	
		5681104*PED	MAY 11, 2015	DS		
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013	DS		
		4681893 4681893*PED	SEP 24, 2009	DS	DP U161	
		4879303 4879303*PED	MAR 24, 2010	DS		
		4879303 4879303*PED	MAR 25, 2007	DS		
		4879303 4879303*PED	SEP 25, 2007	DS		
		4572909 4572909*PED	JUL 31, 2006	DS	DP U3	
		5227995 5227995*PED	JAN 31, 2007	DS	DP U162	
		5271995 5271995*PED	DEC 28, 2010	DS		
		6455574	JUN 28, 2011	DS		
		5966156	AUG 11, 2018	DS	U552	
		5966156*PED	JUL 08, 2016	DS		
		5969156*PED	JUL 08, 2016	DS	U552	
		5686104	JAN 08, 2017	DS		
		5686104*PED	NOV 11, 2014	DP	U213	
		5686104*PED	MAY 11, 2015	DS		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020452 002	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	DP U175		
020452 003	CARBOPLATIN; PARAPLATIN	4657927*PED	OCT 14, 2004	DP U175		
020452 004	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	DP U175		
021621 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4657927*PED	OCT 14, 2004	DP U175		
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4657927*	JUN 25, 2007	DS DP US65		
>ADD>	020989 002 CEVIMELLINE HYDROCHLORIDE; EVOXAC CHLORPHENIRAMINE MALEATE; CHILDREN'S ADVIL ALL 021587 001 CHORTOGONADOTROPIN ALFA; OVIDEL 021688 002 CINACALCET HYDROCHLORIDE; SENSIPAR	6455333	DEC 25, 2007	DS DP US65		
021688 002	CINACALCET HYDROCHLORIDE; SENSIPAR	5340211	JUL 07, 2013	U309	NP	FEB 24, 2007
021688 003	CINACALCET HYDROCHLORIDE; SENSIPAR	6706681	MAR 16, 2012	DP	U559	ODE MAR 08, 2011
019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	6031003	DEC 14, 2016	DS	U560	NCE MAR 08, 2009
019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	6211244	OCT 23, 2015	DS	DP	U560
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	6313146	DEC 14, 2016	DS	DP	ODE NCE MAR 08, 2011
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	6011068	DEC 14, 2016	DS	DP	U560
019847 001	CIPROFLOXACIN; CIPRO	6031003	DEC 14, 2016	DS	DP	U560
020780 001	CIPROFLOXACIN; CIPRO	6211244	OCT 23, 2015	DS	DP	ODE NCE MAR 08, 2011
020780 002	CIPROFLOXACIN; CIPRO	6313146	DEC 14, 2016	DS	DP	U560
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	6011068	DEC 14, 2016	DS	DP	ODE NCE MAR 08, 2009
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLO	4670444	DEC 09, 2003	I-421	SEP 25, 2007	
021473 002	CIPROFLOXACIN; CIPRO XR	4705789	NOV 10, 2004	I-421	SEP 25, 2007	
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4957922	SEP 18, 2007	I-421	SEP 25, 2007	
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLO	4808583	FEB 28, 2006	I-421	SEP 25, 2007	
021473 002	CIPROFLOXACIN; CIPRO XR	4670444*PED	JUN 09, 2004	I-421	SEP 25, 2007	
		4705789*PED	MAY 10, 2005	I-421	SEP 25, 2007	
		4808583*PED	AUG 28, 2006	I-421	SEP 25, 2007	
		4957922*PED	MAR 18, 2008	I-421	SEP 25, 2007	
		4670444	DEC 09, 2003	DS DP US55		
		4670444*PED	JUN 09, 2004			

PRESCRIPITION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021644 001 021638 001	CLOBETASOL PROPIONATE; CLOBEX DEXMEDETOMIDINE; PRECEDEX	6716867	MAR 31, 2019	U572	NDF	FEB 05, 2007
021192 001 021192 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-113	APR 09, 2007
021192 003 021192 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-113	APR 09, 2007
021192 005 021192 006	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-113	APR 09, 2007
>ADD> 021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	6713086	DEC 18, 2018	DP U579		
>ADD> 021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	5212326 6528090	JAN 29, 2008 DEC 18, 2018	DS DP DP		
>ADD> 021168 003	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	6713086 5212326 6528090	DEC 18, 2018 JAN 29, 2008 DEC 18, 2018	DP U579 DS DP DP		
>ADD> 020449 001 020931 001	DOCETAZEL; TAXOTERE DOFETILIDE; TIROSYN DOFETILIDE; TIROSYN	4959366 499366 499366	SEP 25, 2007 SEP 25, 2007 SEP 25,	U561		
020931 002 020931 003	DOFETILIDE; TIROSYN	6316443	APR 17, 2011	DP U561		
020869 001 020408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413 461939 461939	APR 28, 2008 OCT 28, 2003 OCT 28, 2003	DS DP U104 DP U104 DP U104		
020862 001 020862 002	DOXERCALCIFEROL; HECTOTOROL DOXERCALCIFEROL; HECTOTOROL	6703418	FEB 26, 2011	U563		
018651 001 018651 002	DRONABINOL; MARINOL DRONABINOL; MARINOL	6703418 6703418	FEB 26, 2011 FEB 26, 2011	U563		
018651 003 021500 001	DRONABINOL; MARINOL EMETICITABINE; ENTRIVA EPINEPHRINE; LIPOSITE TOPICAL SYS	6703418 6703496	FEB 26, 2011 MAR 09, 2021	DS DP		
>ADD> 021504 001	ESTRADIOL; ESTRAGEL ESTRADIOL; ESTRAGEL					
021371 001 02166 001	ESTRADIOL; PREFEST ESTRADIOL; PREFEST	6747019	MAR 20, 2020	U311		
021040 001 020992 002	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN					
020992 003 020992 004	ETHINYL ESTRADIOL; OVCON-35 FINASTERIDE; PROSCAR	6667050	JUN 12, 2021	DP U1		
020992 005 020992 006	FINOLDOPAM MESYLATE; CORLOPAM	476071 5886184	JUN 19, 2006 NOV 19, 2012	DS DP U262 DS		
021490 001 019222 001	FLUCONAZOLE; DIFLUCAN	6046183	MAR 20, 2011	DP U577		
020180 001	FLUCONAZOLE; DIFLUCAN	4404216 4404216*PED	JAN 29, JUL 29,	2004 2004		
019949 001	FLUCONAZOLE; DIFLUCAN	4404216 4404216*PED	JAN 29, JUL 29,	2004 2004		
019949 002	FLUCONAZOLE; DIFLUCAN	4404216 4404216*PED	JAN 29, JUL 29,	2004 2004		
019949 003	FLUCONAZOLE; DIFLUCAN	4404216 4404216*PED	JAN 29, JUL 29,	2004 2004		
019949 004	FLUCONAZOLE; DIFLUCAN	4404216 4404216*PED	JAN 29, JUL 29,	2004 2004		
020090 001	FLUCONAZOLE; DIFLUCAN	4404216 4404216*PED	JUL 29,	2004		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPRES S
020090 002	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
019950 003	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216 *PED	JUL 29, 2004			
019950 005	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216 *PED	JAN 29, 2004			
019950 001	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
019950 002	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216 *PED	JUL 29, 2004			
019950 004	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
020985 001	FLUOROURACIL; CARAC	4404216 *PED	JUL 29, 2004			
021235 001	FLUOXETINE HYDROCHLORIDE; PROZAC WEEKLY	6670315	JUN 02, 2021	DP U68	M-33	APR 21, 2007
>ADD>	021077 001	FLUTICASONE PROPIONATE; ADVAIR DISKUS 100/50	5910319	MAY 29, 2017	U396	NP
>ADD>	021433 001	FLUTICASONE PROPIONATE; FLOVENT HFA	5985322	MAY 29, 2017	U397	NP
>ADD>	021433 002	FLUTICASONE PROPIONATE; FLOVENT HFA				MAY 14, 2007
>ADD>	021433 003	FLUTICASONE PROPIONATE; FLOVENT HFA				MAY 14, 2007
021211 001	FOLLITROPIN ALFA/BETA; FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567	NP	NP
021765 001	FOLLITROPIN ALFA/BETA; GONAL-F	5767251	JUN 16, 2015	DS		
021765 002	FOLLITROPIN ALFA/BETA; GONAL-F	4584042	JUL 26, 2004	U568		
021765 003	GATIFLOXACIN; ZYMAR	4584042	JUL 26, 2004	U569		
021493 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	6333045	AUG 20, 2019	DP		
>ADD>	020509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR	480614	MAY 15, 2010	DS	I-428
>ADD>	021158 001	GEMIFLOXACIN MESYLATE; FACTIVE	480614	MAY 15, 2010	DS	I-428
076345 001	GLYBURIDE; GLYBURIDE AND METFOR	672734	MAR 20, 2018	DS DP	PC	OCT 31, 2004
076345 002	GLYBURIDE; GLYBURIDE AND METFOR	4584042	JUL 26, 2004	U569	NP	MAR 25, 2007
076345 003	HYDROCODONE BITARTRATE; HYDROCODONE BITARTRA				NP	MAR 25, 2007
>ADD>	021604 001	IBUPROFEN; CHILDREN'S ELIXISURE			PC	OCT 31, 2004
076478 001	IBUPROFEN; TRUPROFEN AND PSEUDO				PC	OCT 31, 2004
020723 001	IMIGUIMOD; ALDARA				PC	OCT 31, 2004
020685 001	INDINAVIR SULFATE; CRIVAN	6689761	FEB 10, 2021	U554	NP	JAN 07, 2007
020685 003	INDINAVIR SULFATE; CRIVAN	6689761	FEB 10, 2021	U554	PC	OCT 11, 2004
020685 005	INDINAVIR SULFATE; CRIVAN	6689761	FEB 10, 2021	U554	PC	OCT 11, 2004
020685 006	INDINAVIR SULFATE; CRIVAN	6689761	FEB 10, 2021	U554	PC	OCT 11, 2004
>ADD>	021629 001	INSULIN GLULISINE RECOMBINANT; APIDRA	6221633	JUN 18, 2018	DS DP U471	NP
>ADD>	020563 001	INSULIN LISPRO RECOMBINANT; HUMALOG			NCE	APR 16, 2009
>ADD>	020563 002	INSULIN LISPRO RECOMBINANT; HUMALOG PEN			D-86	JUN 02, 2007
>ADD>	021425 003	IOPROMIDE; ULTRAVIST (PHARMACY)	4361921	MAR 06, 2005	DS DP U113	D-86
020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	4604463	AUG 20, 2007			
>ADD>		640569	APR 28, 2020	U449		
>ADD>		4604463 *PED	FEB 20, 2008			
		6403569 *PED	OCT 28, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content.

APPL/PROD NUMBER	INGREDIENT NAME : TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021281 001 LANSOPRAZOLE; PREVACID					AUG 30, 2005
>ADD>	021281 002 LANSOPRAZOLE; PREVACID					M-12
>ADD>	021428 001 LANSOPRAZOLE; PREVACID					M-12
>ADD>	021428 002 LANSOPRAZOLE; PREVACID					AUG 30, 2005
>ADD>	021566 001 LANSOPRAZOLE; PREVACID IV					M-12
>ADD>	020905 001 LEFLUNOMIDE; ARAVA					MAY 27, 2007
020905 002 LEFLUNOMIDE; ARAVA						MAR 05, 2007
020905 003 LEFLUNOMIDE; ARAVA						M-32
020182 001 LEVOCARNITINE; CARNITOR	6696493	JAN 18, 2021	U433		PED	SEP 05, 2007
021571 001 LEVOFLOXACIN; IQUIX	6031007	APR 01, 2017	DP U553		PED	MAR 05, 2007
021451 001 LIDOCaine; ORAQIX	6703403	JUN 26, 2016	U257		NPP	MAR 01, 2007
021226 001 LOPINAVIR; KALETRA	6703403	JUN 26, 2016	U257		PC	AUG 20, 2004
021251 001 LOPINAVIR; KALETRA					NPP	MAR 11, 2007
075505 001 LORATADINE; LORATADINE					PED	SEP 11, 2007
020386 001 LOSARTAN POTASSIUM; COZAAR					NPP	MAR 11, 2007
020386 002 LOSARTAN POTASSIUM; COZAAR					PED	SEP 11, 2007
020803 001 LOTEPREDNOL ETABONATE; ALREX	5747061	OCT 25, 2013	DP U576		NPP	MAR 11, 2007
020583 001 LOTEPREDNOL ETABONATE; LOTEMAX	5747061	OCT 25, 2013	DP U575		PC	SEP 11, 2007
021249 001 LOVASTATIN; ADVICOR	6677967	SEP 20, 2013	U548			
021249 002 LOVASTATIN; ADVICOR	6677967	SEP 20, 2013	U548			
021249 003 LOVASTATIN; ADVICOR	6677967	SEP 20, 2013	U548			
013217 001 METAXALONE; SKELAXIN	6677967	SEP 20, 2013	U548			
013217 002 METAXALONE; SKELAXIN	66810102	DEC 03, 2021	U189		NP	APR 27, 2007
021574 001 METFORMIN HYDROCHLORIDE; FORTAMET	66810102	DEC 03, 2021	U189		NP	APR 27, 2007
021574 002 METFORMIN HYDROCHLORIDE; METFORMIN HCL	6683102	DEC 03, 2021	U189		NP	APR 27, 2007
021308 001 MICORAZOLE NITRATE; MONISTAT 1 COMBINATI					PC	MAY 29, 2004
076307 001 MIRTAZAPINE; MIRTZAPINE	6723713 *PED	JAN 27, 2014	U574		RTO	JUN 29, 2004
020762 002 MIRTAZAPINE; MIRTZAPINE	6716630 *PED	JUL 27, 2014			PC	JUN 14, 2004
020762 003 MOMETASONE FURETATE MONOHYDRATE; NASONEX	6716630 *PED	SEP 20, 2019	DP		PC	JUN 14, 2004
021598 001 MOXIPLAQUIN HYDROCHLORIDE; VIGAMOX	6677967	MAR 29, 2020			NCE	JUN 10, 2005
020381 002 NIACIN; NIASPAN	6677967	SEP 20, 2013	U548			
020381 003 NIACIN; NIASPAN	6677967	SEP 20, 2013	U548			
020381 004 NIACIN; NIASPAN	6677967	SEP 20, 2013	U548			
>ADD>	076648 001 NITROFURANTOIN; NITROFURANTOIN (MONO					
021494 001 NIZATIDINE; AXID						
020592 001 OLANZAPINE; ZYPREXA						
020592 002 OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149		NDF	MAY 25, 2007
020592 003 OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149		I-417	JAN 14, 2007
020592 004 OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149		I-417	JAN 14, 2007
>ADD>						

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	PATENT CODE	EXCLUS EXPIRES
020592 005	OLANZAPINE; ZYPREXA	5229382 APR 23, 2011	DS DP U149	I-417	JAN 14, 2007	
020592 006	OLANZAPINE; ZYPREXA	5229382 APR 23, 2011	DS DP U149	I-417	JAN 14, 2007	
021253 001	OLANZAPINE; ZYPREXA	5229382 APR 23, 2011	DS DP U547	NDF	MAR 29, 2007	MAR 29, 2007
021086 001	OLANZAPINE; ZYPREXA ZYDIS	5229382 APR 23, 2011	DS DP U571	NDF	MAR 29, 2007	MAR 29, 2007
021086 002	OLANZAPINE; ZYPREXA ZYDIS	5229382 APR 23, 2011	DS DP U149	I-417	JAN 14, 2007	
021086 003	OLANZAPINE; ZYPREXA ZYDIS	5229382 APR 23, 2011	DS DP U149	I-417	JAN 14, 2007	
021086 004	OLANZAPINE; ZYPREXA ZYDIS	5229382 APR 23, 2011	DS DP U149	I-417	JAN 14, 2007	
021087 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5763483 DEC 27, 2016	DEC 27, 2016	I-400	JUL 10, 2006	
021246 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5866601 FEB 02, 2016	FEB 02, 2016	NCE	OCT 14, 2007	
>ADD>		5952375 FEB 02, 2016	FEB 02, 2016	PED	OCT 27, 2004	
		5763483*PED FEB 02, 2016	FEB 02, 2016	NCE	OCT 27, 2004	
		5866601*PED AUG 02, 2016	AUG 02, 2016	PED	APR 27, 2005	
021492 001	OXALIPLATIN; ELOXATIN	592371*PED AUG 02, 2016	DEC 27, 2016	I-400	JAN 14, 2007	
021492 002	OXALIPLATIN; ELOXATIN	5866601 FEB 02, 2016	FEB 02, 2016	NCE	OCT 14, 2007	
021351 002	OXYBUTYNIN; OXYTROLIN	5952375 JUN 27, 2017	JUN 27, 2017	U376	OCT 27, 2004	
076168 001	OXYCODONE HYDROCHLORIDE; OXYCODONE HCL	5763483*PED JUN 27, 2017	JUN 27, 2017			
020819 001	PARICALCITOL; ZEMPLAR	5866601*PED AUG 02, 2016	AUG 02, 2016	I-425	JAN 09, 2007	
020819 002	PARICALCITOL; ZEMPLAR	5246925 APR 17, 2012	U314	I-425	JAN 09, 2007	
		5246925*PED OCT 17, 2012	OCT 17, 2012	PC	SEP 26, 2004	
		5581497 DEC 24, 2013	DEC 24, 2013	M-31	MAR 31, 2007	
		5581497*PED JUN 24, 2014	JUN 24, 2014	PED	OCT 01, 2007	
		6134799 APR 08, 2018	APR 08, 2018	PED	OCT 01, 2007	
		6134799*PED OCT 08, 2019	OCT 08, 2019	NCE	OCT 01, 2007	
021462 001	PENETREXED DISODIUM; ALIMTA	6361758 APR 08, 2018	DP	I-419	JAN 12, 2007	
020639 001	QUETIAPINE FUMARATE; SERQUEL	5211974 MAR 29, 2011	DS DP U551	I-418	JAN 12, 2007	
020639 002	QUETIAPINE FUMARATE; SERQUEL	5344932 SEP 06, 2011	DS DP U550	I-419	JAN 12, 2007	
020639 003	QUETIAPINE FUMARATE; SERQUEL	4879288 SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007	
020639 004	QUETIAPINE FUMARATE; SERQUEL	4879288 SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007	
020639 005	QUETIAPINE FUMARATE; SERQUEL	4879288 SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007	

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021256 001	SECRETIN SYNTHETIC HUMAN HUMAN SECRETIN	6727283 6509013 6509013	OCT 11, 2019 AUG 11, 2013 AUG 11, 2013	DP US80	ODE NCE	APR 04, 2009 APR 09, 2009
>ADD>	020990 001	SERTBALINE HYDROCHLORIDE; TOLLOFT	JUN 28, 2008	DP	I-386	APR 11, 2006
020826 001	SOMATROPIN RECOMBINANT; NUTROPIN	5096885	MAR 17, 2009	DP		
021168 002	SOMATROPIN RECOMBINANT; NUTROPIN	5096885	MAR 17, 2009	DP		
020522 001	SEVELAMER HYDROCHLORIDE; RENAGEL	5763394	JUN 09, 2015	DP		
021110 003	SIROLIMUS; RAPAMUNE	5763394	JUN 09, 2015	DP		
>ADD>	020280 004	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	4968299	DEC 28, 2006	U72	
020168 001	SOMATROPIN RECOMBINANT; NUTROPIN	4916470	AUG 06, 2008	U72		
020168 002	SOMATROPIN RECOMBINANT; NUTROPIN	4916470	JUN 28, 2007	U72		
020522 001	SOMATROPIN RECOMBINANT; NUTROPIN AQ	4916470	FEB 06, 2009	U72		
020522 002	SOMATROPIN RECOMBINANT; NUTROPIN AQ PEN	4916470	DEC 28, 2006	U72		
020980 001	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	58633559	JAN 26, 2016	U72		
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	6020001	MAR 02, 2012	U444		
020626 001	SUMATRIPTAN; IMITREX	6020001*PED	SEP 04, 2012	U444		
		6368637*PED	SEP 02, 2012	U72		
		4816470*PED	JUN 28, 2007	U72		
		5037845*PED	FEB 06, 2009	U72		
		58633559*PED	JUL 28, 2016	U72		
		4816470	DEC 06, 2006	U72		
		5037845	AUG 06, 2008	U72		
		58633559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012	U444		
		6368637*PED	JUL 26, 2016	U72		
		5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368637	MAR 02, 2012	U444		
		58633559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012	U444		
		6368637*PED	JUL 26, 2016	U72		
		4816470*PED	AUG 06, 2008	U72		
		5037845*PED	JUN 28, 2007	U72		
		4816470	DEC 28, 2006	U72		
		58633559*PED	JUL 26, 2016	U72		
		4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		5307953	DEC 02, 2012	U232		
		5544639	SEP 10, 2013	U232		
		5705520	MAR 10, 2014	U232		
		554463*PED	JUN 10, 2012	U232		
		5705520*PED	JUN 28, 2007	U232		
		4816470*PED	FEB 06, 2009	U232		
		5037845*PED	JUN 02, 2013	U232		
		5307953*PED				

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCL CODE	EXCLUS EXPIRES
>ADD> 020505 004	TOPIRAMATE; TOPAMAX				D-88	DEC 16, 2006
>ADD> 020505 005	TOPIRAMATE; TOPAMAX				D-88	DEC 16, 2006
>ADD> 020505 006	TOPIRAMATE; TOPAMAX				D-88	DEC 16, 2006
>ADD> 02044 001	TOPIRAMATE; TOPAMAX SPRINKLE				D-88	DEC 16, 2006
>ADD> 02044 002	TOPIRAMATE; TOPAMAX SPRINKLE				D-88	DEC 16, 2006
>ADD> 02044 003	TOPIRAMATE; TOPAMAX SPRINKLE				D-88	DEC 16, 2006
021257 001	TRAVOPROST; TRAVATAN	6011062	DEC 22, 2014	DP	D-88	DEC 16, 2006
>ADD> 021595 001	TROSPiUM CHLORIDE; SANCTURA	5849792	DEC 22, 2014	DP U383		
021630 001	VORICONAZOLE; VFEND	5889052	DEC 02, 2014	DP U383		
		551033	AUG 03, 2013	DP U383		
>ADD>		5116844	AUG 11, 2009	NCE	MAY 28, 2009	
		5364438	NOV 15, 2011	DS	MAY 24, 2007	
		5567817	OCT 22, 2013	DS DP U540	NOV 14, 2006	
		5773443	JAN 25, 2011	DS DP U540	I-049	

Footnote:

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53 (c) (5).
- Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at
<http://www.fda.gov/cder/orange/patex.htm>
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
- *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT [HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM](http://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM).

PATENT & EXCLUSIVITY ABBREVIATIONS

- W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL

EXCLUSIVITY INDICATION

- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER

EXCLUSIVITY MISCELLANEOUS

- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA

PATENT USE

- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

- U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928

Gao

Order Processing Code:
8414

Approved Drug Products, ADP

SUBSCRIPTION ORDER FORM

Easy Secure Internet: bookstore.gpo.gov

Toll Free: (866) 512-1800
Phone: (202) 512-1800
Fax: (202) 512-2250

Mail: Superintendent of Documents
P.O. Box 371954
Pittsburgh, PA 15250-7954

YES, enter my subscription(s) as follows:


subscription(s) of Approved Drug I Supplements, for \$110.00 per year. The total subject to change. International customers p

Personal name _____ (Please type or print)

Company name

卷之三

Purchase order number (optional)



02/04

Authorizing signature

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90044 6374

Approved drug products with
therapeutic equivalence evaluations.
Cumulative supplement.

RM 301.45 .A66 2004 v.24 suppl.5

Library Use Only

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110